{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "xwi9mzFPPDv7"
      },
      "source": [
        "# Identifying Entities in Healthcare Data"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3wwzoMzrUDtr"
      },
      "source": [
        "##Workspace set up: Import and Install useful packages."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 815,
      "metadata": {
        "id": "T4hxafMCE1nn"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: sklearn-crfsuite in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (0.3.6)\n",
            "Requirement already satisfied: python-crfsuite>=0.8.3 in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (from sklearn-crfsuite) (0.9.10)\n",
            "Requirement already satisfied: six in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (from sklearn-crfsuite) (1.16.0)\n",
            "Requirement already satisfied: tabulate in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (from sklearn-crfsuite) (0.9.0)\n",
            "Requirement already satisfied: tqdm>=2.0 in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (from sklearn-crfsuite) (4.66.4)\n",
            "Requirement already satisfied: colorama in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (from tqdm>=2.0->sklearn-crfsuite) (0.4.6)\n",
            "Requirement already satisfied: pandas in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (2.0.3)\n"
          ]
        },
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "ERROR: Could not find a version that satisfies the requirement as (from versions: none)\n",
            "ERROR: No matching distribution found for as\n"
          ]
        },
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Requirement already satisfied: seaborn in d:\\upgrad\\nlp-syntactic processing\\.venv\\lib\\site-packages (0.13.2)\n"
          ]
        },
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "ERROR: Could not find a version that satisfies the requirement as (from versions: none)\n",
            "ERROR: No matching distribution found for as\n",
            "[nltk_data] Downloading package punkt to\n",
            "[nltk_data]     C:\\Users\\SreekumarRadhakrishn\\AppData\\Roaming\\nltk_dat\n",
            "[nltk_data]     a...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n",
            "[nltk_data] Downloading package averaged_perceptron_tagger to\n",
            "[nltk_data]     C:\\Users\\SreekumarRadhakrishn\\AppData\\Roaming\\nltk_dat\n",
            "[nltk_data]     a...\n",
            "[nltk_data]   Package averaged_perceptron_tagger is already up-to-\n",
            "[nltk_data]       date!\n"
          ]
        },
        {
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "execution_count": 815,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "#!pip install pycrf\n",
        "!pip install sklearn-crfsuite\n",
        "!pip install pandas as pd\n",
        "!pip install seaborn as sns\n",
        "\n",
        "import spacy\n",
        "import sklearn_crfsuite\n",
        "from sklearn_crfsuite.metrics import flat_f1_score\n",
        "from collections import Counter\n",
        "\n",
        "model = spacy.load(\"en_core_web_sm\")\n",
        "\n",
        "import nltk #use of nltk is clear from the work as you scroll down\n",
        "from nltk.tokenize import word_tokenize\n",
        "\n",
        "nltk.download('punkt')\n",
        "nltk.download('averaged_perceptron_tagger')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "bE9Hwb3AUHwG"
      },
      "source": [
        "##Data Preprocessing\n",
        "\n",
        "The dataset provided is in the form of one word per line. Let's understand the format of data below:\n",
        "- Suppose there are *x* words in a sentence, then there will be *x* continuous lines with one word in each line. \n",
        "- Further, the two sentences are separated by empty lines. The labels for the data follow the same format.\n",
        "\n",
        "**We need to pre-process the data to recover the complete sentences and their labels.**\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "nBU_BNUuK8tm"
      },
      "source": [
        "### Construct the proper sentences from individual words and print the 5 sentences."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "b4OjXEhjhkCW"
      },
      "source": [
        "![image.png](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAocAAAFOCAYAAAD0G7cDAAAgAElEQVR4Ae2dSZMcx3m/5ws55kPYMfMJHIG7D3P1BUdf5uQTDnaEIhg2iYUj7itIcQEoSpBBUAQXgbIJjAQpCFlcZGLIP0kAAxIgkP/4NfgbvkhUL9ldVZ3d/VREs5bMfPPNJ2tQD7NmWUtsEIAABCAAAQhAAAIQ+JHAGiQgAAEIQAACEIAABCBgAsihSbCvlsALL7yQfvOb36S3336bT4UMTp8+nTRHbBCAAAQgsBwEkMPlmMelHsXx48fT+fPn04ULF/hUyEDi/uSTTy71PcjgIAABCKwSAeRwlWZ7Qcf66KOPpuvXry9o9suf9l//+tf08ssvL/9AGSEEIACBFSGAHK7IRC/yMJHDumcPOax7fsgOAhCAQCkB5LCUGPV7J4Ac9o68qEPksAgXlSEAAQhUTwA5rH6KSBA5rPseQA7rnh+ygwAEIFBKADksJUb93gkgh70jL+oQOSzCRWUIQAAC1RNADqufIhJEDuu+B5DDuueH7CAAAQiUEkAOS4lRv3cCyGHvyIs6RA6LcFEZAhCAQPUEkMPqp4gEkcO67wHksO75ITsIQAACpQSQw1Ji1O+dwDg53NvbS5ubm2ltbe3gc/bs2d7zXNUOkcNVnXnGDQEILCsB5HBZZ3aJxjVKDiWBksIog7u7u2l9fT3t7OwsEYV6h4Ic1js3ZAYBCEBgGgLI4TTUaNMrgWFy6BXDKIZOTNe0mqg62iyMXl2UPOqayw4dOpSOHDlysPK4tbWV9vf3B+WuozZuH8XTebhse3v7vnaHDx9O+qhcZZ988slB+TIcIIfLMIuMAQIQgMBPBJDDn1hwVCmBYXKYC+Cw9C2GlkhJn+TPAuhyS51lzwLoc7eP5/FY/Tu22zq2z4fluMjXkcNFnj1yhwAEIPAgAeTwQSZcqYzAMDmUcFnwSlOObSVwGxsbByuJiiVRtCzGunk/KnM9lymeViIljk2xXW9Z9sjhsswk44AABCBwjwByyJ1QPYG25NCrfH79a7FsErgoh/E4h6Uyx4t7v9Juip3HWPRz5HDRZ5D8IQABCNxPADm8nwdnFRIYJoeTvlaOUqiVPm1xNbBJ4KIQxuMcz6gy1W2KncdY9HPkcNFnkPwhAAEI3E8AObyfB2cVEhgmh5Y+fy9gTD1Kmcq9Sug6JXIY67q996PKVCfm4TbLtkcOl21GGQ8EILDqBJDDVb8DFmD8w+RQqUv89Do3CqKETD9ZrFU91/FrXp+rjYWxSeDiimAuofGHTlwmSfQWhbEptustyx45XJaZZBwQgAAE7hFADrkTqicwSg6VvGUwfs9flEXVkey5XFJ46tSpgUCqbZPARTls6sPi2VRm6XRZ/sMuur5MG3K4TLPJWCAAAQikhBxyF1RPYJwcVj+AJU8QOVzyCWZ4EIDAyhFADlduyhdvwMhh3XOGHNY9P2QHAQhAoJQAclhKjPq9E0AOe0de1CFyWISLyhCAAASqJ4AcVj9FJIgc1n0PIId1zw/ZQQACECglgByWEqN+7wSQw96RF3WIHBbhojIEIACB6gkgh9VPEQkih3XfA8hh3fNDdhCAAARKCSCHpcSo3zsB5LB35EUdIodFuKgMAQhAoHoCyGH1U0SCx48fTxcvXkx//vOf+VTI4N13303PPPMMNyoEIAABCCwJAeRwSSZymYdx7Nix9Morrwx+cbV+eTWfuhi8+OKLg79Vvcz3IGODAAQgsEoEkMNVmu0FHSuvleueOF4r1z0/ZAcBCECglAByWEqM+r0TQA57R17UIXJYhIvKEIAABKongBxWP0UkiBzWfQ8gh3XPD9lBAAIQKCWAHJYSo37vBJDD3pEXdYgcFuGiMgQgAIHqCSCH1U8RCSKHdd8DyGHd80N2EIAABEoJIIelxKjfOwHksHfkRR0ih0W4qAwBCECgegLIYfVTRILIYd33AHJY9/yQHQQgAIFSAshhKTHq904AOewdeVGHyGERLipDAAIQqJ4Aclj9FJHgMDnc3d1NGxsbSXu2+RFADufHnp4hAAEIdEEAOeyCKjFbJTBMDlvthGBTE0AOp0ZHQwhAAAJVEkAOq5wWkooEhslhvnK4vb2d1tbWBp/Nzc20t7cXw3DcEQHksCOwhIUABCAwJwIDOXzuuefS6dOn0zvvvMMHBp3cA2+99VY6c+ZMunLlSvGtPokc7uzspK2trbS/vz+IH8/v3LlT3CcNJieAHE7OipoQgAAEFoHAQA7feOON9PDDD6ezZ8/ygUEn98Brr72W/vM//zNJEku3aeSwtA/qT08AOZyeHS0hAAEI1EhgIIdaMZQY3rhxgw8MOrkHPvvss/TKK6+k8+fPF38dTCKHeoWsV8l6rby+vs4PqRRTnr4Bcjg9O1pCAAIQqJEAcogMdiKD+f9odC2H/uLSa2W9XpYk+vsOb9++7WL2HRBADjuASkgIQAACcySAHCKHSyWH/lrySqJWxL/99ltfZt8BAeSwA6iEhAAEIDBHAsghcrgUchh/AEVfT5JCVg77+ZcFOeyHM71AAAIQ6IsAcogcLoUcxtfJfN9hX/983OsHOeyXN71BAAIQ6JoAcogcLqwcdv3FQfzJCCCHk3GiFgQgAIFFIYAcIofI4aJ8tVaaJ3JY6cSQFgQgAIEpCSCHyCFyOOUXD83uEUAOuRMgAAEILBcB5BA5RA6X62u699Egh70jp0MIQAACnRJADpFD5LDTL7HlD44cLv8cM0IIQGC1CCCHyCFyuFpf862PFjlsHSkBIQABCMyVwERyqL+9/E//9E9Jv1g4/8sXk57/y7/8S9Jn0vrzqKfxaZwab1f9t8HSuT3yyCNVMJ2EWxd/IWWuXzl0fkAAOTxAwQEEIACBpSDQmxxaaGreTyI5s+aPHE73t5WvXr2arl+/zqdCBpcvX04nT55cin8QGQQEIAABCKQ0Vg4vXbo0+Du1+sXC//AP/5C0SqAVq3/9138dnOu6hMdipXN/VM8yFVcOdRzbO4brjtsrrvv4u7/7u3ThwoWDftR2WLly/8d//Mf07//+7wftPaY8/5h7zEcx1Mb9x3rK45//+Z8HH5XnK6Xi5Hbud1S+KlNMjdHt3F8c46SrusNieXwxZuRayu3jjz++bz4Uf5aVw6NHj6YTJ06kRx99lE+FDDw3/IMKAQhAAALLQWCsHOrBnq92SSKiPFisogzldXI5jO1VN8qSZaVpr1xi3fxcsaIsxXKLncvzvH2uNk19u736UHl+bvlyeVMMxXb/Kp8kX+fj/nyutpF5U3++lrfNzyfJw3mbk/v2ufNyn3E/ixxKCrVqyFYnAd1LL7/8cp3JkRUEIAABCBQTmFoOLQpRAOKxROnv//7vD1b1cjm0WKhNXjfGyY8lIFEOY7keUloZVLx4XX1JfnIhUp0oReMkJ9Z1/JjPJONQfbObJl/369wjx1iWHzeN3XWmySOyGMdN/SCHxV+bC9NA9w9yuDDTRaIQgAAExhJoXQ4lK34FGlcHdd0iE48lDpNIlUXGIuI+4mqV4qhPl8V9G3KY5+3cJaR6QE4yjiiH4/JVfOXtcZifWagsv+aypv2wWOPyaBJLxbLkek7iXOT9I4djvxYXtgJyuLBTR+IQgAAEGgm0JoeSFEmMhSEXpShW8VgSkdfNxWLYufu0hI6LM6vk5Hk791nkMK6uDhunrku8LIkSM10rlUPHz2N1zU39IoeNX39LcRE5XIppZBAQgAAEDgi0Iod6OOSvc3PhiGIVjyUOeV1LzCR7r1pJlJrkL8ZoKi9ZAYt1HVei5dfck4xD9S3QTfk47rB9zEHHYjms7rjrjqWfNtUYlFtTm6Y83Vb8PQfD2ismcnjwNbd0B7o/eK28dNPKgCAAgRUm0JocRrmwTHhFT3IQhTAeq2wSqbK0RBlraitpsayp3LmoXTx2vBLJcXu1ibF9Psk4lIflUDFK8rWEuT/tJ5VD526Ba4rVFTeNEzlc3n9ldG8hh8s7v4wMAhBYPQITyaHFwrInKYmCo4e/pMOvPVVP55INi0wUwnistpNIler5o/buS3sLz7hyjyPWz8eic8UcJl2O4f49vknH4fZmqXajxhO55nmJm+JEqTODpv2oWKPycM6TctOvP8r7Rw6X9x8X3R/I4fLOLyODAARWj8BEcpg/6Dn/SVRhMRkL5HB5/3FBDpd3bhkZBCCwmgSQw7AiiehNJnrTcOpCDvVq/NChQ2l3d7ezr96dnZ20vb09dXy139raSvv7++nOnTtTx6m5IXJY8+yQGwQgAIFyAlXJob8Pzq9sm/bx1eY0krKMbRaBG3KIHJb/80QLCEAAAhCYB4Gq5PDatWvpww8/TK+99trQz+eff/7A97Mto/CVjGkRuLUth99//33a3Nw8+N7Ts2fPDlYQDx8+nPTR/1h4xU+rd/4fjfX19ftWGrWip5U9l2uv+tpiO6/+5fV93V+8EnXnpb6Ui+uwcmhK7CEAAQhAoGYCVclhiRBRt7tXwF2wbVsO9UWVv1bW62UJmeVOdXRsOdO5JFLyprYWPUuk60eBVHuXu36MrzKXWwxd7nzcP3IowmwQgAAEIFA7AeSQ7znsZSW2Lznc2Ng4WBnM5dFfjJI5C5yveS+hizGiHEosLXquH/uI4ulytXcb5NBU2EMAAhCAQM0EkEPkcGnl0Ct38ZWxj3M5lDC6bNjKodq4Tty7fhRBf9FHoUQOTYU9BCAAAQjUTAA5RA6XWg7jKmDTF6Kl0Kt7o1YOm+QvxmwqRw4jIY4hAAEIQGARCCCHyOHSyqG/B1CC1rTFV8IuHyWHTa+N3U77pvIojKwcRlocQwACEIBArQSQQ+RwaeVQX3SSM/8Ais6jMMbjWObXxG7vHzjxD6T4XOVRCF2uPrX5tbZXJZHDARb+AwEIQAAClRMYyKF+d+DRo0fT22+/zQcGndwDp0+fTg8//PBApkq/Jh599NF0/fr1xmZ+LSwhy1f93MB1/H2CcSVRx74uKbTs5YJnwbRQuo2vu69YrrIjR47wAymGwx4CEIAABBaCwEAO33vvvfTkk0+m119/nQ8MOrkH9Ld3n3vuufTRRx8Vf2GMksPiYDRonQB/IaV1pASEAAQgMFcCAznU77W7evUqHxh0eg9oVU2vXks35LCUWL/1kcN+edMbBCAAga4JDOSw606ID4FZCCCHs9Drvi1y2D1jeoAABCDQJwHksE/a9DUVAeRwKmy9NUIOe0NNRxCAAAR6IYAc9oKZTmYhgBzOQq/7tshh94zpAQIQgECfBJDDPmnT11QEkMOpsPXWCDnsDTUdQQACEOiFAHLYC2Y6mYUAcjgLve7bIofdM6YHCEAAAn0SQA77pE1fUxFADqfC1lsj5LA31HQEAQhAoBcCyGEvmOlkFgL6Be1PPPFEeuqpp/hUyOCxxx5LEng2CEAAAhBYDgLI4XLM41KP4sSJE+nTTz9NX375JZ8KGVy6dCm98MILS30PMjgIQAACq0QAOVyl2V7QsfJaue6J47Vy3fNDdhCAAARKCSCHpcSo3zsB5LB35EUdIodFuKgMAQhAoHoCyGH1U0SCyGHd9wByWPf8kB0EIACBUgLIYSkx6vdOADnsHXlRh8hhES4qQwACEKieAHJY/RSRIHJY9z2AHNY9P2QHAQhAoJQAclhKjPq9E0AOe0de1CFyWISLyhCAAASqJ4AcVj9FJIgc1n0PIId1zw/ZQQACECglgByWEqN+7wSGyeHu7m7a2NhI2rPNjwByOD/29AwBCECgCwLIYRdUidkqAeSwVZytB0MOW0dKQAhAAAJzJYAczhU/nU9CYJwcHj58OK2trQ0+29vbg5BNq4pnz55Nm5ubaW9vL92+fXuSrqkzAQHkcAJIVIEABCCwQASQwwWarFVNdZQcrq+vp62trbS/vz/46FiCqHMd7+zsHGDT9Xh+UMDBTASQw5nw0RgCEIBAdQSQw+qmhIRyAqPkMP+ew7g6KBG0OGq18NChQ3x/Yg63hXPksAWIhIAABCBQEQHksKLJIJVmAqPkUMIn8fMWXyfr2OU61utnrSiytUsAOWyXJ9EgAAEIzJsAcjjvGaD/sQSmlUO/WtZqolYReaU8FvVUFZDDqbDRCAIQgEC1BJDDaqeGxExglByOeq2s9hJCrRjqo9VDtvYJIIftMyUiBCAAgXkSQA7nSZ++JyIwSg71Ayn+CWW9XtZPI8cVQglh/KGViTqkUhEB5LAIF5UhAAEIVE8AOax+ikhwlBzqewqPHDnywK+yMTW/Wo7C6DL27RBADtvhSBQIQAACtRBADmuZCfIYSmCYHA5tEAokh7xSDkA6OEQOO4BKSAhAAAJzJIAczhE+XU9GYBY55KeUJ2M8Sy3kcBZ6tIUABCBQHwHksL45IaOMwLRyqO9F1Pcb8oMoGdCWT5HDloESDgIQgMCcCSCHc54Auh9PYFo5HB+ZGm0QQA7boEgMCEAAAvUQQA7rmQsyGUIAORwCppLLyGElE0EaEIAABFoigBy2BJIw3RFADrtj20Zk5LANisSAAAQgUA8B5LCeuSCTIQSQwyFgKrmMHFYyEaQBAQhAoCUCyGFLIAnTHQHksDu2bURGDtugSAwIQAAC9RBADuuZCzIZQuDYsWPpl7/8ZTpz5gyfChm8+uqr6bHHHhsye1yGAAQgAIFFI4AcLtqMrWC+x48fTxcuXEgXL17kUyGDc+fOpaeffnoF70yGDAEIQGA5CSCHyzmvSzUqXivXPZ28Vq57fsgOAhCAQCkB5LCUGPV7J4Ac9o68qEPksAgXlSEAAQhUTwA5rH6KSBA5rPseQA7rnh+ygwAEIFBKADksJUb93gkgh70jL+oQOSzCRWUIQAAC1RNADqufIhJEDuu+B5DDuueH7CAAAQiUEkAOS4lRv3cCyGHvyIs6RA6LcFEZAhCAQPUEkMPqp4gEkcO67wHksO75ITsIQAACpQSQw1Ji1O+dAHLYO/KiDpHDIlxUhgAEIFA9AeSw+ikiwWnkcHd3N21sbCTta9h2dnbS9vb2QSo6jucHBQt4gBwu4KSRMgQgAIERBJDDEXAoqoMAcljHPAzLAjkcRobrEIAABBaTAHK4mPO2UlmPkkOtDK6vr6e1tbXBRyt02rxyePjw4YOyra2ttL+/f8Bub28vbW5uHpTHlTyv9OmaY589ezbpus9jfQWNZYqr+Pl156C2Oo79K7435aly9+V2KldcnR85cmRQ7jK1d33t8xzUZz4exTOruMqqWG5/+/Ztp9W4Rw4bsXARAhCAwMISQA4XdupWJ/Fhcmi5s1TFc0ujBc5llkefu61lzOUWPZf73PFyoVK5ZUoz03TutirXsaTWQhbr57m4vts7d5+rXHnGeHkd56+9NvNRu2H9ue6gwYj/IIcj4FAEAQhAYAEJIIcLOGmrlvIwOZS8eNUsZ5LLm8olUxYqtfWx26rNoUOHBitzeew8noVKcmURs0gqnsstWHl/MRfVj/EVJx+X+lBuqtfUn8cQ97GPfDyqN6w89hXjDTtGDoeR4ToEIACBxSSAHC7mvK1U1sPkMMpNDiTKlstifR3HV7A+9upfLlOKZ3FUPMufRK6pL9VRH9PIodo4n7j3yuAoOVQu8TW7ctCmmD4eXPjxmiU0jk/Heh2vMU6yIYeTUKIOBCAAgcUhgBwuzlytbKZdyWEuSxHwvOXQ0hZz8nGTHEYp9AqmxucxjpPDKLuqq8+kG3I4KSnqQQACEFgMAsjhYszTSmc5TA5zgYuQJEv5r7LJZWmUgOWx48qa+oky1SRrLrdkaW9RU/uYi85jvpI7r2DGMfm4qb88ft5HPp68XOeqoxVDfZTPpBtyOCmp5a93586d9P7776df//rX6b/+67/4wIB7oPJ74MyZM43/3iOHy//v9cKPcJgc5pIUhSzKlgFEIXNbCZG3KFDxWOWj5FDlqh+Frul8Ujn0OGL9KIzO3SuE7j/KrvrXK2nH8LnbNPHRNb2SjnHMZtQeORxFZ7XKJId62Lz++uuDrxndU3xgwD1Q5z1w8eLFdPLkyfTBBx888A8VcvgAEi7URmCYHCpPC42/N88ypOujVg6b2kYpkkzFc8Ub9j2H5mUBUy5RFGNfvq48navLY74WQI/L7VTXZRY9XbNQur5iKx+307Hy18d1YvsYQ3VLNuSwhNZy15Ucvvfee+n8+fPp1q1bfGDAPVDxPfDdd9+lN954I/3hD3944B8m5PABJFyojcAoOawt11rzkfBF2W3KU4JZ+kpZcZDDJpqreU1yqFUICSIbBCBQN4Effvghvfnmm+ny5csPJIocPoCEC7URQA5nn5FJ5FCroyU/peyskEOTYI8ccg9AYHEIIIeLM1dk2kAAOWyAUnhpnBzqNbR/VU5haFYOS4EtcX3kcIknl6EtHQHkcOmmdLUGhBzOPt9/+9vfBt9Xood303blypX07rvvphs3bjQVj7zGyuFIPCtViByu1HQz2AUngBwu+ASuevrIYd13AHJY9/z0mR1y2Cdt+oLAbASQw9n40XrOBJDDOU/AmO6RwzGAVqgYOVyhyWaoC08AOVz4KVztASCHdc8/cljX/HzxxRfpnXfeSR9//HHviSGHvSOnQwhMTQA5nBodDWsgcPz48fThhx+mS5cu8amQwblz59LTTz9dw61CDj/+7s+f/exn6fHHH0//93//1yuTSeQw/52c+r2bpb9bs9dBZZ01/Q7VrErjqced/37RxspTXhTH+PtTS8OMGlvT71ctjT9J/b76mSQX1dF8xV8DNu6H+yaNW0M95LCGWSCHqQkcO3Zs8Is69Se5+NTH4JVXXkmPPfbY1PNLw3YJ6HeWSQwffvjhdPr06V4FcZwcSj70U/FRBi0Ds0hNuwS7iYYcTsbV90OXEj1ZJvdqIYcltKgLgR4J8Fq5R9hTdMVr5SmgddhEcvjqq6+mX/3qV0ni3qcgjpLDmzdvDlZgohgaQ75iZZHyX/PJVxclkkeOHBn8BSDXiTJhwXBZLp7KwWXxVzipnVaJFFvlccVoWK7DYrm+9vl41EZj9t8yV1/OUeNwbtrHcSmW6sVyt4t5xLzj9ThW5xfjKZ/4l5pcR3szjfVjP7ruXFTfY1b/TZvjeSxu6+uxH/+lJ8dxbLeNeYir/hLUCy+8cMBJsfw/JmqTx4vMI6N43W00nvyvTeVjHMVcuTz00EOD/0lyXzE35efrGu+w8ajMHGL/5pffN2YX96wcRhocLxwB5LDuKUMO65ofy+H//M//DL7vsE9BHCWHymuYeESCfuBZFlSmh198YKosnqvcD2+39wMzP9f1KBN6iLqtH6yx75ibjvWw9jhiW5Xl57Gt8/BD20LgPJvax75Urrzy3CUTjqlYMfdRY83jOb/INeZvNmaVt8/HbqlRu3xzXx57PHc/HqfLPC6fu63zcLm55ufOO2+vvOOYm86di/pSv5F5Xn8S5s5F8Zyv4mhzfu7T5T53ucfX1J/rDgKO+A9yOAIORfUTQA7rniPksK75iXJ4/fr1XgVxlBzqh2TiQ7GEmh6QFjK104PRD0edx3I9ZIf1I/HQqo/qx02x9JC1mPhBHev4eNK+XN97P9QdO8ZRnbzc7ZRXHKuva5/nG+tOM9Y8p1F9qSzWH5VLjKPjcXOk+TMn1Y8CpOu5/MSxxpzU1lwVw5s5NZWpTry/8v5iLqobxx3zcF+O5/5j7FgnHsc+8vGoXuSXl/tejvGGHSOHw8hwfSEIIId1TxNyWNf85HLYpyC2LYd60GmVJn/Vlj9g4wMyPljzmVE9rRI5ZtyrXXzQ5219HvuyXDhOFBrX9951XSfGUR337Vhxr/HGTbnGcsfUddcdN9a8f+fQJM/Dypyz+1ffykGbjn19cCH8R3VywXNxHlPXY30dx7H72Kt/+bhy7o6n/Jr6iuU61hhirjEXlccY45irvvrVJ98cx+Nxn4qpOVG5tzjGOD4d61sDVD7JhhxOQok61RJADqudmkFiyGFd89Mkh30J4ig5nPS1smjq4amHZHxATrpymD+84+zEh2q87mM/oIdJjeoNi+GcLSmO6X18iDfFmaRvi5FXRvM2Krd4DMvT+TSVK94scmiR0r8JmjvFa9pGzVE+JrWP9eNxU+x8XDl3xxOnpr5iuY49JsVxme9LnccYed+DBtl/1K/nKLbX/a6xaYtjVMxRcuj6iqm6kkPnOgg24j/I4Qg4FNVPADmse46Qw7rmZ5gc9iGIo+Rw1A+kxAesjnNByR+6+QM2luthbnnKZyb2k5fpfFy56sS+8hgWET/kY7nLLJ55HJc3tVUcl7u9ruX5qq3FIy+LuTS11bU8p9imKV5eX3U0d/qBC+cRY/i4dI6iLI1q2zSGJm7m5LKceby/1F+UwZiL+otc4rHHmu9jbJXl8XUt9pEzdpt4j6uOuOsHqfKx5P3Hc+Qw0uB44Qggh3VPWU1yqL8NrV/+rB/GuHjx4kp+Xn/99fTEE08MGEgI84/4dPVDKqPkUHexHmJaWYsPMD9Q/QD2uR6a2nweV+TyB2x8gDY98GN99R0frI6v/uLxsK+62JfaxFixLG/vvDyuproqi+N0G+UcjxXb51pxckzV01i9jRqr6qjc3B0v9u842ptNXj/2p3o6jznFGD52X+rfm+fI/XhMKm/KM/arup6HnKv7yuO5va7HMTede8x5LjrP8x3H3OP0uGPuuqbzfNVc+Tlfjyey87U4DscftUcOR9GhrHoCyGHdU1STHP7hD38Y/ELuZ599dvDrXPQrXVbto19IfurUqfTJJ588IIYWxa4EcZwc6k72w1QPQH/ig051/IBUuR54foC6Xv6AzYUg7yM+3BVf7d239oofc/P54GL2n7yvYbGyZoNT5a/+1CaP4/qu4/w8ZpWrjXi4TPOssSleLLco6dq4/GK5Vvzi6/tB0B//I6ZeFXT/OVdV9Vyp/qht2Bz5epwDMYh9uY7ziOPNuVqc8nhm5pwdKxcs9+Xrw3KJ8SNTxc3LYt/qP3vvvLYAACAASURBVNbXODWv7s/j0eti55i3V4xJ8srnAznMiXC+UASQw7qnqyY5PH/+/OAXcusnY//4xz+u7Ofzzz8fKoZdCuIkclj33Ux2sxKQCDXJy6xxV7W95VD7UZvkUJ+SDTksoUXd6gggh9VNyX0J1SSHH3zwQfrFL36Rrly5MlaOLEmrvG97BRE5vO9LYyVPJIZxpWwlIbQ46EnkUKujJT+l7PSQQ5Ngv5AEkMO6pw05fPD7+hZJONsUROSw7q/VLrOTxOhVKKuG7VIeJ4cScb1uLl01VJbIYbtzRbSeCSCHPQMv7A45XGw5lMi2JYjIYeEXzxJV1+rVe++9l/7yl78s0ajmPxRx/f3vfz/019N888036cyZM1P9DXXkcP7zSwYzEEAOZ4DXQ1PkcPHlsC1BRA57+IKjCwi0RAA5bAkkYeZDADmcD/dJe0UOl0MO2xBE5HDSrxrqQWD+BJDD+c8BGcxAADmcAV4PTZHD5ZHDWQUROezhC44uINASAeSwJZCEmQ8B5HA+3CftFTlcLjmMgqhfqP3ZZ59NeiscfIO7frfkf//3f/OBAfdAxffAhx9+mJ5//vn0/vvvP/A1vvbAFS5AoDICyGFlE5KlgxwunxxKEC9dupQefvjhwS/kvXXrVjbrzadaidAv8NVfYLlw4QIfGHAPVHwP6Fd/SQ7feuutB76gkcMHkHChNgLD5NC/uZ7fqTXfGUMOl08O9bX129/+Nh0/fjy9/fbbaVI51GtltTt37ly6du0aHxhwD1R8D3z99deD/5nTnxvNN+QwJ8J5dQSGyWF1ia5oQsjhcsmhxFBC+Pjjjx9I3qS3Nt9zOCkp6kFg/gT4nsP5zwEZzEAAOZwBXg9NkcPlkcNZxFC3GnLYwxccXUCgJQLIYUsgCTMfAsjhfLhP2ityuBxyOKsY6n5BDif9qqEeBOZPADmc/xyQwQwEkMMZ4PXQFDlcfDlsQwx1qyGHPXzB0QUEWiKAHLYEkjDzIYAczof7pL0ih4sth22Joe4X5HDSrxrqQWD+BJDD+c8BGcxAADmcAV4PTZHDxZXDNsVQtxpy2MMXHF1AoCUCyGFLIAkzHwLI4Xy4T9orcriYcti2GOp+QQ4n/aqhHgTmTwA5nP8ckMEMBE6cOJE++eST9NVXX/GpkIF+WfILL7wwwwy31/T8+fPpP/7jP9LJkyfTmTNnVvLzxhtvpPfeey998cUXSb/MuunThRhqFieRw/39/bS1tZXW1tYOPjs7O+3dBD1EUr4ag8ayqNukY9jd3U0bGxtJ+6Zt0jhqO67u9vZ20qeWbdzYa8lz2jyQw2nJ0a4KAo888sjgd649+eSTiU99DB577LGk1d0atj/96U8DMXzppZfSa6+9tpIfzcUTTzyRLl++3KsYav7HyaEetuvr6wNJ8P0iUd3c3KxKCpzbsP04yRnWbhGvtylI47jVJoeLOF8lOSOHJbSoWx0BXitXNyX3JVTTa+XvvvsuffPNN0m/+X9VP7/73e/Siy++mPRXD/JVw65WDH1DjJLDmzdvDlbbJAj51iQgqufVRcmjcvcmiXjooYcGoinZVPt8RTKuQKn80KFD6ciRIwcx85U//aUl96d93qf71l65KZ4+bpOPS/27TPs8H+Xt8rxt7EvHMVaeV8zbLNRG1/O65iCW6tMMLOjOJ89VK4eHDx8+yNftzCKej4oV+1Rb5WMOylVxYt+qo0318tVL9SP+KtMWOWgc+djVt8cXOTm+81Adz0fsV8fj7qFRYx8kWdl/kMPKJoR0ygggh2W8+q5dkxz2PfYa+9OK4auvvvqAHOrBNe1fPpl0nKPkUHnlD/hhcfVwjg/3/FwCEcsthhaL/FwPdj38Xe6HuCVAYhGFweWun+epdpIItdOWt1e7KEwWF+0d223z86a+Yiz17fO833jeFFdtPSbH+fLLLwfxdK7N7Hw+jp3jqF3eZx4r1nVcc9BeTJ1f5JDHUZnqD+PgPBxLdeP9Es9dV9e0xXPl6HvW+Tqm65mTzx2nKec4phqOkcMaZoEcpiaAHE6NrpeGyGEvmCfupEkO9eDqWgyV4Cg5fOedd+57QA8bUP6QVb38QasHtB/SKo8Pe8fNH+x+yLs8j+Hr3o8qj5Kj+k05O05ePq7usHbxuo5zJi6Pecdj17e8eAy5HDqO95Gjr8W4jqP4OlZZ3NReK24ad17Xcuf6Ma6veR/b6prq6tqwzbE87mF187gxXhx7PHYd96FzxdF53OLY4/VajpHDWmaCPKYigBxOha23Rshhb6gn6iiXQz2U+xBDJdeGHDY9hBU7ykB8KKus6QGvcfu1Y1PMPIbiqF58vZg/7FVHW97fMOFTPb/KjCuN8fqwPtRPU973MhgupIrtmFGaFcuSlo9B9ZxnLmxNOUR2kYWuO07ce9Uur+s8PaaYu695H/OIc+ty7VUnn79hc+N2cSy+5n3sMx67PLYdN3a3qWmPHNY0G+RSTAA5LEbWawPksFfcYzuLcqgHY19iqMRGyeGkr5WbHsKKrYev5MHHOvcWpcPXokA0xYwPdpVbKryyFssd0/u8v1xAVC45shTl5Y4Tpcxjc5n2TXm7fFhMxTGbWCdeVwydN4mgOThGUw6RTYwTrzvPuB9XN88xto0rgOIWcx81f5FBjOfjUTnHscfjpraj4rh+bXvksLYZIZ8iAshhEa7eKyOHvSMf2aHl8P333+9VDJXUKDkc9QMp8QEejz3QKAa6lj+IJQsWMbeJD/N47PIYo0lKYrnbeB8lR9dizs7VkpmXO0bc5/FcFuP6mvfuR23jluetc/0wiWQq5jSsT8WKPCdhZ1EbFVNxY3k8dv557r7uvdtoPDr2pmO1jZtjDePkuo6pevkWxx6PXc996HxUHNevbY8c1jYj5FNEADkswtV7ZeSwd+QjO5Qc6qeVn3rqqcGvgDp37ly6du3ayDZtFY6SQ/WhB6xWpuKD3QJkwVA9lUfZy8/jQ1n1LQAWhPy89MGu/rTy53g5H5XHfD0GSZX7Vp2Ym+KpPNaN5a4/rq8objoWT41PW37ua+o71tN1j6Hpew4j3xJ2Hlsci/sRl3jsuso55jmMuer4/jHLQcMwFvWhTf3E+YvMHMffg5rnEecvjj0eu9/IyXGGjd1tatojhzXNBrkUE0AOi5H12gA57BX32M4uXryYfvazn6V/+7d/S32KoRIbJ4eq44eoHt7+xAeqB+gHvOpEUVR5fCi7vh/qjhklY9yDvamt+s/7dV8qGyaHqhMlRvmcOnVqUN85SVacp/a+7vj5XuWun0tejJWXKY55x3x1PY4hzzfWHccuxlHcUbFG1VWfWhEcxcLzlM+Lr5uRYqivWE/nLtfeUtqUs3OIY4/HaqNN9VxX56PG7nmI/d6LMr//IofzY0/PLRBADluA2GEI5LBDuFOE1l8TeuaZZ9Lp06d7WzF0mpPIoeuyhwAE5ksAOZwvf3qfkQByOCPAjpsjhx0DLgx/+/btwWqRfgl43xty2Ddx+oPA9ASQw+nZ0bICAshhBZMwIgXkcAScFStCDtud8Nt//Wu6e/Nm+v7SpXT3++/TrYsX051r19L32n/55WB/+/PP0+2PP063r1xJP3z2Wbq1u5vu7O2lW5cupTvffjuoc/e77+6d37x5r/zbb+/FUr3d3UE7tT+IcelS+mFv714/164N6qTvv7+Xh/K5eDHdVQzVu3o13frjH9MPn36afvjf/x3k8sPf/nYv/ldf3at7/fq9vfvf37+Xz9dfp+8/+ijd+eKLdPvPf063P/kkacxs/RBADvvhTC8dEUAOOwLbUljksCWQSxAGOWx3Er//8MN07ec/T/tnztzbv/lmurazk/Zff32wv/7SS+n644+n6889l64/+2y69uST6caLLw7Kbr722mB/45e/vHeuGGr7y1+mb3d20nWXK8YTTxzEuPHEE2n/5ZfT9dDPTfX785+nm87jjTfuxX7llcH++smT6fpTTw1yuPH88+na44+nG7/4xb06P+aqGN8++mja//WvB/ubjvHqq+nao4+m6y+8kK49/fRgLwFm654Actg9Y3rokABy2CHcFkIjhy1AXJIQyGEHE/n99/eC3r492N+9cWOwv/P//p9+Aijd+frrwerinRs30p1vvkl3b98erCqq0t3r1++1vXXrXlvvf7yu1cf0ww/3Yuzvpzv66NsRFPerr+714xju/8d87v4ocFphTOrzm2/SnevX7+Xy1Vfp7o+5DfLwr4lxjO++u5fPt98O9oMYt24NVjoRwwGSXv6DHPaCmU66IoAcdkW2nbjIYTsclyEKcrgMs8gYVoUAcrgqM72k40QO655Y5LDu+ekzO+SwT9r0BYHZCCCHs/Gj9ZwJIIdznoAx3SOHYwCtULHk8Fe/+lV6880301/+8hc+MOAeqPgeuHLlSnr55ZeT/ppSvq3lFziHQG0EkMPaZuT+fJDD+3ms8plWIl555ZV08uTJ9M477/CBAfdAxffAb3/72/Tcc8+lt95664F/tpDDB5BwoTYCyGFtM3J/Psjh/TxW+ezu3bvp888/T59++ungdy3qr0LwgQH3QJ33wNWrV5N+ab7mJ9+Qw5wI59URQA6rm5L7EkIO78PBCQQgAIGFJ4AcLvwULv8AkMO65xg5rHt+yA4CEIBAKQHksJQY9XsngBz2jryoQ+SwCBeVIQABCFRPADmsfopIEDms+x5ADuueH7KDAAQgUEoAOSwlRv3eCSCHvSMv6hA5LMJFZQhAAALVE0AOq58iEkQO674HkMO654fsIAABCJQSQA5LiVG/dwLIYe/IizpEDotwURkCEIBA9QSQw+qniASRw7rvAeSw7vkhOwhAAAKlBJDDUmLU753A0aNHkwRxZ2eHT4UMTpw4MZif3m8MOoQABCAAgU4IIIedYCVomwQkH1988UW6du0anwoZXL58Ob344ottTjmxIAABCEBgjgSQwznCp+vJCPBaeTJO86rFa+V5kadfCEAAAt0QQA674UrUFgkghy3C7CAUctgBVEJCAAIQmCMB5HCO8Ol6MgLI4WSc5lULOZwXefqFAAQg0A0B5LAbrkRtkQBy2CLMDkIhhx1AJSQEIACBORJADucIn64nI4AcTsZpXrWQw3mRp18IQAAC3RBADrvhStQWCSCHLcLsIBRy2AFUQkIAAhCYIwHkcI7w6XoyAsjhZJzmVQs5nBd5+oUABCDQDQHksBuuRG2RwDg53NvbS5ubm2ltbe3gc/bs2RYzINQoAsjhKDqUQQACEFg8Asjh4s3ZymU8Sg4lgZLCKIO7u7tpfX198NdUVg7WHAaMHM4BOl1CAAIQ6JAActghXEK3Q2CYHHrFMIqhe9Q1rSaqjrb9/f20tbV1sLK4vb3tqkkyefjw4cFHoukyi6euSTZVz5v+lJ/axJi65i3vTzFiuestwx45XIZZZAwQgAAEfiKAHP7EgqNKCQyTw1wAh6VvUbP05edNK42KHYUwP5foxRXLWJ7HV16q73g3b94clupCXkcOF3LaSBoCEIDAUALI4VA0FNRCYJgcSri0cicZG7U1SaSEcGNjY7AaGI8Vx3KXr/RJLi2Yed+jVjEVM/aBHI6aLcogAAEIQGDeBJDDec8A/Y8lMKsc5iKnDiVzhw4dapTDYaKnOKVyqPpaYYyvppHDsVNOBQhAAAIQmCMB5HCO8Ol6MgLD5LBpRbAp4jzk0FLolU1WDptmhmsQgAAEIFAjAeSwxlkhp/sIDJPDYSt8ahxlrEkiY3k8VttZXyvHVUkPJPbByqGpsIcABCAAgRoJIIc1zgo53UdgmByqksQv/mCIrknE9MMffgVs2Rt2HsXNHSuuf4DE/cTzfDUyimo8Vlufuz1yaMrsIQABCECgRgLIYY2zQk73ERglh6poGfT39uWyqDoWRNexKLq9fzgldmzxVBuLnctHyaHq5G11rl+to3ZXr151mKXY89PKSzGNDAICEIDAAQHk8AAFB7USGCeHtea9Knkhh6sy04wTAhBYFQLI4arM9AKPEzmse/KQw7rnh+wgAAEIlBJADkuJUb93Ashh78iLOkQOi3BRGQIQgED1BJDD6qeIBJHDuu8B5LDu+SE7CEAAAqUEkMNSYtTvnQBy2Dvyog6RwyJcVIYABCBQPQHksPopIkHksO57ADmse37IDgIQgEApAeSwlBj1eyeAHPaOvKhD5LAIF5UhAAEIVE8AOax+ikgQOaz7HkAO654fsoMABCBQSgA5LCVG/d4JHDt2LL366qvp1KlTfCpkcPLkycEv9+79xqBDCEAAAhDohABy2AlWgrZJ4Pjx4+mjjz5Kf/rTn/hUyOD8+fPpmWeeaXPKiQUBCEAAAnMkgBzOET5dT0aA18qTcZpXLV4rz4s8/UIAAhDohgBy2A1XorZIADlsEWYHoZDDDqASEgIQgMAcCSCHc4RP15MRQA4n4zSvWsjhvMjTLwQgAIFuCCCH3XAlaosEkMMWYXYQCjnsACohIQABCMyRAHI4R/h0PRkB5HAyTvOqhRzOizz9QgACEOiGAHLYDVeitkgAOWwRZgehkMMOoBISAhCAwBwJIIdzhE/XkxFADifjNK9ayOG8yNMvBCAAgW4IIIfdcCVqiwSQwxZhdhAKOewAKiEhAAEIzJEAcjhH+HQ9GYFhcri7u5s2NjaS9mzzI4Aczo89PUMAAhDoggBy2AVVYrZKADlsFWfrwZDD1pESEAIQgMBcCSCHc8VP55MQGCeHhw8fTmtra4PP1tZW2t/fPwi7vb19UKY6Ove2t7eXNjc3D8pjmeuwH08AORzPiBoQgAAEFokAcrhIs7WiuY6Sw/X19QPhs+zt7OwMSEn2oiyePXt2IILaSyBV5rrx/OrVqytKerphI4fTcaMVBCAAgVoJIIe1zgx5HRAYJYf59xxKCIetAFoem+TwoDMOigkgh8XIaAABCECgagLIYdXTQ3IiMKscanXQr521lxxq80qirsUVRqiXEUAOy3hRGwIQgEDtBJDD2meI/KaWQ0uhvq9Qq4Zx5TBi1U876/W0vyfxk08+icUcjyGAHI4BRDEEIACBBSOAHC7YhK1iutOsHPp7CL1KKG7D5NBMVVci+cEHH/gS+wkIIIcTQKIKBCAAgQUigBwu0GStaqqzyGH+Ayd+rWx5dLnY+vsVWTksu9OQwzJe1IYABCBQOwHksPYZIr+pXyvH18WSwlOnTg2+t9A/sJKX+/sO79y5A/UCAshhASyqQgACEFgAAsjhAkzSqqc4bOVw1bnUMn7ksJaZIA8IQAAC7RBADtvhSJQOCSCHHcJtITRy2AJEQkAAAhCoiAByWNFkkEozAeSwmUstV5HDWmaCPCAAAQi0QwA5bIcjUTokgBx2CLeF0MhhCxAJAQEIQKAiAshhRZNBKs0EkMNmLrVcRQ5rmQnygAAEINAOAeSwHY5E6ZAActgh3BZCI4ctQCQEBCAAgYoIIIcVTQapNBNADpu51HIVOaxlJsgDAhCAQDsEkMN2OBKlQwLHjx9P7777brpw4QKfChn85je/SU899VSHdwChIQABCECgTwLIYZ+06WsqAseOHUtnzpxJ586d41Mhg9OnT6fHH398qrmlEQQgAAEI1EcAOaxvTsgoI8Br5QxIZae8Vq5sQkgHAhCAwIwEkMMZAdK8ewLIYfeMZ+kBOZyFHm0hAAEI1EcAOaxvTsgoI4AcZkAqO0UOK5sQ0oEABCAwIwHkcEaANO+eAHLYPeNZekAOZ6FHWwhAAAL1EUAO65sTMsoIIIcZkMpOkcPKJoR0IAABCMxIADmcESDNuyeAHHbPeJYekMNZ6NEWAhCAQH0EkMP65oSMMgLIYQakslPksLIJIR0IQAACMxJADmcESPPuCSCH3TOepQfkcBZ6tIUABCBQHwHksL45IaOMQN9yuLu7mzY2NpL2o7a9vb20ubmZzp4921htXHlsNK7uzs5O2traSvv7++nOnTux6dyPkcO5TwEJQAACEGiVAHLYKk6CdUGgbzmcdAzjhG7SOKo3LhZyWEKTuhCAAAQgMAsB5HAWerTthcAoOdTq3vr6elpbWxt8JFHeLFx5mVbftAoX66rN9vb24Fq+cqh6jqG+vKLo+Grncq0k6ro2l3tl0f26rlcCm+q6reqqz8OHD7NyOKDKfyAAAQhAoGsCyGHXhIk/M4FhcmiBsnzFcx9bAPNzXc/l7NChQwPxi3Ko2FH44rljOo7lT7KozeVq4zLno3LVa6rrdq5rAXY/vFae+ZYiAAQgAAEIjCCAHI6AQ1EdBIbJYS54Mdumsih2UQDVTmWWr1gW28T4OrbEqY632G8sj/FdV+UW0rxuFFLVj3GRQxNkDwEIQAACXRBADrugSsxWCQyTw7jylnfYVCbpk4xJxPKVPNWXgGmLcuh6fhUcRTAKnfuPEhfLdd0x4t6vqfO6FlXHjXKJHJoKewhAAAIQ6IIActgFVWK2SqALOVSCFjn9tK1X8HQ9ymEciATS3wOoOlHoXM8xJZWxPF533bgfVxc5jLQ4hgAEIACBLgkgh13SJXYrBIbJ4SjhaiqTYMXXtZbAhx566OCVshL2de3zzSuJih+FzvViv7E879v1vR9XN8Zl5dDU2EMAAhCAQBcEkMMuqBKzVQLD5DAKlTpsEjdJlTbX9Xmsr9VArQp6i3KYS10sc0zV8RYlLpY7t9hPjN1U17mqT71+9qtm5NC02UMAAhCAQBcEkMMuqBKzVQLD5FCdWJz8fXxRvixcLrNsxeR0TeVR8KIAqq5fJzuO6zq+z1V3mByqzPUdJ65iusyxfK66qnfkyBHkME4cxxCAAAQg0BkB5LAztARui8AoOWyrD+JMT4C/kDI9O1pCAAIQqJEAcljjrJDTfQSQw/twVHeCHFY3JSQEAQhAYCYCyOFM+GjcBwHksA/K0/eBHE7PjpYQgAAEaiSAHNY4K+R0HwHk8D4c1Z0gh9VNCQlBAAIQmIkAcjgTPhr3QQA57IPy9H0gh9OzoyUEIACBGgkghzXOCjndRwA5vA9HdSfIYXVTQkIQgAAEZiKAHM6Ej8Z9EEAO+6A8fR/I4fTsaAkBCECgRgLIYY2zQk73EThx4kS6cuVK+vzzz/lUyOD3v/99eu655+6bM04gAAEIQGBxCSCHizt3K5P50aNHB/Lx/PPPJz71MXjqqaeSVnfZIAABCEBgOQggh8sxj0s9Cl4r1z29vFaue37IDgIQgEApAeSwlBj1eyeAHPaOvKhD5LAIF5UhAAEIVE8AOax+ikgQOaz7HkAO654fsoMABCBQSgA5LCVG/d4JIIe9Iy/qEDkswkVlCEAAAtUTQA6rnyISRA7rvgeQw7rnh+wgAAEIlBJADkuJUb93Ashh78iLOkQOi3BRGQIQgED1BJDD6qeIBJHDuu8B5LDu+SE7CEAAAqUEkMNSYtTvnQBy2Dvyog6RwyJcVIYABCBQPQHksPopIsGa5HB3dzdtbGwk7dnuEUAOuRMgAAEILBcB5HC55nMpR1OTHC4l4BkHhRzOCJDmEIAABCojgBxWNiGk8yCBJjn84Ycf0tbWVtrZ2bmvwfb29sG1s2fPprW1tYPP5uZm2tvbO6iv1b/19fWD8hhrWFlcOVSsQ4cOpYceeuggRt7H/v7+IE/noZx1bZk25HCZZpOxQAACEEgJOeQuqJ5AkxwqaclclC3LmgROYijx07E2lUncJI/xXPXyc9dtKsvlUDGdg0XQffg8SqfKXD7oeAn+gxwuwSQyBAhAAAKBAHIYYHBYJ4FhchhFTZlL5ixqTSOJYpaLZaw/qiz2mUukYsS2TflEgb1582bsdmGPkcOFnToShwAEINBIADlsxMLFmggMk8N8ZU7yF1fpNAbJXHx17FW7KIr5WEeVlcihcvHr5Lj3iiZymJPnHAIQgAAEaiCAHNYwC+QwksAwOVQjr9Rp9Urf/yd50xal0K+Ho/TF47zzUWWlcjhqJTPvd1HPWTlc1JkjbwhAAALNBJDDZi5crYjAKDm0rOmHQqKISRoleXGL0mepbPrhkFFl7k/7SV4r5z+gEvNZlmPkcFlmknFAAAIQuEcAOeROqJ7AKDn0q2W9to0ymAuezmOdXOwcR/VGlZXIoWPGvLSKaWG8fft29ewnSRA5nIQSdSAAAQgsDgHkcHHmamUzHSWHgmLx8+tjXbOY+Xv9JGiqZzFTHYle0/cjjiorkUPFsWg6j9i/ypdhQw6XYRYZAwQgAIGfCCCHP7HgqFIC4+Sw0rRXJi3kcGWmmoFCAAIrQgA5XJGJXuRhIod1zx5yWPf8kB0EIACBUgLIYSkx6vdOADnsHXlRh8hhES4qQwACEKieAHJY/RSRIHJY9z2AHNY9P2QHAQhAoJQAclhKjPq9E0AOe0de1CFyWISLyhCAAASqJ4AcVj9FJIgc1n0PIId1zw/ZQQACECglgByWEqN+7wSQw96RF3WIHBbhojIEIACB6gkgh9VPEQlKDq9du5bu3r3Lp0IGyCFfoxCAAASWiwByuFzzuZSjOXr0aHrkkUf4VMxAAs8GAQhAAALLQQA5XI55XOpRnDhxIn399dfp1q1bfCpk8PHHH6eXXnppqe9BBgcBCEBglQggh6s02ws6Vr7nsO6J47Vy3fNDdhCAAARKCSCHpcSo3zsB5LB35EUdIodFuKgMAQhAoHoCyGH1U0SCyGHd9wByWPf8kB0EIACBUgLIYSkx6vdOADnsHXlRh8hhES4qQwACEKieAHJY/RSRIHJY9z2AHNY9P2QHAQhAoJQAclhKjPq9E0AOe0de1CFyWISLyhCAAASqJ4AcVj9FJIgc1n0PIId1zw/ZQQACECglgByWEqN+7wSQw96RF3WIHBbhojIEIACB6gkgh9VPEQkih3XfA8hh3fNDdhCAAARKCSCHpcSo3zsB5LB35EUdIodFuKgMAQhAoHoCyGH1U0SCyGHd9wByWPf8kB0EIACBUgLIYSkxmmopHgAAAfRJREFU6vdOADnsHXlRh8hhES4qQwACEKieAHJY/RSRIHJY9z2AHNY9P2QHAQhAoJQAclhKjPq9E0AOe0de1CFyWISLyhCAAASqJ4AcVj9FJIgc1n0PIId1zw/ZQQACECglgByWEqN+7wSQw96RF3WIHBbhojIEIACB6gkgh9VPEQkOk8O9vb20ubmZzp49C6Q5EkAO5wifriEAAQh0QAA57AAqIdslMEwO2+2FaNMSQA6nJUc7CEAAAnUSQA7rnBeyCgSQwwCjwkPksMJJISUIQAACMxBADmeAR9N+CCCH/XCethfkcFpytIMABCBQJwHksM55IatAADkMMCo8RA4rnBRSggAEIDADAeRwBng07YcActgP52l7QQ6nJUc7CEAAAnUSQA7rnBeyCgSQwwCjwkPksMJJISUIQAACMxBADmeAR9N+CCCH/XCethfkcFpytIMABCBQJwHksM55IatAADkMMCo8RA4rnBRSggAEIDADAeRwBng07YfA0aNH08mTJ9PLL7/Mp0IGzz77bJLAs0EAAhCAwHIQQA6XYx6XehS/+93v0uXLl5NWqPjUx0Dzow8bBCAAAQgsBwHkcDnmkVFAAAIQgAAEIACBVgggh61gJAgEIAABCEAAAhBYDgLI4XLMI6OAAAQgAAEIQAACrRD4/1cIdg72Q0hoAAAAAElFTkSuQmCC)\n",
        "\n",
        "![image.png](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAokAAAFNCAYAAABsRvUeAAAgAElEQVR4Ae2d25LU1tWA+4VSPERS6SdI1dznom/zArnhKte58E2Kw4wnnIw5DIRzsHHGnAw2zgEGcApSwaECk5RT4MFFM+y/VuffZI+Q1K2traUl6esqVXdLe6+19C018yFNa0aOBwQ6QODEiRPus88+c9euXWMxyODixYtOesQDAhCAAAT6Q2DUn11hT/pMYHl52d28edPduXOHxSADEfjDhw/3+RBk3yAAAQgMjgCSOLiWd3OHP/zwQ/fy5ctuFj+Aqv/+97+706dPD2BP2UUIQAACwyGAJA6n153eUyTRdvuQRNv9oToIQAACMQSQxBhqzFEngCSqI6+UEEmshIvBEIAABDpBAEnsRJsoEkm0fQwgibb7Q3UQgAAEYgggiTHUmKNOAElUR14pIZJYCReDIQABCHSCAJLYiTZRJJJo+xhAEm33h+ogAAEIxBBAEmOoMUedAJKojrxSQiSxEi4GQwACEOgEASSxE22iSCTR9jGAJNruD9VBAAIQiCGAJMZQY446gSJJ3NzcdOPx2I1Gox3Lrl273MbGhnqdQ02IJA618+w3BCDQZwJIYp+726N9K5PEpaWl94RwfX3dIYp6BwCSqMeaTBCAAAS0CCCJWqTJU4tAVUmUZKurq24ymbitrS23vb1dKz+TywkgieV82AoBCECgiwSQxC52bYA1x0iiXG6Ws4xySXo6nQ6Qmt4uI4l6rMkEAQhAQIsAkqhFmjy1CMRIosihvxT96tWrWvmZXE4ASSznw1YIQAACXSSAJHaxawOsGUm03XQk0XZ/qA4CEIBADAEkMYYac9QJxEgil5v12oQk6rEmEwQgAAEtAkiiFmny1CIQI4l8caUW8kqTkcRKuBgMAQhAoBMEkMROtIkiq0oit8DRPWaQRF3eZIMABCCgQQBJ1KBMjtoEyiQx72bask6+uMJDhwCSqMOZLBCAAAQ0CSCJmrTJFU2gSBKjAzIxKQEkMSlOgkEAAhAwQQBJNNEGiphHAEmcR6jd7Uhiu/zJDgEIQKAJAkhiE1SJmZwAkpgcadKASGJSnASDAAQgYIIAkmiiDRQxjwCSOI9Qu9uRxHb5kx0CEIBAEwSQxCaoEjM5ASQxOdKkAZHEpDgJBgEIQMAEASTRRBsoYh4BJHEeoXa3I4nt8ic7BCAAgSYIIIlNUCVmcgJIYnKkSQMiiUlxEgwCEICACQJIook2UMQ8AsvLy+7u3bvur3/9K4tBBl988YU7evTovDayHQIQgAAEOkQASexQs4Zc6v79+92ZM2fchQsXWAwyOHnypJM/g8gDAhCAAAT6QwBJ7E8ve70nXG623V4uN9vuD9VBAAIQiCGAJMZQY446ASRRHXmlhEhiJVwMhgAEINAJAkhiJ9pEkUii7WMASbTdH6qDAAQgEEMASYyhxhx1AkiiOvJKCZHESrgYDAEIQKATBJDETrSJIpFE28cAkmi7P1QHAQhAIIYAkhhDjTnqBJBEdeSVEiKJlXAxGAIQgEAnCCCJnWgTRSKJto8BJNF2f6gOAhCAQAwBJDGGGnPUCSCJ6sgrJUQSK+FiMAQgAIFOEEASO9EmipwniZubm248HrvRaPRu4ebOescNkqjHmkwQgAAEtAggiVqkyVOLQJkkrq+vz8QwlMKtrS03mUxmi7zm0SwBJLFZvkSHAAQg0AYBJLEN6uSsTKBIEv0ZRBHF7MOLYiiP2TG8T0MASUzDkSgQgAAELBF4J4nHjh1zFy9edDdu3GCBgfox8Omnn7rr1687kb68R5EkihzKZeaiebJdziiKMG5vb+eFZl0CAkhiAoiEgAAEIGCMwDtJvHTpktuzZ4+TH6osMNA+Bo4ePerkjN/9+/dzPyJFkihzvATmTdzY2HBLS0sziZxOp3lDWJeAAJKYACIhIAABCBgj8E4S5QyiiMH333/PAgP1Y+DevXvu3Llz7sGDB7kfESQxF4uZlUiimVZQCAQgAIFkBJBEhFBdCPP+IxIrifIfGy43J/v3IDoQkhiNjokQgAAEzBJAEpHETksiX1yx8W8LkmijD1QBAQhAICUBJBFJ7LQkyodBzibK/RHDbzH7bzaX/b5iyg/S0GMhiUM/Ath/CECgjwSQRCSx85IoH0x/RpGbabfzzxSS2A53skIAAhBokgCSiCT2QhKb/JAQez4BJHE+I0ZAAAIQ6BoBJBFJRBK79qk1WC+SaLAplAQBCECgJgEkEUlEEmt+iJjuHJLIUQABCECgfwSQRCQRSezf51p9j5BEdeQkhAAEINA4ASQRSUQSG/+Y9T8Bktj/HrOHEIDA8AggiUgikji8z33yPUYSkyMlIAQgAIHWCSwsifJD4Gc/+5m7c+dOtFTs3bvX/fznP5/driTvr25UWffLX/7SybLInCpjs/Fkv3/yk584+dvW2W0p3qfg6uuoGqtKP6qM9fWEz/N6EPsXV1r/BFHAjIAce6dPn4YGBCAAAQj0iICqJIbSUPf1POkI41cZG86T10jif/+WtwVJfP78uXv58iWLQQYPHz50a2trPfqnkV2BAAQgAIGFJFF+OMvZNH+jYjmrJmcUf/GLX8wWWS8iJlIlz35cuF62haIhr2W+nFn042VdVtKK3mfFryyvbJM8fh9+9KMfvXdGVHL7OsLti0hiOFdyyBypW54l769+9atZ7OxZVB/b5/VnK7PrpX7PoWhbdr2P5eflPUvdYU0yx9ciz+G+yFg5kyyLH5PNkZ0fbs/2K1vPvDOJ+/btcysrK+7DDz9kMcjA94Z/UiEAAQhAoD8EFpJE+YEuEhJebhZJFJkSefA/8L2MyV+/kHVeGrwshFIir0U2/DZ5DuXMxyx6DqVjXl7ZXpYrrMvX7QXJy5evM1uPzPVjZVv43s+V/Nl5/n2Wq5/j8wlLETmJG76W+dn32Vg+R9FzuN9Z/r4OX7uMFYbyLPF8/32d8hxykO0//vGP38m4xPGx8uqZJ4kih3IWkYdNAnK8cLnZZm+oCgIQgEAsgVqSGEpA3g9+LxpeJEIpCV/L3OzYvHjhujLpyMbKjg3lSsaG8utzyBypMRvLb5fnvG3Z2CJOfv/Duf51Nr/kzMqUCJfUKJf0vDD6+eFzNla4Le91tgfZMSG3vLF+u9/n7H6G++LHZnP490hi7EfYxjw59pBEG72gCghAAAKpCDQiiSIH/pJkeAYvFI3wtYhCnnB5gch7zpOOorwyVraFcfx8f0YsrNe/ljlldWXPlvn4Pl/ZXD9WxoSSKnN9/vDZn6UTEfPrw0vFEi8by+coes72QMZleUg9sl7G+tc+np8v8ir1+brCZz9Hnv1rPz98RhJTfaTbiSPHHpLYDnuyQgACEGiKQFJJFGkQQfBCk5UkLxVy5il8LbKQHRsKRN7rUDrm5ZWxMiaM4+cXiZ4fW1ZX0Vyfr2xuGD8riTLfby96DmXOj5d8YayiuX592IMwnj8j6BnJeBnr82Tne0n08/z28DmMFa73r5HEpj7iOnHl2EMSdViTBQIQgIAWgWSSmHfJMStJoZSEr0UUsmO9PBQ9e+lYJK8f62P5OVLDvLxl2/O2VYnt9zsUuywXX3PRs4hZKOVhrKI5fn2YS15nJTDkFo718/32cJ/9tuyzH5td798jiVof+WbyyGcBSWyGLVEhAAEItEUguSSKTMgPfi8OcmbRn2EKRSN8LePzhMsLRN6zlw6fpyyvjA2/FCNjvVhJ7Oz7sJbwdV4d2bnh+3lzJZ6MCcXOz5E4Pp+8lkvLT548ee93Ej2HvFh+ftGzjysMw9cyXt5L7yR++N73Up5Dptn32b6EdebVgyS29U9Amrxy3CKJaVgSBQIQgIAVAgtLovxglx/0Ig4iEHmXWsNLljLu1KlTM6kJRcP/Hl1WSrwceQnJE4lwXSgd8/LKWLkNjf+9uVBufEy/b1K3LL6OReryQiXzQvlcZG6Wq7zP7o9nNm9bXixZV7SEPfBS5/dfeMh2vz/yOnvLIs/Ixw85SBx577eF/fLrwmck0co/CXF1IIlx3JgFAQhAwDKBSpIY/lDndbF8waY6GyTR8j8T82tDEuczYgQEIACBrhFAEkvOtCF71WUvllldSZQzoePxeHYW2J8NXV1d7drnsbP1IomdbR2FQwACECgkYFISs5d+/Q99/xxexoyVkr7P6xrDOpK4vr4+k8NQCre2ttxkMpkt8ppHswSQxGb5Eh0CEIBAGwRMSqIXhnPnzrm85dGjR+9+163vshe7f11j6Ot98OBB7ueg6C+u+DOIIorZhxfFUB6zY3ifhgCSmIYjUSAAAQhYImBSEmPFiHl6l4dTs46VRJFDucwsspj3kO1yRlGEcXt7O28I6xIQQBITQCQEBCAAAWMEkER+J9HEWdlYSZSzhF4C8z5bGxsbbmlpaSaR0+k0bwjrEhBAEhNAJAQEIAABYwSQRCQRSTT2oexiOUhiF7tGzRCAAATKCSCJSGKnJZHLzeUfcK2tSKIWafJAAAIQ0COAJCKJnZZEvrii949FWSYksYwO2yAAAQh0kwCSiCR2WhLlYydnE+X2SOG3mP03m8t+X7GbH1mbVSOJNvtCVRCAAATqEHgnifIn1vbt2+euXbvGAgP1Y+D48ePut7/9rbt//37u8Vx0Cxw/2J9R9PfSzEqjH8dzMwSQxGa4EhUCEIBAmwTeSeKtW7fc4cOH3fnz51lgoH4MiCRevnzZPXv2LPfzME8ScyexUo0AkqiGmkQQgAAE1Ai8k0S5793z589ZYNDaMfDy5Uv39u3b3IMfSczFYmYlkmimFRQCAQhAIBmBd5KYLCKBINAAASSxAagJQyKJCWESCgIQgIARAkiikUZQRjkBJLGcT9tbkcS2O0B+CEAAAukJIInpmRKxAQJIYgNQE4ZEEhPCJBQEIAABIwSQRCONoIxyAkhiOZ+2tyKJbXeA/BCAAATSE0AS0zMlYgMEkMQGoCYMiSQmhEkoCEAAAkYIIIlGGkEZ5QSQxHI+bW9FEtvuAPkhAAEIpCeAJKZnSsQGCMiN3g8dOuSOHDnCYpDBgQMHnIg8DwhAAAIQ6A8BJLE/vez1nqysrLhvv/3W/etf/2IxyODevXvuxIkTvT4G2TkIQAACQyOAJA6t4x3dXy43224cl5tt94fqIAABCMQQQBJjqDFHnQCSqI68UkIksRIuBkMAAhDoBAEksRNtokgk0fYxgCTa7g/VQQACEIghgCTGUGOOOgEkUR15pYRIYiVcDIYABCDQCQJIYifaRJFIou1jAEm03R+qgwAEIBBDAEmMocYcdQJIojrySgmRxEq4GAwBCECgEwSQxE60iSKRRNvHAJJouz9UBwEIQCCGAJIYQ4056gTmSeLm5qYbj8duNBq9W1ZXV9XrHGpCJHGonWe/IQCBPhNAEvvc3R7tW5kkrq+vz8QwlMKtrS03mUxmi7zm0SwBJLFZvkSHAAQg0AYBJLEN6uSsTKBIEv0ZRBHF7MOLYiiP2TG8T0MASUzDkSgQgAAELBFAEi11g1oKCRRJosihXGYWWcx7yHY5oyjCuL29nTeEdQkIIIkJIBICAhCAgDECSKKxhlBOPoEiSZSzhF4C82ZubGy4paWlmUROp9O8IaxLQABJTACREBCAAASMEUASjTWEcvIJIIn5XKysRRKtdII6IAABCKQjgCSmY0mkBgkUSSKXmxuEXiE0klgBFkMhAAEIdIQAktiRRg29zCJJ5IsrNo4MJNFGH6gCAhCAQEoCSGJKmsRqjECRJEpCOZso90cMv8Xsv9lc9vuKjRU7wMBI4gCbzi5DAAK9J4Ak9r7F/djBMkmUPfRnFLmZdjv9RhLb4U5WCEAAAk0SQBKbpEvsZATmSWKyRASKIoAkRmFjEgQgAAHTBJBE0+2hOE8ASfQkbD4jiTb7QlUQgAAE6hBAEuvQY64aASRRDXVUIiQxChuTIAABCJgmgCSabg/FeQJIoidh8xlJtNkXqoIABCBQhwCSWIcec9UIIIlqqKMSIYlR2JgEAQhAwDQBJNF0eyjOE0ASPQmbz0iizb5QFQQgAIE6BJDEOvSYq0YASVRDHZUISYzCxiQIQAACpgkgiabbQ3GeAJLoSdh8RhJt9oWqIAABCNQhgCTWocdcNQL79+93v//9792VK1dYDDI4e/asO3DggNrxQCIIQAACEGieAJLYPGMyJCCwvLzs7ty54+7evctikMHVq1fdRx99lKDThIAABCAAASsEkEQrnaCOUgJcbi7F0/pGLje33gIKgAAEIJCcAJKYHCkBmyCAJDZBNV1MJDEdSyJBAAIQsEIASbTSCeooJYAkluJpfSOS2HoLKAACEIBAcgJIYnKkBGyCAJLYBNV0MZHEdCyJBAEIQMAKASTRSieoo5QAkliKp/WNSGLrLaAACEAAAskJIInJkRKwCQJIYhNU08VEEtOxJBIEIAABKwSQRCudoI5SAkhiKZ7WNyKJrbeAAiAAAQgkJ4AkJkdKwCYIIIlNUE0XE0lMx5JIEIAABKwQQBKtdII6SgnkSeKbN2/cZDJxo9EodxmPx25zc9NNp9PS2GysTwBJrM+QCBCAAASsEUASrXWEenIJ5EliduDq6qrbvXt3djXvFQggiQqQSQEBCEBAmQCSqAycdHEEkMQ4blqzkEQt0uSBAAQgoEcASdRjTaYaBJDEGvAUpiKJCpBJAQEIQECZAJKoDJx0cQSQxDhuWrOQRC3S5IEABCCgRwBJ1GNNphoEkMQa8BSmIokKkEkBAQhAQJkAkqgMnHRxBJDEOG5as5BELdLkgQAEIKBHAEnUY02mGgSQxBrwFKYiiQqQO5Jie3vb3b5923366afuD3/4AwsMOAaMHwNXrlxxGxsbuf/CIIm5WFhpjQCSaK0jO+tBEnfyGPI7kUT5oXP+/PnZDx754cMCA44Bm8fA3bt33dramvvyyy9z/9lCEnOxsNIaASTRWkd21oMk7uQx5Hciibdu3XI3b950r1+/ZoEBx4DhY+CHH35wly5dcvfv38/9ZwtJzMXCSmsEFpFEazUPqR4kcUjdLt9XkUQ5KyGiyAMCELBNQP5y2eXLl93Dhw9zC0USc7Gw0hoBJNFaR3bWgyTu5DHkd0jikLvPvneNAJLYtY5Rby4BJDEXi5mVSKKZVrReCJLYegsoAAILE0ASF0bFQMsEkETL3XEOSbTdH83qkERN2uSCQD0CSGI9fsw2QgBJNNKIgjKQxAIwA1yNJA6w6exyZwkgiZ1tHYWHBJDEkIa910iivZ60VRGS2BZ58kKgOgEksTozZhgkgCQabEpQEpIYwDDw8tmzZ+7GjRvu0aNH6tUgierISQiBaAJIYjQ6JloisLy87L7++mt37949FoMMrl696j766CNLh8yga5EbF3/wwQfu4MGD7p///KcqizJJfPXqlZtMJm40Gr23rK+vL1Tn6urqjrnj8dhtbm6amyv7k7effp3sR9FD9kf2y4+V57LxRXFYD4F5BJDEeYTY3gkC+/fvn93wU/7UF4s9BmfOnHEHDhzoxLE0hCLlnmciiHv27HEXL15UFcVFJDErhCK1u3btctn1Ya+2trZmgpmVQi9jFuf6+kX6lpaWCv/0mR8nz35/Qin0+y6CLa95QCAVASQxFUnitEqAy82t4p+bnMvNcxGpDhBJPHv2rPvkk0+cCLymKMZIosAROcoKYAhNpKlIkqzO9fUvKon+DGKe8HpRDOXRx+cZArEEkMRYcswzRQBJNNWO94pBEt9D0uoKL4l//vOfZ7+XqCmKsZJYJlLzBMlvj5GrpuaGB0DZvoXj5smubPei/Pbt23AqryEQRQBJjMLGJGsEkERrHdlZD5K4k0fb70JJfPnypaooxkpimayVnWHzrHfv3p37e3ttzfV1yfOiklh2tlTiyGV5uWwt8YQzDwjUJYAk1iXIfBMEkEQTbSgsAkksRNPKhqwkaooikvh+y5HE95mwxgYBJNFGH6iiJgEksSbAhqcjiQ0Drhg+TxK1RDFWEstEyp9lLPp9PL+dy80VDxSGD54Akjj4Q6AfAJBE231EEm31p0gSNUQxVhLn/T5e2aVYq3P9UVEmwH6MPMs4+fJOjOyGcXgNgUUJIImLkmKcaQJIoun2mPrbzd9///3sd/DkSxt3794d5HL+/Hl36NAhJwxEDLOL3GS7qS+zxEgit8D53+dbBDF7X0R/ptR/aeV/o3kFgXoEkMR6/JhthACSaKQRBWVYOpN4//792Y29P/7449ltYORWMENb5MbmFy5ccE+ePHlPEL0wNiWKi0hieJNoeS33SBRRXOQhZxTD+WW3zcnGa2vuomcSfb3+jGK4n0WX2v0cniEQQwBJjKHGHHME5kki/6i22zJLknjz5s3Zjb3lz9I9ePBgsMvTp08LBbFJUSyTxHaPUrJDAAJZAkhilgjvO0mgTBK5PNN+Sy1J4pdfful+97vfucePH8+VJC9LQ35OfUYRSWz/80gFEFiUAJK4KCnGmSZQJIn+DCK/6N1u+5DE93/vr0vimVIUkcR2P4tkh0AVAkhiFVqMNUugSBJFDst+J0m2+1/2lh9ePJohgCR2WxJFaFOJIpLYzGeMqBBoggCS2ARVYqoTKJLEsttiSJHhXyiYTqfqdQ8lIZLYfUlMJYpI4lA+9exnHwggiX3oIvvgkETbBwGS2A9JTCGKSKLtzyrVQSAkgCSGNHjdWQJFksjlZhstRRL7I4l1RRFJtPGZpAoILEIASVyEEmPMEyiSRL64YqN1SGK/JDEURbkx9z/+8Y+FDzT/Q0fuTfmnP/2JBQYcA4aPga+//todP37c3b59O/czPspdy0oIGCNQJIlSppxNlJvOhjeb5S8U6DYQSeyfJIoo3rt3z+3Zs2d2Y+7Xr18vdFCJJMqNvOUvuty5c4cFBhwDho8BuWWYSOLnn3+e+/lGEnOxsNIagTJJlFr9GUX+QkE7nUMS+yeJ8pm6fv26W15edteuXXOLSqJcbpZ5V69edS9evGCBAceA4WPgu+++m/2nTv6EZ94DScyjwjpzBOZJormCB1YQktgvSRRBFDE8ePDgO9lb9JDmdxIXJcU4CLRPwP96yMOHD3OLQRJzsbDSGgEk0VpHdtaDJPZHEusIohwVSOLOzwbvIGCZAJJouTvUtjABJHFhVK0MRBL7IYl1BVEOPiSxlY8gSSEQRQBJjMLGJGsEkERrHdlZD5LYfUlMIYhyVCCJOz8bvIOAZQJIouXuUNvCBJDEhVG1MhBJ7LYkphJEOfiQxFY+giSFQBQBJDEKG5OsEUASrXVkZz1IYnclMaUgylGBJO78bPAOApYJIImWu0NtCxNAEhdG1cpAJLGbkphaEOXgQxJb+QiSFAJRBJDEKGxMskZgZWXFPXnyxP373/9mMchAbrp84sQJE4fNzZs33W9+8xu3trbmrly5Msjl0qVL7tatW+7Zs2dOboqdtzQhiHIAlEniq1ev3GQymd38PrynqbyWm+Iv8pCb5odzx+Px7D6pRXP9zfbDOeHr8Cb8EsPfiD8cE76umm/Xrl1uY2OjqDzWQ6BVAkhiq/hJnorA3r17Z/dsO3z4sGOxx+DAgQNOzvZaeHzzzTczQTx16pQ7d+7cIBfpxaFDh5zc+0xTEKX/i0hiVghFokSmsuvD48nLW1bSvASWzfVxRIyXlpYqSZtI5O7du32I0mcZl5VCv29ZGS0NxEYIKBFAEpVAk6ZZAlxubpZv3eiWLjf/8MMP7j//+Y+TvyQw1OWrr75yJ0+edPJXFLKS2NQZRH8MxUiizBXJywqgjynPIllyFlJkMfuYN9ePb1ISy2oQUfzpT39aSU59zTxDoEkCSGKTdImtRgBJVEMdlciSJEbtQM8myRnEs2fPvieJTQuiYIyVxDKB82cRi87G+e3zziaW5Sg6BBY9kyhnEcvOOMq2ovqLcrMeAk0TQBKbJkx8FQJIogrm6CRIYjS6RibmSaKGIMrOxEpimehJ7XKWsUwCF5GwpiTR114mgYvKZiMHBEEhUEAASSwAw+puEUASbfcLSbTVn6wkagmiUEAS848FJDGfC2vbJYAktsuf7IkIIImJQDYUBklsCGxk2FASNQVRyo2VxLKzfPPO1PntZWcapbayHEWoF5U7LjcXEWS9ZQJIouXuUNvCBJDEhVG1MhBJbAV7YVIvibdv33bXrl2b3Rng6tWr7sWLF4VzUm2IlcSyL35IbSJrfHElVZeIA4H/EkASORJ6QQBJtN1GJNFWf0QS5dvNR44cURVEoRAjif42MWVnAv3Zwuw3oGWO3MewbK7vTpNnEiWHnE3kFjieNs9dIIAkdqFL1DiXAJI4F1GrA5DEVvG/l/zu3bvugw8+cL/+9a+d1hlEX8QikhjenFpeZ8XKx8p7ljOK4fysNObN8eualkTJ46XV11hl33ydPENAiwCSqEWaPI0SQBIbxVs7OJJYG2HSAPLXiY4ePeouXryocok5LL5MEsNxvIYABNongCS23wMqSEAASUwAscEQSGKDcCNCT6fT2Zc05Gbi2g8kUZs4+SAQTwBJjGfHTEMEkERDzcgpBUnMgTLQVUjiQBvPbneSAJLYybZRdJYAkpglYus9kmirH21WgyS2SZ/cEKhGAEmsxovRRgkgiUYb8/9lIYm2+6NZHZKoSZtcEKhHAEmsx4/ZRgggiUYaUVAGklgAZoCrkcQBNp1d7iwBJLGzraPwkACSGNKw9xpJtNeTtipCEtsiT14IVCeAJFZnxgyDBJBEg00JSkISAxgDfymS+Mknn7jLly+7v/3tbyww4BgwfAw8fvzYnT592slfZ8p7jPJWsg4C1gggidY6srMeJHEnjyG/kzMTZ86ccWtra+7GjRssMOAYMHwMXL9+3R07dsx9/vnnuf9sIYm5WFhpjQCSaK0jO+tBEnfyGPK7t2/fuqdPn7pvv/12dq9G+SsnLDDgGLB5DDx//tzJzfelP3kPJDGPCuvMEUASzbVkR0FI4g4cvIEABM6i+VsAABC0SURBVCDQCwJIYi/a2P+dQBJt9xhJtN0fqoMABCAQQwBJjKHGHHUCSKI68koJkcRKuBgMAQhAoBMEkMROtIkikUTbxwCSaLs/VAcBCEAghgCSGEONOeoEkER15JUSIomVcDEYAhCAQCcIIImdaBNFIom2jwEk0XZ/qA4CEIBADAEkMYYac9QJIInqyCslRBIr4WIwBCAAgU4QQBI70SaKRBJtHwNIou3+UB0EIACBGAJIYgw15qgT2LdvnxNRXF1dZTHIYGVlZdYf9QODhBCAAAQg0BgBJLExtAROSUAk5NmzZ+7FixcsBhk8fPjQnTx5MmXLiQUBCEAAAi0TQBJbbgDpFyPA5ebFOLU1isvNbZEnLwQgAIHmCCCJzbElckICSGJCmA2EQhIbgEpICEAAAi0TQBJbbgDpFyOAJC7Gqa1RSGJb5MkLAQhAoDkCSGJzbImckACSmBBmA6GQxAagEhICEIBAywSQxJYbQPrFCCCJi3FqaxSS2BZ58kIAAhBojgCS2BxbIickgCQmhNlAKCSxAaiEhAAEINAyASSx5QaQfjECSOJinNoahSS2RZ68EIAABJojgCQ2x5bICQkUSeLm5qYbj8duNBrtWHbt2uU2NjYSVkCoMgJIYhkdtkEAAhDoJgEksZt9G1zVZZK4tLT0nhCur687RFHvMEES9ViTCQIQgIAWASRRizR5ahGoKomSTP6E32QycVtbW257e7tWfiaXE0ASy/mwFQIQgEAXCSCJXezaAGuOkUS53CxnGeWS9HQ6HSA1vV1GEvVYkwkCEICAFgEkUYs0eWoRiJFEkUN/KfrVq1e18jO5nACSWM6HrRCAAAS6SABJ7GLXBlgzkmi76Uii7f5QHQQgAIEYAkhiDDXmqBOIkUQuN+u1CUnUY00mCEAAAloEkEQt0uSpRSBGEvniSi3klSYjiZVwMRgCEIBAJwggiZ1oE0VWlURugaN7zCCJurzJBgEIQECDAJKoQZkctQmUSWLezbRlnXxxhYcOASRRhzNZIAABCGgSQBI1aZMrmkCRJEYHZGJSAkhiUpwEgwAEIGCCAJJoog0UMY8AkjiPULvbkcR2+ZMdAhCAQBMEkMQmqBIzOQEkMTnSpAGRxKQ4CQYBCEDABAEk0UQbKGIeASRxHqF2tyOJ7fInOwQgAIEmCCCJTVAlZnICSGJypEkDIolJcRIMAhCAgAkCSKKJNlDEPAJI4jxC7W5HEtvlT3YIQAACTRBAEpugSszkBJDE5EiTBkQSk+IkGAQgAAETBJBEE22giHkEkMR5hNrdjiS2y5/sEIAABJoggCQ2QZWYyQns37/fnT171l24cIHFIIO1tTUnfwaRBwQgAAEI9IcAktifXvZ6T5aXl91f/vIX980337AYZHDz5k139OjRXh+D7BwEIACBoRFAEofW8Y7uL5ebbTeOy822+0N1EIAABGIIIIkx1JijTgBJVEdeKSGSWAkXgyEAAQh0ggCS2Ik2USSSaPsYQBJt94fqIAABCMQQQBJjqDFHnQCSqI68UkIksRIuBkMAAhDoBAEksRNtokgk0fYxgCTa7g/VQQACEIghgCTGUGOOOgEkUR15pYRIYiVcDIYABCDQCQJIYifaRJFIou1jAEm03R+qgwAEIBBDAEmMocYcdQJIojrySgmRxEq4GAwBCECgEwSQxE60iSLnSeLm5qYbj8duNBq9W/gLIHrHDZKox5pMEIAABLQIIIlapMlTi0CZJK6vr8/EMJTCra0tN5lMZou85tEsASSxWb5EhwAEINAGASSxDerkrEygSBL9GUQRxezDi2Ioj9kxvE9DAElMw5EoEIAABCwRQBItdYNaCgkUSaLIoVxmFlnMe8h2OaMowri9vZ03hHUJCCCJCSASAgIQgIAxAkiisYZQTj6BIkmUs4ReAvNmbmxsuKWlpZlETqfTvCGsS0AASUwAkRAQgAAEjBFAEo01hHLyCSCJ+VysrEUSrXSCOiAAAQikI4AkpmNJpAYJFEkil5sbhF4hNJJYARZDIQABCHSEAJLYkUYNvcwiSeSLKzaODCTRRh+oAgIQgEBKAkhiSprEaoxAkSRKQjmbKPdHDL/F7L/ZXPb7io0VO8DASOIAm84uQwACvSeAJPa+xf3YwTJJlD30ZxS5mXY7/UYS2+FOVghAAAJNEkASm6RL7GQE5kliskQEiiKAJEZhYxIEIAAB0wSQRNPtoThPAEn0JGw+I4k2+0JVEIAABOoQQBLr0GOuGgEkUQ11VCIkMQobkyAAAQiYJoAkmm4PxXkCSKInYfMZSbTZF6qCAAQgUIcAkliHHnPVCCCJaqijEiGJUdiYBAEIQMA0ASTRdHsozhNAEj0Jm89Ios2+UBUEIACBOgSQxDr0mKtGAElUQx2VCEmMwsYkCEAAAqYJIImm20NxnsDy8rL74osv3J07d1gMMvjss8/ckSNHfLt4hgAEIACBHhBAEnvQxCHswv79+92VK1fc1atXWQwyuHjxojt48OAQDkX2EQIQgMBgCCCJg2l1t3eUy822+8flZtv9oToIQAACMQSQxBhqzFEngCSqI6+UEEmshIvBEIAABDpBAEnsRJsoEkm0fQwgibb7Q3UQgAAEYgggiTHUmKNOAElUR14pIZJYCReDIQABCHSCAJLYiTZRJJJo+xhAEm33h+ogAAEIxBBAEmOoMUedAJKojrxSQiSxEi4GQwACEOgEASSxE22iSCTR9jGAJNruD9VBAAIQiCGAJMZQY446ASRRHXmlhEhiJVwMhgAEINAJAkhiJ9pEkXmS+ObNGzeZTNxoNMpdxuOx29zcdNPpFIANE0ASGwZMeAhAAAItEEASW4BOyuoE8iQxG2V1ddXt3r07u5r3CgSQRAXIpIAABCCgTABJVAZOujgCSGIcN61ZSKIWafJAAAIQ0COAJOqxJlMNAkhiDXgKU5FEBcikgAAEIKBMAElUBk66OAJIYhw3rVlIohZp8kAAAhDQI4Ak6rEmUw0CSGINeApTkUQFyKSAAAQgoEwASVQGTro4AkhiHDetWUiiFmnyQAACENAjgCTqsSZTDQJIYg14ClORRAXIpIAABCCgTABJVAZOujgCSGIcN61ZSKIWafJAAAIQ0COAJOqxJlMNAkhiDXgKU5FEBcikgAAEIKBMAElUBk66OAKLSGJcZGalIIAkpqBIDAhAAAK2CCCJtvpBNQUEkMQCMEZWI4lGGkEZEIAABBISQBITwiRUcwSQxObYpoiMJKagSAwIQAACtgggibb6QTUFBJDEAjBGViOJRhpBGRCAAAQSEkASE8IkVHMEkMTm2KaIjCSmoEgMCEAAArYIIIm2+kE1BQSQxAIwRlYjiUYaQRkQgAAEEhJAEhPCJFRzBJDE5timiIwkpqBIDAhAAAK2CCCJtvpBNQUEVlZW3OPHj93Tp09ZDDL44x//6I4dO1bQPVZDAAIQgEAXCSCJXezaAGvet2/fTEKOHz/uWOwxOHLkiJOzvTwgAAEIQKA/BJDE/vSy13vC5Wbb7eVys+3+UB0EIACBGAJIYgw15qgTQBLVkVdKiCRWwsVgCEAAAp0ggCR2ok0UiSTaPgaQRNv9oToIQAACMQSQxBhqzFEngCSqI6+UEEmshIvBEIAABDpBAEnsRJsoEkm0fQwgibb7Q3UQgAAEYgggiTHUmKNOAElUR14pIZJYCReDIQABCHSCAJLYiTZRJJJo+xhAEm33h+ogAAEIxBBAEmOoMUedAJKojrxSQiSxEi4GQwACEOgEASSxE22iyDxJfPPmjZtMJm40GuUu4/HYbW5uuul0CsCGCSCJDQMmPAQgAIEWCCCJLUAnZXUCeZKYjbK6uup2796dXc17BQJIogJkUkAAAhBQJoAkKgMnXRwBJDGOm9YsJFGLNHkgAAEI6BFAEvVYk6kGASSxBjyFqUiiAmRSQAACEFAmgCQqAyddHAEkMY6b1iwkUYs0eSAAAQjoEUAS9ViTqQYBJLEGPIWpSKICZFJAAAIQUCaAJCoDJ10cASQxjpvWLCRRizR5IAABCOgRQBL1WJOpBgEksQY8halIogJkUkAAAhBQJoAkKgMnXRwBJDGOm9YsJFGLNHkgAAEI6BFAEvVYk6kGASSxBjyFqUiiAmRSQAACEFAmgCQqAyddHIFFJDEuMrNSEEASU1AkBgQgAAFbBJBEW/2gmgICSGIBGCOrkUQjjaAMCEAAAgkJIIkJYRKqOQJIYnNsU0RGElNQJAYEIAABWwSQRFv9oJoCAkhiARgjq5FEI42gDAhAAAIJCSCJCWESqjkCSGJzbFNERhJTUCQGBCAAAVsEkERb/aCaAgJIYgEYI6uRRCONoAwIQAACCQkgiQlhEqo5Akhic2xTREYSU1AkBgQgAAFbBJBEW/2gmgICIokvXrxwb9++ZTHIAEksOHBZDQEIQKDDBJDEDjdvSKXv27fP7d27l8UwAxF5HhCAAAQg0B8CSGJ/etnrPVlZWXHfffede/36NYtBBo8ePXKnTp3q9THIzkEAAhAYGgEkcWgd7+j+8juJthvH5Wbb/aE6CEAAAjEEkMQYasxRJ4AkqiOvlBBJrISLwRCAAAQ6QQBJ7ESbKBJJtH0MIIm2+0N1EIAABGIIIIkx1JijTgBJVEdeKSGSWAkXgyEAAQh0ggCS2Ik2USSSaPsYQBJt94fqIAABCMQQQBJjqDFHnQCSqI68UkIksRIuBkMAAhDoBAEksRNtokgk0fYxgCTa7g/VQQACEIghgCTGUGOOOoF5kri5uenG47EbjUbvltXVVfU6h5oQSRxq59lvCECgzwSQxD53t0f7ViaJ6+vrMzEMpXBra8tNJpPZIq95NEsASWyWL9EhAAEItEEASWyDOjkrEyiSRH8GUUQx+/CiGMpjdgzv0xBAEtNwJAoEIAABSwSQREvdoJZCAkWSKHIol5lFFvMesl3OKIowbm9v5w1hXQICSGICiISAAAQgYIwAkmisIZSTT6BIEuUsoZfAvJkbGxtuaWlpJpHT6TRvCOsSEEASE0AkBAQgAAFjBJBEYw2hnHwCSGI+FytrkUQrnaAOCEAAAukIIInpWBKpQQJFksjl5gahVwiNJFaAxVAIQAACHSGAJHakUUMvs0gS+eKKjSMDSbTRB6qAAAQgkJIAkpiSJrEaI1AkiZJQzibK/RHDbzH7bzaX/b5iY8UOMDCSOMCms8sQgEDvCSCJvW9xP3awTBJlD/0ZRW6m3U6/kcR2uJMVAhCAQJMEkMQm6RI7GYF5kpgsEYGiCCCJUdiYBAEIQMA0ASTRdHsozhNAEj0Jm89Ios2+UBUEIACBOgSQxDr0mKtGAElUQx2VCEmMwsYkCEAAAqYJIImm20NxngCS6EnYfEYSbfaFqiAAAQjUIYAk1qHHXDUCSKIa6qhESGIUNiZBAAIQME0ASTTdHorzBJBET8LmM5Josy9UBQEIQKAOASSxDj3mqhFAEtVQRyVCEqOwMQkCEICAaQJIoun2UJwngCR6EjafkUSbfaEqCEAAAnUIIIl16DFXjcC+ffvc2tqaO336NItBBh9//LETkecBAQhAAAL9IYAk9qeXvd6Tr776yj18+NDJGSsWewykP7LwgAAEIACB/hBAEvvTS/YEAhCAAAQgAAEIJCOAJCZDSSAIQAACEIAABCDQHwJIYn96yZ5AAAIQgAAEIACBZASQxGQoCQQBCEAAAhCAAAT6Q+D/AN6ucfcp/K+CAAAAAElFTkSuQmCC)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Function to make and return sentences and labels from the training data set and testing data set"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 816,
      "metadata": {},
      "outputs": [],
      "source": [
        "def make_sentences(file_name: str):\n",
        "    with open (file_name, 'r') as f:\n",
        "        train_sent = f.read()\n",
        "    sents = train_sent.split(\"\\n\\n\")  \n",
        "\n",
        "    # removing blank sentences from the input text ie if there is an occurence of \"\\n\\n\" and there is no string after that\n",
        "    for sent in sents:\n",
        "        if sent == '':\n",
        "            sents.remove('')\n",
        "    \n",
        "    i = 0\n",
        "    sentences = []\n",
        "    while i < len(sents):        \n",
        "        sentence = \" \".join(sents[i].split(\"\\n\"))\n",
        "        sentences.append(sentence)\n",
        "        i+=1\n",
        "    \n",
        "    return sentences\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making list of training sentences using the function \"make_sentences\" and printing the first 5 sentences in training dataset"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 817,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['All live births > or = 23 weeks at the University of Vermont in 1995 ( n = 2395 ) were retrospectively analyzed for delivery route , indication for cesarean , gestational age , parity , and practice group ( to reflect risk status )',\n",
              " 'The total cesarean rate was 14.4 % ( 344 of 2395 ) , and the primary rate was 11.4 % ( 244 of 2144 )',\n",
              " 'Abnormal presentation was the most common indication ( 25.6 % , 88 of 344 )',\n",
              " \"The `` corrected '' cesarean rate ( maternal-fetal medicine and transported patients excluded ) was 12.4 % ( 273 of 2194 ) , and the `` corrected '' primary rate was 9.6 % ( 190 of 1975 )\",\n",
              " \"Arrest of dilation was the most common indication in both `` corrected '' subgroups ( 23.4 and 24.6 % , respectively )\"]"
            ]
          },
          "execution_count": 817,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "train_sentences = make_sentences(\"train_sent.txt\")\n",
        "train_sentences[:5]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making list of test sentences using the function \"make_sentences\" and printing the first 5 sentences in test data set\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 818,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['Furthermore , when all deliveries were analyzed , regardless of risk status but limited to gestational age > or = 36 weeks , the rates did not change ( 12.6 % , 280 of 2214 ; primary 9.2 % , 183 of 1994 )',\n",
              " 'As the ambient temperature increases , there is an increase in insensible fluid loss and the potential for dehydration',\n",
              " 'The daily high temperature ranged from 71 to 104 degrees F and AFI values ranged from 1.7 to 24.7 cm during the study period',\n",
              " 'There was a significant correlation between the 2- , 3- , and 4-day mean temperature and AFI , with the 4-day mean being the most significant ( r = 0.31 , p & # 60 ; 0.001 )',\n",
              " 'Fluctuations in ambient temperature are inversely correlated to changes in AFI']"
            ]
          },
          "execution_count": 818,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "test_sentences = make_sentences(\"test_sent.txt\")\n",
        "test_sentences[:5]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "urCxIOBTMBwG"
      },
      "source": [
        "### Count the number of sentences in the processed train and test dataset "
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 819,
      "metadata": {
        "id": "zwa18H_IMFXV"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "No. of training sentences: 2599\n",
            "No. of test sentences: 1056\n"
          ]
        }
      ],
      "source": [
        "print(\"No. of training sentences:\", len(train_sentences))\n",
        "print(\"No. of test sentences:\",len(test_sentences))"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making list of labels for each corresponding sentence in training data and printing the first 5 label lists"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 820,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O O O O']"
            ]
          },
          "execution_count": 820,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "train_labels = make_sentences(\"train_label.txt\")\n",
        "train_labels[:5]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making list of labels for each corresponding sentence in test data and printing the first 5 label lists"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 821,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O',\n",
              " 'O O O O O O O O O O O']"
            ]
          },
          "execution_count": 821,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "test_labels = make_sentences(\"test_label.txt\")\n",
        "test_labels[:5]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Jjg2DK7hLcO_"
      },
      "source": [
        "### Count the number of lines of labels in the processed train and test dataset."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 822,
      "metadata": {
        "id": "unXoD2bWLPZD"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "No. of training label sequences: 2599\n",
            "No. of testing label sequences: 1056\n"
          ]
        }
      ],
      "source": [
        "print(\"No. of training label sequences:\",len(train_labels))\n",
        "print(\"No. of testing label sequences:\",len(test_labels))"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "r9Hy2tECbd9a"
      },
      "source": [
        "##Concept Identification\n",
        "\n",
        "We will first explore what are the various concepts present in the dataset. For this, we will use PoS Tagging. \n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3YGpfOK7Mk3X"
      },
      "source": [
        "### Extract those tokens which have NOUN or PROPN as their PoS tag and find their frequency"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 823,
      "metadata": {
        "id": "7w8nJSPlZqjw"
      },
      "outputs": [],
      "source": [
        "noun_propn_words = [] #initiating empty list of words which are nouns and propns\n",
        "noun_propn_tags = [] #initiating empty list of nouns and propns tags\n",
        "for sent in train_sentences:#for training data\n",
        "    tokenized = model(sent) #tokenizing using spacy model\n",
        "    for token in tokenized:\n",
        "        if token.pos_ in (['NOUN', 'PROPN']):#checking for NOUN and PROPN tags\n",
        "            noun_propn_words.append(token)#appending to words list\n",
        "            noun_propn_tags.append(token.pos_)#appending to tags list\n",
        "for sent in test_sentences:#for test data\n",
        "    tokenized = model(sent)#tokenizing using spacy model\n",
        "    for token in tokenized:\n",
        "        if token.pos_ in (['NOUN', 'PROPN']):#checking for NOUN and PROPN tags\n",
        "            noun_propn_words.append(token)#appending to words list\n",
        "            noun_propn_tags.append(token.pos_)#appending to tags list\n",
        "    "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Counting number of tokens or words identified as NOUN or PROPN"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 824,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "24376\n"
          ]
        }
      ],
      "source": [
        "print(len(noun_propn_words))\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "-SQG8wRxMo6A"
      },
      "source": [
        "### Print the top 25 most common tokens with NOUN or PROPN PoS tags using Counter method from Collections library"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 825,
      "metadata": {
        "id": "DhDY4jjoawTa"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "patients -- 492 -- NOUN\n",
            "treatment -- 281 -- NOUN\n",
            "% -- 247 -- NOUN\n",
            "cancer -- 200 -- NOUN\n",
            "therapy -- 175 -- NOUN\n",
            "study -- 154 -- NOUN\n",
            "disease -- 142 -- NOUN\n",
            "cell -- 140 -- NOUN\n",
            "lung -- 116 -- NOUN\n",
            "group -- 94 -- NOUN\n",
            "chemotherapy -- 88 -- NOUN\n",
            "gene -- 87 -- NOUN\n",
            "effects -- 85 -- NOUN\n",
            "results -- 79 -- NOUN\n",
            "women -- 77 -- NOUN\n",
            "use -- 74 -- NOUN\n",
            "TO_SEE -- 74 -- PROPN\n",
            "risk -- 71 -- NOUN\n",
            "cases -- 71 -- NOUN\n",
            "surgery -- 71 -- NOUN\n",
            "analysis -- 70 -- NOUN\n",
            "rate -- 67 -- NOUN\n",
            "response -- 66 -- NOUN\n",
            "survival -- 65 -- NOUN\n",
            "children -- 64 -- NOUN\n"
          ]
        }
      ],
      "source": [
        "super_sent = [token.text for token in noun_propn_words]\n",
        "word_count = Counter(super_sent)#Counter method from Collections Library\n",
        "\n",
        "for word, count in word_count.most_common(25):\n",
        "    print(word, \"--\", count, \"--\", noun_propn_words[super_sent.index(word)].pos_)\n",
        "    #PRints the word, number of occurences in the corpus(training data) and the corresponding PoS\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### From the above, we can get an understanding that the use case is mostly related to the disease cancer and its treatment"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "## Checking the best method to split the sentences. \n",
        "#### The number of items in each label sequence and the number of words in the corresponding sentence should match. That means the splitting of the sentences should be in such a way that the number of labels should match. Different splitting methods are used to check the best option.\n",
        "- 1. using string split() method which splits the sentence at white spaces.\n",
        "- 2. using spacy to split the sentence into words based on spacy's logic.\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 826,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "No. of mismatches: 0\n"
          ]
        }
      ],
      "source": [
        "# USing split() method\n",
        "x = 0\n",
        "for i in range(len(train_sentences)):\n",
        "    if (len((train_sentences[i].split())) != len(train_labels[i].split())):\n",
        "        print(\"Not Matching:\\n\", i, \"\\n\", len((train_sentences[i].split()), \"\\n\",  len(train_labels[i].split())))\n",
        "        x+=1\n",
        "print(\"No. of mismatches:\", x)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### It can be seen from the above that the number of words using split() method applied to each sentence is matching the number of labels in the label sequence corresponding to that sentence"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 827,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "No. of mismatches:  796\n"
          ]
        }
      ],
      "source": [
        "x = 0\n",
        "for i in range(len(train_sentences)):\n",
        "    if (len(model(train_sentences[i])) != len(train_labels[i].split())):\n",
        "        #print(\"Not Matching:\\n\", i, \"\\n\", len(model(train_sentences[i])), \"\\n\",  len(train_labels[i].split()))\n",
        "        x+=1\n",
        "print(\"No. of mismatches: \", x)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### It can be seen from the above that the number of words using spacy's model applied to each sentence is NOT matching with the number of labels in the label sequence corresponding to that sentence. This could pose a potential problem in training. \n",
        "\n",
        "For example, 'maternal-fetal' is being considered as three separate tokens 'maternal', '-', 'fetal' when using spacy, where as in labels, it is just a single token. In the same manner 'ca2+' is considered as 'ca2' and '+' when using spacy, but considered as a single token in labels. Then there is the case of two punctuation symbols occuring together, which spacy splits into two where as we don't want that as per the labels. Tried tweaking(like removing hyphenation etc) the spacy model but there are numerous other edge cases. Therefore spacy is ruled ot for CRF training, in obtaining features and PoS tags.\n",
        "\n",
        " The way may be to use split() method, but we wont get PoS tags and NLP related attributes from split(). We have to use an NLP method. \n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Alternative is to use nltk methods. \n",
        "Therefore trying out with nltk models. Here, each split token from a sentence using split() method can be passed on to NLTK model to get the PoS tag. nltk wont further split cases like 'maternal-fetal' and 'ca2+'. The number of tokens will be same when using the split() method and can match with the sequence of labels for each corresponding sentence"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Using nltk methods"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 828,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "45 45\n",
            "25 25\n",
            "15 15\n",
            "38 38\n",
            "22 22\n",
            "24 24\n",
            "19 19\n",
            "14 14\n",
            "40 40\n",
            "12 12\n",
            "22 22\n",
            "17 17\n",
            "31 31\n",
            "22 22\n",
            "22 22\n",
            "13 13\n",
            "8 8\n",
            "17 17\n",
            "26 26\n",
            "27 27\n",
            "28 28\n",
            "34 34\n",
            "18 18\n",
            "25 25\n",
            "16 16\n",
            "7 7\n",
            "15 15\n",
            "29 29\n",
            "30 30\n",
            "13 13\n",
            "9 9\n",
            "15 15\n",
            "15 15\n",
            "29 29\n",
            "10 10\n",
            "10 10\n",
            "9 9\n",
            "9 9\n",
            "13 13\n",
            "52 52\n",
            "40 40\n",
            "41 41\n",
            "44 44\n",
            "33 33\n",
            "29 29\n",
            "17 17\n",
            "33 33\n",
            "9 9\n",
            "51 51\n",
            "11 11\n",
            "12 12\n",
            "34 34\n",
            "12 12\n",
            "75 75\n",
            "26 26\n",
            "19 19\n",
            "8 8\n",
            "26 26\n",
            "46 46\n",
            "24 24\n",
            "29 29\n",
            "17 17\n",
            "26 26\n",
            "16 16\n",
            "27 27\n",
            "21 21\n",
            "12 12\n",
            "48 48\n",
            "23 23\n",
            "17 17\n",
            "62 62\n",
            "38 38\n",
            "48 48\n",
            "51 51\n",
            "14 14\n",
            "29 29\n",
            "19 19\n",
            "32 32\n",
            "22 22\n",
            "15 15\n",
            "25 25\n",
            "30 30\n",
            "15 15\n",
            "13 13\n",
            "9 9\n",
            "32 32\n",
            "31 31\n",
            "25 25\n",
            "27 27\n",
            "32 32\n",
            "31 31\n",
            "50 50\n",
            "35 35\n",
            "13 13\n",
            "30 30\n",
            "27 27\n",
            "22 22\n",
            "26 26\n",
            "51 51\n",
            "12 12\n",
            "27 27\n",
            "12 12\n",
            "28 28\n",
            "16 16\n",
            "18 18\n",
            "29 29\n",
            "18 18\n",
            "45 45\n",
            "27 27\n",
            "10 10\n",
            "21 21\n",
            "19 19\n",
            "19 19\n",
            "12 12\n",
            "20 20\n",
            "19 19\n",
            "22 22\n",
            "18 18\n",
            "15 15\n",
            "16 16\n",
            "17 17\n",
            "7 7\n",
            "27 27\n",
            "10 10\n",
            "72 72\n",
            "31 31\n",
            "60 60\n",
            "22 22\n",
            "26 26\n",
            "22 22\n",
            "38 38\n",
            "24 24\n",
            "24 24\n",
            "19 19\n",
            "19 19\n",
            "24 24\n",
            "18 18\n",
            "8 8\n",
            "12 12\n",
            "22 22\n",
            "7 7\n",
            "22 22\n",
            "23 23\n",
            "46 46\n",
            "51 51\n",
            "27 27\n",
            "38 38\n",
            "23 23\n",
            "46 46\n",
            "33 33\n",
            "34 34\n",
            "33 33\n",
            "29 29\n",
            "25 25\n",
            "6 6\n",
            "16 16\n",
            "22 22\n",
            "36 36\n",
            "9 9\n",
            "36 36\n",
            "15 15\n",
            "18 18\n",
            "8 8\n",
            "33 33\n",
            "58 58\n",
            "41 41\n",
            "16 16\n",
            "25 25\n",
            "28 28\n",
            "7 7\n",
            "32 32\n",
            "23 23\n",
            "44 44\n",
            "7 7\n",
            "9 9\n",
            "16 16\n",
            "16 16\n",
            "31 31\n",
            "28 28\n",
            "29 29\n",
            "12 12\n",
            "19 19\n",
            "58 58\n",
            "64 64\n",
            "20 20\n",
            "24 24\n",
            "14 14\n",
            "36 36\n",
            "20 20\n",
            "12 12\n",
            "13 13\n",
            "35 35\n",
            "18 18\n",
            "18 18\n",
            "25 25\n",
            "20 20\n",
            "20 20\n",
            "37 37\n",
            "28 28\n",
            "25 25\n",
            "47 47\n",
            "30 30\n",
            "13 13\n",
            "32 32\n",
            "20 20\n",
            "21 21\n",
            "18 18\n",
            "33 33\n",
            "48 48\n",
            "35 35\n",
            "36 36\n",
            "26 26\n",
            "21 21\n",
            "11 11\n",
            "18 18\n",
            "35 35\n",
            "21 21\n",
            "27 27\n",
            "24 24\n",
            "34 34\n",
            "33 33\n",
            "34 34\n",
            "14 14\n",
            "14 14\n",
            "22 22\n",
            "14 14\n",
            "16 16\n",
            "54 54\n",
            "12 12\n",
            "22 22\n",
            "22 22\n",
            "18 18\n",
            "98 98\n",
            "22 22\n",
            "19 19\n",
            "24 24\n",
            "28 28\n",
            "27 27\n",
            "31 31\n",
            "38 38\n",
            "25 25\n",
            "47 47\n",
            "38 38\n",
            "13 13\n",
            "32 32\n",
            "31 31\n",
            "36 36\n",
            "8 8\n",
            "28 28\n",
            "23 23\n",
            "29 29\n",
            "27 27\n",
            "24 24\n",
            "18 18\n",
            "13 13\n",
            "31 31\n",
            "13 13\n",
            "26 26\n",
            "23 23\n",
            "57 57\n",
            "25 25\n",
            "30 30\n",
            "28 28\n",
            "39 39\n",
            "21 21\n",
            "16 16\n",
            "11 11\n",
            "25 25\n",
            "19 19\n",
            "15 15\n",
            "10 10\n",
            "14 14\n",
            "26 26\n",
            "51 51\n",
            "32 32\n",
            "10 10\n",
            "24 24\n",
            "17 17\n",
            "38 38\n",
            "25 25\n",
            "53 53\n",
            "20 20\n",
            "47 47\n",
            "40 40\n",
            "22 22\n",
            "26 26\n",
            "10 10\n",
            "23 23\n",
            "18 18\n",
            "21 21\n",
            "25 25\n",
            "21 21\n",
            "25 25\n",
            "9 9\n",
            "25 25\n",
            "15 15\n",
            "26 26\n",
            "24 24\n",
            "39 39\n",
            "34 34\n",
            "38 38\n",
            "60 60\n",
            "73 73\n",
            "22 22\n",
            "51 51\n",
            "20 20\n",
            "37 37\n",
            "62 62\n",
            "35 35\n",
            "25 25\n",
            "53 53\n",
            "22 22\n",
            "8 8\n",
            "17 17\n",
            "19 19\n",
            "18 18\n",
            "13 13\n",
            "28 28\n",
            "42 42\n",
            "15 15\n",
            "23 23\n",
            "19 19\n",
            "20 20\n",
            "15 15\n",
            "32 32\n",
            "24 24\n",
            "29 29\n",
            "15 15\n",
            "12 12\n",
            "23 23\n",
            "27 27\n",
            "23 23\n",
            "9 9\n",
            "1 1\n",
            "42 42\n",
            "1 1\n",
            "3 3\n",
            "1 1\n",
            "15 15\n",
            "1 1\n",
            "1 1\n",
            "3 3\n",
            "1 1\n",
            "7 7\n",
            "30 30\n",
            "38 38\n",
            "26 26\n",
            "21 21\n",
            "34 34\n",
            "32 32\n",
            "1 1\n",
            "6 6\n",
            "66 66\n",
            "110 110\n",
            "87 87\n",
            "27 27\n",
            "24 24\n",
            "9 9\n",
            "41 41\n",
            "73 73\n",
            "47 47\n",
            "18 18\n",
            "36 36\n",
            "10 10\n",
            "16 16\n",
            "16 16\n",
            "8 8\n",
            "20 20\n",
            "6 6\n",
            "12 12\n",
            "28 28\n",
            "30 30\n",
            "15 15\n",
            "66 66\n",
            "12 12\n",
            "15 15\n",
            "23 23\n",
            "16 16\n",
            "21 21\n",
            "34 34\n",
            "29 29\n",
            "10 10\n",
            "25 25\n",
            "24 24\n",
            "10 10\n",
            "12 12\n",
            "14 14\n",
            "16 16\n",
            "20 20\n",
            "33 33\n",
            "28 28\n",
            "8 8\n",
            "21 21\n",
            "14 14\n",
            "22 22\n",
            "15 15\n",
            "7 7\n",
            "22 22\n",
            "23 23\n",
            "19 19\n",
            "5 5\n",
            "8 8\n",
            "28 28\n",
            "34 34\n",
            "20 20\n",
            "18 18\n",
            "13 13\n",
            "37 37\n",
            "33 33\n",
            "70 70\n",
            "47 47\n",
            "18 18\n",
            "16 16\n",
            "27 27\n",
            "15 15\n",
            "35 35\n",
            "36 36\n",
            "25 25\n",
            "18 18\n",
            "48 48\n",
            "56 56\n",
            "32 32\n",
            "25 25\n",
            "9 9\n",
            "28 28\n",
            "16 16\n",
            "24 24\n",
            "29 29\n",
            "18 18\n",
            "16 16\n",
            "23 23\n",
            "20 20\n",
            "55 55\n",
            "27 27\n",
            "45 45\n",
            "17 17\n",
            "34 34\n",
            "2 2\n",
            "42 42\n",
            "17 17\n",
            "21 21\n",
            "37 37\n",
            "33 33\n",
            "64 64\n",
            "13 13\n",
            "43 43\n",
            "24 24\n",
            "24 24\n",
            "26 26\n",
            "34 34\n",
            "13 13\n",
            "44 44\n",
            "56 56\n",
            "13 13\n",
            "7 7\n",
            "37 37\n",
            "23 23\n",
            "20 20\n",
            "17 17\n",
            "10 10\n",
            "19 19\n",
            "22 22\n",
            "71 71\n",
            "51 51\n",
            "44 44\n",
            "37 37\n",
            "24 24\n",
            "19 19\n",
            "15 15\n",
            "52 52\n",
            "22 22\n",
            "16 16\n",
            "27 27\n",
            "18 18\n",
            "21 21\n",
            "32 32\n",
            "29 29\n",
            "36 36\n",
            "13 13\n",
            "24 24\n",
            "14 14\n",
            "13 13\n",
            "29 29\n",
            "13 13\n",
            "39 39\n",
            "18 18\n",
            "27 27\n",
            "13 13\n",
            "12 12\n",
            "12 12\n",
            "17 17\n",
            "43 43\n",
            "52 52\n",
            "35 35\n",
            "24 24\n",
            "9 9\n",
            "28 28\n",
            "12 12\n",
            "15 15\n",
            "19 19\n",
            "23 23\n",
            "28 28\n",
            "28 28\n",
            "10 10\n",
            "33 33\n",
            "30 30\n",
            "29 29\n",
            "15 15\n",
            "18 18\n",
            "27 27\n",
            "26 26\n",
            "41 41\n",
            "26 26\n",
            "23 23\n",
            "30 30\n",
            "29 29\n",
            "40 40\n",
            "23 23\n",
            "30 30\n",
            "21 21\n",
            "18 18\n",
            "12 12\n",
            "10 10\n",
            "15 15\n",
            "19 19\n",
            "17 17\n",
            "20 20\n",
            "26 26\n",
            "73 73\n",
            "27 27\n",
            "12 12\n",
            "21 21\n",
            "12 12\n",
            "10 10\n",
            "57 57\n",
            "19 19\n",
            "41 41\n",
            "32 32\n",
            "20 20\n",
            "26 26\n",
            "26 26\n",
            "33 33\n",
            "25 25\n",
            "25 25\n",
            "23 23\n",
            "31 31\n",
            "18 18\n",
            "64 64\n",
            "70 70\n",
            "24 24\n",
            "36 36\n",
            "31 31\n",
            "22 22\n",
            "19 19\n",
            "19 19\n",
            "24 24\n",
            "6 6\n",
            "6 6\n",
            "20 20\n",
            "23 23\n",
            "7 7\n",
            "20 20\n",
            "9 9\n",
            "47 47\n",
            "28 28\n",
            "11 11\n",
            "32 32\n",
            "29 29\n",
            "41 41\n",
            "8 8\n",
            "12 12\n",
            "4 4\n",
            "13 13\n",
            "1 1\n",
            "10 10\n",
            "25 25\n",
            "8 8\n",
            "7 7\n",
            "32 32\n",
            "13 13\n",
            "8 8\n",
            "9 9\n",
            "3 3\n",
            "11 11\n",
            "7 7\n",
            "7 7\n",
            "28 28\n",
            "4 4\n",
            "13 13\n",
            "18 18\n",
            "20 20\n",
            "16 16\n",
            "31 31\n",
            "36 36\n",
            "17 17\n",
            "31 31\n",
            "13 13\n",
            "21 21\n",
            "11 11\n",
            "16 16\n",
            "16 16\n",
            "94 94\n",
            "14 14\n",
            "13 13\n",
            "16 16\n",
            "23 23\n",
            "18 18\n",
            "22 22\n",
            "39 39\n",
            "46 46\n",
            "65 65\n",
            "27 27\n",
            "13 13\n",
            "24 24\n",
            "28 28\n",
            "16 16\n",
            "29 29\n",
            "21 21\n",
            "53 53\n",
            "22 22\n",
            "24 24\n",
            "16 16\n",
            "16 16\n",
            "13 13\n",
            "23 23\n",
            "22 22\n",
            "26 26\n",
            "24 24\n",
            "16 16\n",
            "18 18\n",
            "44 44\n",
            "21 21\n",
            "24 24\n",
            "15 15\n",
            "16 16\n",
            "19 19\n",
            "27 27\n",
            "125 125\n",
            "10 10\n",
            "24 24\n",
            "33 33\n",
            "36 36\n",
            "45 45\n",
            "28 28\n",
            "43 43\n",
            "11 11\n",
            "40 40\n",
            "20 20\n",
            "28 28\n",
            "37 37\n",
            "24 24\n",
            "44 44\n",
            "18 18\n",
            "14 14\n",
            "13 13\n",
            "16 16\n",
            "22 22\n",
            "34 34\n",
            "41 41\n",
            "33 33\n",
            "23 23\n",
            "25 25\n",
            "27 27\n",
            "16 16\n",
            "12 12\n",
            "13 13\n",
            "28 28\n",
            "9 9\n",
            "32 32\n",
            "32 32\n",
            "24 24\n",
            "10 10\n",
            "48 48\n",
            "24 24\n",
            "34 34\n",
            "17 17\n",
            "31 31\n",
            "20 20\n",
            "36 36\n",
            "13 13\n",
            "21 21\n",
            "29 29\n",
            "26 26\n",
            "11 11\n",
            "23 23\n",
            "15 15\n",
            "14 14\n",
            "8 8\n",
            "25 25\n",
            "22 22\n",
            "11 11\n",
            "13 13\n",
            "15 15\n",
            "16 16\n",
            "7 7\n",
            "9 9\n",
            "26 26\n",
            "35 35\n",
            "18 18\n",
            "44 44\n",
            "36 36\n",
            "37 37\n",
            "21 21\n",
            "19 19\n",
            "33 33\n",
            "26 26\n",
            "35 35\n",
            "20 20\n",
            "24 24\n",
            "25 25\n",
            "24 24\n",
            "15 15\n",
            "50 50\n",
            "26 26\n",
            "20 20\n",
            "18 18\n",
            "16 16\n",
            "18 18\n",
            "30 30\n",
            "6 6\n",
            "15 15\n",
            "15 15\n",
            "21 21\n",
            "30 30\n",
            "24 24\n",
            "22 22\n",
            "35 35\n",
            "20 20\n",
            "21 21\n",
            "34 34\n",
            "13 13\n",
            "15 15\n",
            "19 19\n",
            "52 52\n",
            "25 25\n",
            "14 14\n",
            "15 15\n",
            "22 22\n",
            "24 24\n",
            "19 19\n",
            "30 30\n",
            "10 10\n",
            "26 26\n",
            "15 15\n",
            "30 30\n",
            "14 14\n",
            "12 12\n",
            "16 16\n",
            "21 21\n",
            "11 11\n",
            "26 26\n",
            "37 37\n",
            "55 55\n",
            "31 31\n",
            "9 9\n",
            "19 19\n",
            "11 11\n",
            "68 68\n",
            "24 24\n",
            "16 16\n",
            "44 44\n",
            "18 18\n",
            "48 48\n",
            "27 27\n",
            "43 43\n",
            "4 4\n",
            "2 2\n",
            "27 27\n",
            "26 26\n",
            "27 27\n",
            "44 44\n",
            "49 49\n",
            "27 27\n",
            "18 18\n",
            "19 19\n",
            "16 16\n",
            "15 15\n",
            "14 14\n",
            "23 23\n",
            "28 28\n",
            "35 35\n",
            "18 18\n",
            "19 19\n",
            "28 28\n",
            "27 27\n",
            "29 29\n",
            "50 50\n",
            "16 16\n",
            "18 18\n",
            "33 33\n",
            "22 22\n",
            "22 22\n",
            "29 29\n",
            "31 31\n",
            "43 43\n",
            "39 39\n",
            "13 13\n",
            "41 41\n",
            "22 22\n",
            "10 10\n",
            "26 26\n",
            "18 18\n",
            "18 18\n",
            "17 17\n",
            "32 32\n",
            "25 25\n",
            "47 47\n",
            "24 24\n",
            "42 42\n",
            "27 27\n",
            "17 17\n",
            "16 16\n",
            "15 15\n",
            "38 38\n",
            "21 21\n",
            "38 38\n",
            "26 26\n",
            "16 16\n",
            "53 53\n",
            "23 23\n",
            "31 31\n",
            "28 28\n",
            "18 18\n",
            "15 15\n",
            "19 19\n",
            "23 23\n",
            "33 33\n",
            "24 24\n",
            "42 42\n",
            "23 23\n",
            "38 38\n",
            "41 41\n",
            "48 48\n",
            "1 1\n",
            "20 20\n",
            "26 26\n",
            "18 18\n",
            "29 29\n",
            "13 13\n",
            "11 11\n",
            "12 12\n",
            "25 25\n",
            "22 22\n",
            "21 21\n",
            "24 24\n",
            "29 29\n",
            "24 24\n",
            "9 9\n",
            "15 15\n",
            "29 29\n",
            "32 32\n",
            "7 7\n",
            "24 24\n",
            "11 11\n",
            "51 51\n",
            "65 65\n",
            "15 15\n",
            "23 23\n",
            "14 14\n",
            "26 26\n",
            "40 40\n",
            "34 34\n",
            "16 16\n",
            "17 17\n",
            "45 45\n",
            "17 17\n",
            "18 18\n",
            "21 21\n",
            "19 19\n",
            "9 9\n",
            "45 45\n",
            "35 35\n",
            "16 16\n",
            "30 30\n",
            "29 29\n",
            "20 20\n",
            "32 32\n",
            "34 34\n",
            "16 16\n",
            "32 32\n",
            "17 17\n",
            "39 39\n",
            "38 38\n",
            "20 20\n",
            "51 51\n",
            "29 29\n",
            "43 43\n",
            "10 10\n",
            "24 24\n",
            "23 23\n",
            "20 20\n",
            "21 21\n",
            "26 26\n",
            "18 18\n",
            "13 13\n",
            "18 18\n",
            "35 35\n",
            "29 29\n",
            "15 15\n",
            "14 14\n",
            "6 6\n",
            "5 5\n",
            "13 13\n",
            "4 4\n",
            "6 6\n",
            "9 9\n",
            "6 6\n",
            "12 12\n",
            "8 8\n",
            "4 4\n",
            "3 3\n",
            "5 5\n",
            "11 11\n",
            "12 12\n",
            "1 1\n",
            "6 6\n",
            "15 15\n",
            "9 9\n",
            "5 5\n",
            "3 3\n",
            "20 20\n",
            "10 10\n",
            "11 11\n",
            "8 8\n",
            "23 23\n",
            "12 12\n",
            "9 9\n",
            "9 9\n",
            "11 11\n",
            "7 7\n",
            "9 9\n",
            "10 10\n",
            "4 4\n",
            "9 9\n",
            "15 15\n",
            "9 9\n",
            "7 7\n",
            "1 1\n",
            "12 12\n",
            "9 9\n",
            "11 11\n",
            "13 13\n",
            "15 15\n",
            "5 5\n",
            "6 6\n",
            "10 10\n",
            "9 9\n",
            "7 7\n",
            "5 5\n",
            "11 11\n",
            "23 23\n",
            "4 4\n",
            "11 11\n",
            "8 8\n",
            "8 8\n",
            "10 10\n",
            "10 10\n",
            "20 20\n",
            "8 8\n",
            "5 5\n",
            "7 7\n",
            "5 5\n",
            "12 12\n",
            "2 2\n",
            "9 9\n",
            "20 20\n",
            "3 3\n",
            "8 8\n",
            "7 7\n",
            "6 6\n",
            "6 6\n",
            "8 8\n",
            "1 1\n",
            "4 4\n",
            "8 8\n",
            "3 3\n",
            "11 11\n",
            "6 6\n",
            "5 5\n",
            "4 4\n",
            "5 5\n",
            "5 5\n",
            "15 15\n",
            "13 13\n",
            "7 7\n",
            "1 1\n",
            "12 12\n",
            "8 8\n",
            "8 8\n",
            "11 11\n",
            "7 7\n",
            "13 13\n",
            "11 11\n",
            "9 9\n",
            "4 4\n",
            "12 12\n",
            "11 11\n",
            "14 14\n",
            "12 12\n",
            "14 14\n",
            "10 10\n",
            "18 18\n",
            "10 10\n",
            "6 6\n",
            "12 12\n",
            "5 5\n",
            "4 4\n",
            "2 2\n",
            "9 9\n",
            "17 17\n",
            "6 6\n",
            "1 1\n",
            "9 9\n",
            "19 19\n",
            "16 16\n",
            "15 15\n",
            "23 23\n",
            "14 14\n",
            "12 12\n",
            "12 12\n",
            "4 4\n",
            "6 6\n",
            "12 12\n",
            "12 12\n",
            "3 3\n",
            "6 6\n",
            "6 6\n",
            "4 4\n",
            "8 8\n",
            "5 5\n",
            "6 6\n",
            "8 8\n",
            "4 4\n",
            "7 7\n",
            "9 9\n",
            "10 10\n",
            "14 14\n",
            "11 11\n",
            "5 5\n",
            "7 7\n",
            "18 18\n",
            "14 14\n",
            "21 21\n",
            "12 12\n",
            "17 17\n",
            "9 9\n",
            "7 7\n",
            "5 5\n",
            "5 5\n",
            "5 5\n",
            "8 8\n",
            "10 10\n",
            "16 16\n",
            "5 5\n",
            "4 4\n",
            "2 2\n",
            "1 1\n",
            "3 3\n",
            "11 11\n",
            "15 15\n",
            "5 5\n",
            "3 3\n",
            "7 7\n",
            "1 1\n",
            "9 9\n",
            "1 1\n",
            "4 4\n",
            "13 13\n",
            "6 6\n",
            "12 12\n",
            "1 1\n",
            "10 10\n",
            "1 1\n",
            "23 23\n",
            "10 10\n",
            "12 12\n",
            "11 11\n",
            "6 6\n",
            "3 3\n",
            "1 1\n",
            "1 1\n",
            "4 4\n",
            "6 6\n",
            "8 8\n",
            "10 10\n",
            "12 12\n",
            "10 10\n",
            "6 6\n",
            "8 8\n",
            "4 4\n",
            "3 3\n",
            "6 6\n",
            "9 9\n",
            "20 20\n",
            "6 6\n",
            "8 8\n",
            "3 3\n",
            "18 18\n",
            "8 8\n",
            "6 6\n",
            "3 3\n",
            "12 12\n",
            "9 9\n",
            "20 20\n",
            "6 6\n",
            "8 8\n",
            "6 6\n",
            "13 13\n",
            "11 11\n",
            "18 18\n",
            "12 12\n",
            "11 11\n",
            "11 11\n",
            "13 13\n",
            "15 15\n",
            "3 3\n",
            "18 18\n",
            "11 11\n",
            "19 19\n",
            "12 12\n",
            "14 14\n",
            "11 11\n",
            "3 3\n",
            "19 19\n",
            "10 10\n",
            "6 6\n",
            "5 5\n",
            "10 10\n",
            "14 14\n",
            "6 6\n",
            "8 8\n",
            "7 7\n",
            "10 10\n",
            "3 3\n",
            "5 5\n",
            "7 7\n",
            "4 4\n",
            "11 11\n",
            "13 13\n",
            "18 18\n",
            "6 6\n",
            "11 11\n",
            "11 11\n",
            "15 15\n",
            "11 11\n",
            "7 7\n",
            "10 10\n",
            "5 5\n",
            "8 8\n",
            "13 13\n",
            "1 1\n",
            "5 5\n",
            "4 4\n",
            "8 8\n",
            "10 10\n",
            "13 13\n",
            "6 6\n",
            "13 13\n",
            "16 16\n",
            "9 9\n",
            "8 8\n",
            "9 9\n",
            "9 9\n",
            "6 6\n",
            "7 7\n",
            "8 8\n",
            "8 8\n",
            "18 18\n",
            "10 10\n",
            "4 4\n",
            "5 5\n",
            "6 6\n",
            "9 9\n",
            "11 11\n",
            "7 7\n",
            "11 11\n",
            "8 8\n",
            "11 11\n",
            "6 6\n",
            "19 19\n",
            "21 21\n",
            "13 13\n",
            "13 13\n",
            "11 11\n",
            "15 15\n",
            "26 26\n",
            "6 6\n",
            "10 10\n",
            "10 10\n",
            "6 6\n",
            "7 7\n",
            "12 12\n",
            "2 2\n",
            "8 8\n",
            "8 8\n",
            "6 6\n",
            "9 9\n",
            "2 2\n",
            "1 1\n",
            "8 8\n",
            "8 8\n",
            "2 2\n",
            "1 1\n",
            "2 2\n",
            "1 1\n",
            "5 5\n",
            "1 1\n",
            "14 14\n",
            "17 17\n",
            "6 6\n",
            "22 22\n",
            "19 19\n",
            "12 12\n",
            "23 23\n",
            "6 6\n",
            "2 2\n",
            "1 1\n",
            "6 6\n",
            "5 5\n",
            "9 9\n",
            "2 2\n",
            "1 1\n",
            "3 3\n",
            "12 12\n",
            "8 8\n",
            "12 12\n",
            "9 9\n",
            "12 12\n",
            "10 10\n",
            "4 4\n",
            "10 10\n",
            "13 13\n",
            "2 2\n",
            "3 3\n",
            "1 1\n",
            "4 4\n",
            "11 11\n",
            "8 8\n",
            "7 7\n",
            "13 13\n",
            "5 5\n",
            "8 8\n",
            "6 6\n",
            "6 6\n",
            "8 8\n",
            "11 11\n",
            "7 7\n",
            "16 16\n",
            "9 9\n",
            "6 6\n",
            "3 3\n",
            "3 3\n",
            "6 6\n",
            "13 13\n",
            "9 9\n",
            "13 13\n",
            "7 7\n",
            "3 3\n",
            "11 11\n",
            "6 6\n",
            "9 9\n",
            "7 7\n",
            "1 1\n",
            "8 8\n",
            "9 9\n",
            "4 4\n",
            "4 4\n",
            "3 3\n",
            "11 11\n",
            "7 7\n",
            "18 18\n",
            "8 8\n",
            "1 1\n",
            "6 6\n",
            "4 4\n",
            "3 3\n",
            "2 2\n",
            "6 6\n",
            "5 5\n",
            "8 8\n",
            "13 13\n",
            "8 8\n",
            "9 9\n",
            "6 6\n",
            "20 20\n",
            "4 4\n",
            "5 5\n",
            "10 10\n",
            "5 5\n",
            "10 10\n",
            "4 4\n",
            "3 3\n",
            "8 8\n",
            "5 5\n",
            "7 7\n",
            "5 5\n",
            "10 10\n",
            "20 20\n",
            "8 8\n",
            "11 11\n",
            "5 5\n",
            "14 14\n",
            "4 4\n",
            "7 7\n",
            "3 3\n",
            "9 9\n",
            "8 8\n",
            "3 3\n",
            "1 1\n",
            "3 3\n",
            "6 6\n",
            "10 10\n",
            "4 4\n",
            "4 4\n",
            "7 7\n",
            "8 8\n",
            "7 7\n",
            "2 2\n",
            "5 5\n",
            "3 3\n",
            "12 12\n",
            "12 12\n",
            "14 14\n",
            "10 10\n",
            "20 20\n",
            "15 15\n",
            "7 7\n",
            "16 16\n",
            "8 8\n",
            "4 4\n",
            "5 5\n",
            "31 31\n",
            "17 17\n",
            "4 4\n",
            "12 12\n",
            "11 11\n",
            "7 7\n",
            "14 14\n",
            "6 6\n",
            "4 4\n",
            "3 3\n",
            "6 6\n",
            "5 5\n",
            "9 9\n",
            "4 4\n",
            "7 7\n",
            "17 17\n",
            "18 18\n",
            "18 18\n",
            "8 8\n",
            "3 3\n",
            "4 4\n",
            "9 9\n",
            "4 4\n",
            "3 3\n",
            "9 9\n",
            "13 13\n",
            "5 5\n",
            "6 6\n",
            "12 12\n",
            "7 7\n",
            "5 5\n",
            "6 6\n",
            "7 7\n",
            "9 9\n",
            "21 21\n",
            "11 11\n",
            "9 9\n",
            "4 4\n",
            "12 12\n",
            "20 20\n",
            "19 19\n",
            "10 10\n",
            "12 12\n",
            "12 12\n",
            "9 9\n",
            "15 15\n",
            "12 12\n",
            "21 21\n",
            "2 2\n",
            "16 16\n",
            "2 2\n",
            "13 13\n",
            "7 7\n",
            "13 13\n",
            "7 7\n",
            "14 14\n",
            "7 7\n",
            "18 18\n",
            "7 7\n",
            "10 10\n",
            "7 7\n",
            "2 2\n",
            "11 11\n",
            "12 12\n",
            "4 4\n",
            "3 3\n",
            "14 14\n",
            "9 9\n",
            "7 7\n",
            "8 8\n",
            "9 9\n",
            "20 20\n",
            "16 16\n",
            "5 5\n",
            "6 6\n",
            "17 17\n",
            "8 8\n",
            "7 7\n",
            "2 2\n",
            "14 14\n",
            "23 23\n",
            "10 10\n",
            "6 6\n",
            "6 6\n",
            "11 11\n",
            "4 4\n",
            "1 1\n",
            "4 4\n",
            "7 7\n",
            "4 4\n",
            "6 6\n",
            "22 22\n",
            "25 25\n",
            "11 11\n",
            "9 9\n",
            "11 11\n",
            "9 9\n",
            "8 8\n",
            "11 11\n",
            "11 11\n",
            "6 6\n",
            "4 4\n",
            "8 8\n",
            "2 2\n",
            "7 7\n",
            "11 11\n",
            "10 10\n",
            "2 2\n",
            "6 6\n",
            "10 10\n",
            "14 14\n",
            "7 7\n",
            "2 2\n",
            "8 8\n",
            "3 3\n",
            "13 13\n",
            "5 5\n",
            "6 6\n",
            "4 4\n",
            "2 2\n",
            "13 13\n",
            "10 10\n",
            "21 21\n",
            "7 7\n",
            "7 7\n",
            "14 14\n",
            "8 8\n",
            "18 18\n",
            "17 17\n",
            "22 22\n",
            "15 15\n",
            "8 8\n",
            "6 6\n",
            "13 13\n",
            "9 9\n",
            "9 9\n",
            "4 4\n",
            "14 14\n",
            "17 17\n",
            "9 9\n",
            "3 3\n",
            "9 9\n",
            "14 14\n",
            "7 7\n",
            "12 12\n",
            "3 3\n",
            "14 14\n",
            "5 5\n",
            "4 4\n",
            "19 19\n",
            "3 3\n",
            "9 9\n",
            "4 4\n",
            "5 5\n",
            "15 15\n",
            "10 10\n",
            "2 2\n",
            "3 3\n",
            "11 11\n",
            "16 16\n",
            "9 9\n",
            "9 9\n",
            "12 12\n",
            "21 21\n",
            "18 18\n",
            "4 4\n",
            "3 3\n",
            "4 4\n",
            "7 7\n",
            "3 3\n",
            "6 6\n",
            "7 7\n",
            "7 7\n",
            "9 9\n",
            "5 5\n",
            "27 27\n",
            "27 27\n",
            "27 27\n",
            "8 8\n",
            "9 9\n",
            "7 7\n",
            "15 15\n",
            "6 6\n",
            "14 14\n",
            "12 12\n",
            "1 1\n",
            "8 8\n",
            "16 16\n",
            "11 11\n",
            "5 5\n",
            "11 11\n",
            "9 9\n",
            "5 5\n",
            "11 11\n",
            "4 4\n",
            "13 13\n",
            "19 19\n",
            "4 4\n",
            "9 9\n",
            "6 6\n",
            "4 4\n",
            "17 17\n",
            "8 8\n",
            "22 22\n",
            "6 6\n",
            "7 7\n",
            "2 2\n",
            "11 11\n",
            "12 12\n",
            "5 5\n",
            "13 13\n",
            "3 3\n",
            "7 7\n",
            "7 7\n",
            "9 9\n",
            "17 17\n",
            "7 7\n",
            "21 21\n",
            "6 6\n",
            "7 7\n",
            "9 9\n",
            "12 12\n",
            "2 2\n",
            "8 8\n",
            "17 17\n",
            "7 7\n",
            "12 12\n",
            "5 5\n",
            "12 12\n",
            "6 6\n",
            "4 4\n",
            "6 6\n",
            "7 7\n",
            "3 3\n",
            "5 5\n",
            "10 10\n",
            "5 5\n",
            "20 20\n",
            "11 11\n",
            "14 14\n",
            "18 18\n",
            "6 6\n",
            "11 11\n",
            "13 13\n",
            "9 9\n",
            "25 25\n",
            "7 7\n",
            "10 10\n",
            "10 10\n",
            "18 18\n",
            "13 13\n",
            "15 15\n",
            "3 3\n",
            "24 24\n",
            "3 3\n",
            "3 3\n",
            "24 24\n",
            "3 3\n",
            "13 13\n",
            "17 17\n",
            "4 4\n",
            "2 2\n",
            "5 5\n",
            "21 21\n",
            "14 14\n",
            "7 7\n",
            "8 8\n",
            "3 3\n",
            "5 5\n",
            "14 14\n",
            "12 12\n",
            "15 15\n",
            "6 6\n",
            "21 21\n",
            "11 11\n",
            "4 4\n",
            "6 6\n",
            "5 5\n",
            "1 1\n",
            "5 5\n",
            "4 4\n",
            "5 5\n",
            "1 1\n",
            "5 5\n",
            "1 1\n",
            "5 5\n",
            "1 1\n",
            "15 15\n",
            "5 5\n",
            "15 15\n",
            "4 4\n",
            "6 6\n",
            "11 11\n",
            "8 8\n",
            "4 4\n",
            "4 4\n",
            "5 5\n",
            "11 11\n",
            "5 5\n",
            "4 4\n",
            "5 5\n",
            "4 4\n",
            "13 13\n",
            "4 4\n",
            "8 8\n",
            "4 4\n",
            "7 7\n",
            "4 4\n",
            "9 9\n",
            "8 8\n",
            "14 14\n",
            "9 9\n",
            "26 26\n",
            "18 18\n",
            "16 16\n",
            "20 20\n",
            "14 14\n",
            "19 19\n",
            "10 10\n",
            "13 13\n",
            "10 10\n",
            "9 9\n",
            "7 7\n",
            "28 28\n",
            "13 13\n",
            "12 12\n",
            "7 7\n",
            "8 8\n",
            "1 1\n",
            "9 9\n",
            "7 7\n",
            "7 7\n",
            "8 8\n",
            "10 10\n",
            "5 5\n",
            "4 4\n",
            "40 40\n",
            "8 8\n",
            "7 7\n",
            "7 7\n",
            "20 20\n",
            "2 2\n",
            "2 2\n",
            "2 2\n",
            "1 1\n",
            "2 2\n",
            "1 1\n",
            "20 20\n",
            "5 5\n",
            "1 1\n",
            "8 8\n",
            "1 1\n",
            "11 11\n",
            "14 14\n",
            "5 5\n",
            "7 7\n",
            "1 1\n",
            "10 10\n",
            "16 16\n",
            "9 9\n",
            "8 8\n",
            "1 1\n",
            "14 14\n",
            "8 8\n",
            "6 6\n",
            "8 8\n",
            "1 1\n",
            "19 19\n",
            "2 2\n",
            "4 4\n",
            "7 7\n",
            "14 14\n",
            "13 13\n",
            "3 3\n",
            "3 3\n",
            "4 4\n",
            "4 4\n",
            "2 2\n",
            "4 4\n",
            "14 14\n",
            "8 8\n",
            "10 10\n",
            "8 8\n",
            "3 3\n",
            "6 6\n",
            "10 10\n",
            "14 14\n",
            "17 17\n",
            "10 10\n",
            "14 14\n",
            "8 8\n",
            "7 7\n",
            "7 7\n",
            "4 4\n",
            "2 2\n",
            "7 7\n",
            "4 4\n",
            "5 5\n",
            "11 11\n",
            "6 6\n",
            "6 6\n",
            "12 12\n",
            "3 3\n",
            "2 2\n",
            "9 9\n",
            "7 7\n",
            "5 5\n",
            "7 7\n",
            "7 7\n",
            "3 3\n",
            "8 8\n",
            "6 6\n",
            "23 23\n",
            "10 10\n",
            "7 7\n",
            "4 4\n",
            "18 18\n",
            "7 7\n",
            "9 9\n",
            "10 10\n",
            "9 9\n",
            "21 21\n",
            "13 13\n",
            "9 9\n",
            "10 10\n",
            "16 16\n",
            "9 9\n",
            "12 12\n",
            "30 30\n",
            "5 5\n",
            "18 18\n",
            "12 12\n",
            "21 21\n",
            "11 11\n",
            "19 19\n",
            "19 19\n",
            "10 10\n",
            "7 7\n",
            "14 14\n",
            "15 15\n",
            "15 15\n",
            "5 5\n",
            "5 5\n",
            "11 11\n",
            "8 8\n",
            "12 12\n",
            "7 7\n",
            "13 13\n",
            "9 9\n",
            "7 7\n",
            "2 2\n",
            "12 12\n",
            "6 6\n",
            "12 12\n",
            "12 12\n",
            "4 4\n",
            "6 6\n",
            "16 16\n",
            "23 23\n",
            "7 7\n",
            "7 7\n",
            "9 9\n",
            "7 7\n",
            "12 12\n",
            "3 3\n",
            "18 18\n",
            "21 21\n",
            "18 18\n",
            "6 6\n",
            "2 2\n",
            "3 3\n",
            "10 10\n",
            "3 3\n",
            "6 6\n",
            "10 10\n",
            "3 3\n",
            "3 3\n",
            "5 5\n",
            "7 7\n",
            "5 5\n",
            "14 14\n",
            "2 2\n",
            "3 3\n",
            "6 6\n",
            "9 9\n",
            "16 16\n",
            "9 9\n",
            "12 12\n",
            "6 6\n",
            "19 19\n",
            "15 15\n",
            "17 17\n",
            "9 9\n",
            "11 11\n",
            "7 7\n",
            "35 35\n",
            "12 12\n",
            "8 8\n",
            "17 17\n",
            "11 11\n",
            "4 4\n",
            "13 13\n",
            "9 9\n",
            "19 19\n",
            "7 7\n",
            "5 5\n",
            "9 9\n",
            "3 3\n",
            "3 3\n",
            "12 12\n",
            "12 12\n",
            "2 2\n",
            "8 8\n",
            "7 7\n",
            "4 4\n",
            "16 16\n",
            "9 9\n",
            "12 12\n",
            "8 8\n",
            "7 7\n",
            "11 11\n",
            "13 13\n",
            "12 12\n",
            "4 4\n",
            "19 19\n",
            "14 14\n",
            "5 5\n",
            "11 11\n",
            "15 15\n",
            "6 6\n",
            "11 11\n",
            "14 14\n",
            "6 6\n",
            "12 12\n",
            "9 9\n",
            "17 17\n",
            "7 7\n",
            "9 9\n",
            "4 4\n",
            "6 6\n",
            "10 10\n",
            "5 5\n",
            "17 17\n",
            "6 6\n",
            "5 5\n",
            "11 11\n",
            "12 12\n",
            "12 12\n",
            "6 6\n",
            "10 10\n",
            "6 6\n",
            "12 12\n",
            "11 11\n",
            "16 16\n",
            "7 7\n",
            "18 18\n",
            "8 8\n",
            "19 19\n",
            "10 10\n",
            "8 8\n",
            "19 19\n",
            "10 10\n",
            "6 6\n",
            "9 9\n",
            "1 1\n",
            "1 1\n",
            "1 1\n",
            "1 1\n",
            "1 1\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "31 31\n",
            "1 1\n",
            "1 1\n",
            "3 3\n",
            "20 20\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "4 4\n",
            "4 4\n",
            "1 1\n",
            "20 20\n",
            "4 4\n",
            "8 8\n",
            "14 14\n",
            "11 11\n",
            "29 29\n",
            "12 12\n",
            "7 7\n",
            "8 8\n",
            "14 14\n",
            "11 11\n",
            "11 11\n",
            "12 12\n",
            "10 10\n",
            "3 3\n",
            "7 7\n",
            "15 15\n",
            "14 14\n",
            "9 9\n",
            "11 11\n",
            "9 9\n",
            "14 14\n",
            "13 13\n",
            "15 15\n",
            "6 6\n",
            "15 15\n",
            "26 26\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "28 28\n",
            "4 4\n",
            "1 1\n",
            "4 4\n",
            "1 1\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "4 4\n",
            "14 14\n",
            "1 1\n",
            "9 9\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "12 12\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "24 24\n",
            "4 4\n",
            "1 1\n",
            "1 1\n",
            "8 8\n",
            "20 20\n",
            "16 16\n",
            "4 4\n",
            "10 10\n",
            "10 10\n",
            "2 2\n",
            "12 12\n",
            "8 8\n",
            "12 12\n",
            "3 3\n",
            "10 10\n",
            "17 17\n",
            "12 12\n",
            "12 12\n",
            "9 9\n",
            "19 19\n",
            "6 6\n",
            "11 11\n",
            "8 8\n",
            "13 13\n",
            "13 13\n",
            "7 7\n",
            "3 3\n",
            "9 9\n",
            "8 8\n",
            "8 8\n",
            "19 19\n",
            "9 9\n",
            "13 13\n",
            "9 9\n",
            "19 19\n",
            "11 11\n",
            "18 18\n",
            "27 27\n",
            "11 11\n",
            "12 12\n",
            "4 4\n",
            "16 16\n",
            "10 10\n",
            "7 7\n",
            "5 5\n",
            "13 13\n",
            "24 24\n",
            "32 32\n",
            "33 33\n",
            "31 31\n",
            "48 48\n",
            "15 15\n",
            "37 37\n",
            "32 32\n",
            "10 10\n",
            "28 28\n",
            "19 19\n",
            "30 30\n",
            "19 19\n",
            "31 31\n",
            "36 36\n",
            "42 42\n",
            "14 14\n",
            "31 31\n",
            "10 10\n",
            "28 28\n",
            "15 15\n",
            "29 29\n",
            "18 18\n",
            "40 40\n",
            "36 36\n",
            "48 48\n",
            "27 27\n",
            "60 60\n",
            "18 18\n",
            "36 36\n",
            "51 51\n",
            "45 45\n",
            "54 54\n",
            "44 44\n",
            "28 28\n",
            "11 11\n",
            "25 25\n",
            "48 48\n",
            "66 66\n",
            "29 29\n",
            "17 17\n",
            "48 48\n",
            "19 19\n",
            "17 17\n",
            "16 16\n",
            "18 18\n",
            "32 32\n",
            "25 25\n",
            "24 24\n",
            "13 13\n",
            "16 16\n",
            "16 16\n",
            "22 22\n",
            "19 19\n",
            "23 23\n",
            "49 49\n",
            "18 18\n",
            "27 27\n",
            "29 29\n",
            "26 26\n",
            "20 20\n",
            "25 25\n",
            "50 50\n",
            "48 48\n",
            "31 31\n",
            "26 26\n",
            "19 19\n",
            "23 23\n",
            "34 34\n",
            "35 35\n",
            "72 72\n",
            "25 25\n",
            "19 19\n",
            "16 16\n",
            "17 17\n",
            "21 21\n",
            "8 8\n",
            "17 17\n",
            "32 32\n",
            "33 33\n",
            "39 39\n",
            "34 34\n",
            "14 14\n",
            "24 24\n",
            "28 28\n",
            "17 17\n",
            "19 19\n",
            "33 33\n",
            "11 11\n",
            "28 28\n",
            "18 18\n",
            "33 33\n",
            "22 22\n",
            "13 13\n",
            "10 10\n",
            "45 45\n",
            "26 26\n",
            "13 13\n",
            "30 30\n",
            "33 33\n",
            "36 36\n",
            "17 17\n",
            "38 38\n",
            "31 31\n",
            "32 32\n",
            "28 28\n",
            "38 38\n",
            "19 19\n",
            "19 19\n",
            "26 26\n",
            "22 22\n",
            "44 44\n",
            "32 32\n",
            "53 53\n",
            "37 37\n",
            "19 19\n",
            "23 23\n",
            "31 31\n",
            "25 25\n",
            "18 18\n",
            "23 23\n",
            "27 27\n",
            "18 18\n",
            "24 24\n",
            "35 35\n",
            "23 23\n",
            "26 26\n",
            "40 40\n",
            "37 37\n",
            "39 39\n",
            "14 14\n",
            "38 38\n",
            "28 28\n",
            "29 29\n",
            "18 18\n",
            "23 23\n",
            "12 12\n",
            "25 25\n",
            "19 19\n",
            "27 27\n",
            "42 42\n",
            "23 23\n",
            "49 49\n",
            "21 21\n",
            "22 22\n",
            "34 34\n",
            "19 19\n",
            "38 38\n",
            "43 43\n",
            "35 35\n",
            "28 28\n",
            "64 64\n",
            "30 30\n",
            "29 29\n",
            "30 30\n",
            "11 11\n",
            "16 16\n",
            "16 16\n",
            "19 19\n",
            "12 12\n",
            "35 35\n",
            "38 38\n",
            "94 94\n",
            "43 43\n",
            "38 38\n",
            "29 29\n",
            "12 12\n",
            "35 35\n",
            "34 34\n",
            "28 28\n",
            "16 16\n",
            "30 30\n",
            "13 13\n",
            "17 17\n",
            "21 21\n",
            "16 16\n",
            "13 13\n",
            "26 26\n",
            "11 11\n",
            "15 15\n",
            "29 29\n",
            "13 13\n",
            "18 18\n",
            "26 26\n",
            "25 25\n",
            "17 17\n",
            "20 20\n",
            "13 13\n",
            "25 25\n",
            "17 17\n",
            "30 30\n",
            "18 18\n",
            "25 25\n",
            "38 38\n",
            "39 39\n",
            "32 32\n",
            "35 35\n",
            "7 7\n",
            "24 24\n",
            "35 35\n",
            "30 30\n",
            "10 10\n",
            "23 23\n",
            "39 39\n",
            "21 21\n",
            "18 18\n",
            "17 17\n",
            "14 14\n",
            "35 35\n",
            "15 15\n",
            "27 27\n",
            "27 27\n",
            "25 25\n",
            "12 12\n",
            "5 5\n",
            "6 6\n",
            "41 41\n",
            "41 41\n",
            "28 28\n",
            "13 13\n",
            "9 9\n",
            "7 7\n",
            "17 17\n",
            "20 20\n",
            "16 16\n",
            "16 16\n",
            "17 17\n",
            "22 22\n",
            "16 16\n",
            "24 24\n",
            "22 22\n",
            "20 20\n",
            "24 24\n",
            "29 29\n",
            "33 33\n",
            "25 25\n",
            "12 12\n",
            "19 19\n",
            "17 17\n",
            "23 23\n",
            "18 18\n",
            "25 25\n",
            "24 24\n",
            "17 17\n",
            "27 27\n",
            "26 26\n",
            "33 33\n",
            "11 11\n",
            "8 8\n",
            "15 15\n",
            "21 21\n",
            "16 16\n",
            "19 19\n",
            "57 57\n",
            "13 13\n",
            "29 29\n",
            "31 31\n",
            "19 19\n",
            "12 12\n",
            "44 44\n",
            "37 37\n",
            "13 13\n",
            "6 6\n",
            "29 29\n",
            "18 18\n",
            "15 15\n",
            "15 15\n",
            "25 25\n",
            "5 5\n",
            "37 37\n",
            "20 20\n",
            "18 18\n",
            "19 19\n",
            "22 22\n",
            "18 18\n",
            "17 17\n",
            "34 34\n",
            "26 26\n",
            "35 35\n",
            "37 37\n",
            "23 23\n",
            "31 31\n",
            "29 29\n",
            "45 45\n",
            "24 24\n",
            "29 29\n",
            "17 17\n",
            "21 21\n",
            "34 34\n",
            "32 32\n",
            "48 48\n",
            "51 51\n",
            "24 24\n",
            "27 27\n",
            "27 27\n",
            "22 22\n",
            "17 17\n",
            "32 32\n",
            "13 13\n",
            "19 19\n",
            "33 33\n",
            "32 32\n",
            "33 33\n",
            "38 38\n",
            "44 44\n",
            "52 52\n",
            "47 47\n",
            "10 10\n",
            "23 23\n",
            "22 22\n",
            "33 33\n",
            "23 23\n",
            "16 16\n",
            "32 32\n",
            "29 29\n",
            "43 43\n",
            "31 31\n",
            "21 21\n",
            "17 17\n",
            "12 12\n",
            "25 25\n",
            "21 21\n",
            "14 14\n",
            "60 60\n",
            "30 30\n",
            "36 36\n",
            "38 38\n",
            "35 35\n",
            "16 16\n",
            "27 27\n",
            "36 36\n",
            "33 33\n",
            "16 16\n",
            "47 47\n",
            "26 26\n",
            "15 15\n",
            "31 31\n",
            "14 14\n",
            "22 22\n",
            "40 40\n",
            "39 39\n",
            "12 12\n",
            "33 33\n",
            "29 29\n",
            "27 27\n",
            "36 36\n",
            "47 47\n",
            "27 27\n",
            "17 17\n",
            "24 24\n",
            "15 15\n",
            "42 42\n",
            "16 16\n",
            "42 42\n",
            "16 16\n",
            "43 43\n",
            "23 23\n",
            "25 25\n",
            "40 40\n",
            "22 22\n",
            "19 19\n",
            "34 34\n",
            "31 31\n",
            "31 31\n",
            "43 43\n",
            "29 29\n",
            "18 18\n",
            "21 21\n",
            "49 49\n",
            "33 33\n",
            "14 14\n",
            "46 46\n",
            "21 21\n",
            "39 39\n",
            "17 17\n",
            "17 17\n",
            "36 36\n",
            "29 29\n",
            "31 31\n",
            "39 39\n",
            "31 31\n",
            "18 18\n",
            "21 21\n",
            "29 29\n",
            "18 18\n",
            "24 24\n",
            "22 22\n",
            "36 36\n",
            "18 18\n",
            "22 22\n",
            "44 44\n",
            "110 110\n",
            "6 6\n",
            "31 31\n",
            "10 10\n",
            "13 13\n",
            "10 10\n",
            "8 8\n",
            "11 11\n",
            "25 25\n",
            "21 21\n",
            "4 4\n",
            "10 10\n",
            "10 10\n",
            "26 26\n",
            "8 8\n",
            "14 14\n",
            "18 18\n",
            "20 20\n",
            "10 10\n",
            "12 12\n",
            "8 8\n",
            "6 6\n",
            "13 13\n",
            "11 11\n",
            "21 21\n",
            "31 31\n",
            "34 34\n",
            "19 19\n",
            "15 15\n",
            "12 12\n",
            "15 15\n",
            "5 5\n",
            "5 5\n",
            "5 5\n",
            "6 6\n",
            "6 6\n",
            "7 7\n",
            "12 12\n",
            "4 4\n",
            "12 12\n",
            "13 13\n",
            "7 7\n",
            "15 15\n",
            "11 11\n",
            "10 10\n",
            "7 7\n",
            "13 13\n",
            "16 16\n",
            "15 15\n",
            "25 25\n",
            "13 13\n",
            "14 14\n",
            "21 21\n",
            "14 14\n",
            "21 21\n",
            "13 13\n",
            "11 11\n",
            "6 6\n",
            "10 10\n",
            "6 6\n",
            "11 11\n",
            "21 21\n",
            "15 15\n",
            "9 9\n",
            "6 6\n",
            "17 17\n",
            "11 11\n",
            "8 8\n",
            "14 14\n",
            "16 16\n",
            "16 16\n",
            "12 12\n",
            "14 14\n",
            "9 9\n",
            "9 9\n",
            "6 6\n",
            "5 5\n",
            "14 14\n",
            "14 14\n",
            "13 13\n",
            "16 16\n",
            "7 7\n",
            "5 5\n",
            "17 17\n",
            "10 10\n",
            "15 15\n",
            "22 22\n",
            "10 10\n",
            "5 5\n",
            "4 4\n",
            "13 13\n",
            "14 14\n",
            "8 8\n",
            "7 7\n",
            "5 5\n",
            "10 10\n",
            "12 12\n",
            "6 6\n",
            "12 12\n",
            "10 10\n",
            "14 14\n",
            "18 18\n",
            "13 13\n",
            "13 13\n",
            "15 15\n",
            "12 12\n",
            "13 13\n",
            "20 20\n",
            "16 16\n",
            "16 16\n",
            "12 12\n",
            "13 13\n",
            "17 17\n",
            "8 8\n",
            "26 26\n",
            "14 14\n",
            "8 8\n",
            "16 16\n",
            "35 35\n",
            "26 26\n",
            "32 32\n",
            "15 15\n",
            "20 20\n",
            "12 12\n",
            "18 18\n",
            "12 12\n",
            "7 7\n",
            "4 4\n",
            "6 6\n",
            "6 6\n",
            "13 13\n",
            "12 12\n",
            "12 12\n",
            "12 12\n",
            "7 7\n",
            "14 14\n",
            "18 18\n",
            "6 6\n",
            "5 5\n",
            "9 9\n",
            "18 18\n",
            "15 15\n",
            "26 26\n",
            "9 9\n",
            "21 21\n",
            "11 11\n",
            "22 22\n",
            "19 19\n",
            "14 14\n",
            "8 8\n",
            "23 23\n",
            "24 24\n",
            "6 6\n",
            "16 16\n",
            "16 16\n",
            "13 13\n",
            "18 18\n",
            "13 13\n",
            "10 10\n",
            "19 19\n",
            "8 8\n",
            "5 5\n",
            "12 12\n",
            "12 12\n",
            "17 17\n",
            "8 8\n",
            "15 15\n",
            "15 15\n",
            "15 15\n",
            "16 16\n",
            "20 20\n",
            "12 12\n",
            "28 28\n",
            "11 11\n",
            "11 11\n",
            "12 12\n",
            "20 20\n",
            "17 17\n",
            "11 11\n",
            "4 4\n",
            "10 10\n",
            "12 12\n",
            "7 7\n",
            "14 14\n",
            "11 11\n",
            "15 15\n",
            "13 13\n",
            "11 11\n",
            "14 14\n",
            "13 13\n",
            "9 9\n",
            "10 10\n",
            "8 8\n",
            "17 17\n",
            "18 18\n",
            "9 9\n",
            "10 10\n",
            "6 6\n",
            "\n",
            "\n",
            "No. of mismatches= 0\n"
          ]
        }
      ],
      "source": [
        "x = 0\n",
        "labels_cache = []\n",
        "for i in range(len(train_sentences)):\n",
        "    for word in train_sentences[i].split():\n",
        "        labels_cache.append(nltk.pos_tag([word])[0][1])        \n",
        "    if (len(labels_cache) != len(train_labels[i].split())):\n",
        "        x+=1\n",
        "    print(len(labels_cache), len(train_labels[i].split()))    \n",
        "    labels_cache = []\n",
        "print(\"\\n\\nNo. of mismatches=\", x)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### It can be seen from the above that the number of tokens is same when using split() method together with nltk. Therefore spacy is ruled our of feature extraction and using nltk instead"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "bnfAlKgA5fd4"
      },
      "source": [
        "## Defining features for CRF\n",
        "\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 829,
      "metadata": {
        "id": "aS6P1Gog3JMf"
      },
      "outputs": [],
      "source": [
        "# defining the features to get the feature value for one word.\n",
        "\n",
        "def feature_definition_word_only_prev_word(words_split, index):\n",
        "    word = words_split[index]\n",
        "    features = [\n",
        "        \"word.lower=\"+word.lower(),\n",
        "        \"word.PoS=\"+nltk.pos_tag([word])[0][1]\n",
        "        ]\n",
        "    \n",
        "    if(index > 0 and index < (len(words_split)-1)):\n",
        "        prev_word = words_split[index-1]\n",
        "        #next_word = words_split[index+1]\n",
        "        features.extend([\n",
        "            'prev_word.lower=' + prev_word.lower(), \n",
        "            \"prev_word.PoS=\"+nltk.pos_tag([prev_word])[0][1]           \n",
        "        ])\n",
        "        \n",
        "    elif index == 0:\n",
        "        features.append('BEG')\n",
        "\n",
        "    if(index == len(words_split)-1):\n",
        "        features.append('END')\n",
        "        \n",
        "    return features\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 830,
      "metadata": {},
      "outputs": [],
      "source": [
        "# define the features to get the feature value for one word. \n",
        "#Previous word and the next word are used since there is an improvement in f1 score when using both previous and next words\n",
        "\n",
        "def feature_definition_word(words_split, index):\n",
        "    word = words_split[index]\n",
        "    features = [\n",
        "        \"word.lower=\"+word.lower(),\n",
        "        \"word.PoS=\"+nltk.pos_tag([word])[0][1]\n",
        "        ]\n",
        "    \n",
        "    if(index > 0 and index < (len(words_split)-1)):\n",
        "        prev_word = words_split[index-1]\n",
        "        next_word = words_split[index+1]\n",
        "        features.extend([\n",
        "            'prev_word.lower=' + prev_word.lower(), \n",
        "            \"prev_word.PoS=\"+nltk.pos_tag([prev_word])[0][1],\n",
        "            'next_word.lower='+ next_word.lower(),\n",
        "            \"next_word.PoS=\"+nltk.pos_tag([next_word])[0][1]           \n",
        "        ])\n",
        "        \n",
        "    elif index == 0:\n",
        "        features.append('BEG')\n",
        "\n",
        "    if(index == len(words_split)-1):\n",
        "        features.append('END')\n",
        "        \n",
        "    return features\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "haBEOsZGKhb9"
      },
      "source": [
        "## Getting the features"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Fwb8YUdlNcG1"
      },
      "source": [
        "### Write a code/function to get the features for a sentence"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 831,
      "metadata": {
        "id": "emBIm5uK7vtK"
      },
      "outputs": [],
      "source": [
        "# code to get features for a sentence.This was a trial to consider two adjacent punctuation marks together without splitting. \n",
        "# Not used in the final code\n",
        "def feature_definition_sentence_old(sentence):\n",
        "    sentence = model(sentence)\n",
        "    final_words = []\n",
        "    previous_word = None\n",
        "    for word in sentence:\n",
        "        if word.pos_ == 'PUNCT' and previous_word and word.text == previous_word.text:\n",
        "            continue\n",
        "        else:\n",
        "            final_words.append(word)\n",
        "        previous_word = word\n",
        "    words_split = [word.text for word in final_words]\n",
        "    words_spacy = list(sentence)\n",
        "    #words_split = sentence.split()\n",
        "    return [feature_definition_word(words_spacy, words_split, index) for index in range(len(words_split))]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 832,
      "metadata": {},
      "outputs": [],
      "source": [
        "# code to get features for a sentence. Just splitting is now required since nltk and split() will do the work\n",
        "def feature_definition_sentence(sentence):\n",
        "    words_split = sentence.split()\n",
        "    \n",
        "    return [feature_definition_word(words_split, index) for index in range(len(words_split))]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "A7fs-B8CNein"
      },
      "source": [
        "### Write a code/function to get the labels of a sentence"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 833,
      "metadata": {
        "id": "tiA-A_ws8I8-"
      },
      "outputs": [],
      "source": [
        "# code to get the labels for a sentence.\n",
        "def get_labels_sentence(label):\n",
        "    return label.split()"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "QG6hYY6rNjS8"
      },
      "source": [
        "## Define input and target variables\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "DZmjKbXgN44o"
      },
      "source": [
        "Correctly computing X and Y sequence matrices for training and test data.\n",
        "Check that both sentences and labels are processed"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "U1C4djFXNpqN"
      },
      "source": [
        "### Define the features' values for each sentence as input variable  for CRF model in test and the train dataset "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "#### Building model with both previous word and next word as features, together with PoS"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 834,
      "metadata": {
        "id": "8Nuz-MjW8LWm"
      },
      "outputs": [],
      "source": [
        "X_train = [feature_definition_sentence(sentence) for sentence in train_sentences]\n",
        "X_test = [feature_definition_sentence(sentence) for sentence in test_sentences]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 835,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "2599"
            ]
          },
          "execution_count": 835,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "len(X_train)#Checking the length of training dataset"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "q88-s6BQNr0M"
      },
      "source": [
        "### Define the labels as the target variable for test and the train dataset"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 836,
      "metadata": {
        "id": "HrzLkWs0Nvx4"
      },
      "outputs": [],
      "source": [
        "y_train = [get_labels_sentence(label) for label in train_labels]\n",
        "y_test = [get_labels_sentence(label) for label in test_labels]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "#### Building model with only the previous word  as features together with PoS, for comparison of F1-Score"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 837,
      "metadata": {},
      "outputs": [],
      "source": [
        "# code to get features for a sentence. Just splitting is now required since nltk and split() will do the work\n",
        "def feature_definition_sentence_prev(sentence):\n",
        "    words_split = sentence.split()\n",
        "    \n",
        "    return [feature_definition_word_only_prev_word(words_split, index) for index in range(len(words_split))]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 838,
      "metadata": {},
      "outputs": [],
      "source": [
        "X_train_prev = [feature_definition_sentence_prev(sentence) for sentence in train_sentences]\n",
        "X_test_prev = [feature_definition_sentence_prev(sentence) for sentence in test_sentences]"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Checking if the number of words in each sentence is matching the number of labels in the corresponding label sequence after feature definition and extraction."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 839,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "No. of mismatches:  0\n"
          ]
        }
      ],
      "source": [
        "x = 0\n",
        "for i in range(len(train_sentences)):\n",
        "    if (len(feature_definition_sentence(train_sentences[i])) != len(get_labels_sentence(train_labels[i]))):\n",
        "        print(\"Not Matching:\\n\", i, \"\\n\", len(feature_definition_sentence(train_sentences[i])), \"\\n\",  len(get_labels_sentence(train_labels[i])))\n",
        "        x+=1\n",
        "print(\"No. of mismatches: \", x)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Checking random sentence split into words using split() and tokenize method of nltk. "
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 840,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "['Standard', 'versus', 'high-dose', 'therapy', 'in', '10+', 'breast', 'cancer']\n",
            "['Standard', 'versus', 'high-dose', 'therapy', 'in', '10+', 'breast', 'cancer']\n"
          ]
        }
      ],
      "source": [
        "print(train_sentences[2493].split())\n",
        "tokens = word_tokenize(train_sentences[2493])\n",
        "print(word_tokenize(train_sentences[2493]))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 841,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "[('Standard', 'NNP'), ('versus', 'VBZ'), ('high-dose', 'JJ'), ('therapy', 'NN'), ('in', 'IN'), ('10+', 'CD'), ('breast', 'NN'), ('cancer', 'NN')]\n"
          ]
        }
      ],
      "source": [
        "print(nltk.pos_tag(tokens))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 842,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "'NN'"
            ]
          },
          "execution_count": 842,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "nltk.pos_tag([\"my-name\"])[0][1]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 843,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "32 -- 38 -- RESULTS : The HLA effect is due to the class II DR2 haplotype , DRB1*1501-DQA1*0102-DRB1*0602 ; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed\n",
            "55 -- 56 -- Lactate values obtained by continuous catheter operation ex vivo correlate well with those obtained by BIOSEN Med L. First subcutaneous implantation ( dog ) underlines the characteristics obtained ex vivo : after 30 min hydration the lactate catheter follows the lactate concentration measured ex vivo with samples from the leg vein by BIOSEN Med L.\n",
            "12 -- 13 -- Oviposition and its regulation in the polygynous society of Polistes gallicus L.\n",
            "14 -- 15 -- A fine structural analysis of the epidermis of the earthworm , Lumbricus terrestris L.\n",
            "No. of mismatches(nltk tokenizer)=  4\n"
          ]
        }
      ],
      "source": [
        "count = 0\n",
        "for i in train_sentences:\n",
        "    split_len = len(i.split())\n",
        "    nltk_len = len(word_tokenize(i))\n",
        "    if split_len != nltk_len:\n",
        "        print(split_len, \"--\",  nltk_len, \"--\", i)\n",
        "        count+=1\n",
        "print(\"No. of mismatches(nltk tokenizer)= \", count)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### From the above, it can be seen that nltk tokenizer method has still some mismatches though substantially less. But still not perfect."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 844,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "38 -- 42 -- The `` corrected '' cesarean rate ( maternal-fetal medicine and transported patients excluded ) was 12.4 % ( 273 of 2194 ) , and the `` corrected '' primary rate was 9.6 % ( 190 of 1975 )\n",
            "22 -- 23 -- Arrest of dilation was the most common indication in both `` corrected '' subgroups ( 23.4 and 24.6 % , respectively )\n",
            "22 -- 26 -- A 2- , 3- , and 4-day mean temperature prior to the test date was compared to AFI using a Spearman-rank Correlation\n",
            "17 -- 19 -- This relationship should be taken into account when interpreting the AFI as a measure of fetal well-being\n",
            "31 -- 33 -- The study population included 84 women with gestational diabetes , ascertained by universal screening of all women attending the antenatal clinic of the Hadassah Medical Center , over a 2-year period\n",
            "22 -- 23 -- The 60 women ( 71 % ) , who initiated treatment before 34 completed weeks , composed the `` early '' group\n",
            "22 -- 23 -- The 24 women ( 29 % ) , who initiated treatment after the 34th week , composed the `` late '' group\n",
            "16 -- 20 -- Fifty-three triplet pregnancies between 1986 and 1993 at The New York Hospital-Cornell Medical Center were reviewed\n",
            "15 -- 19 -- Student 's t-test , Fisher exact test , and Chi-square were used for statistical analysis\n",
            "30 -- 34 -- In this retrospective , case-controlled study , the rate of severe pre-eclampsia was significantly increased in triplet gestations as compared to twins although the overall rate of preeclampsia was not\n",
            "10 -- 12 -- Inter-NICU variability of thermal equipment use may complicate fluid management\n",
            "10 -- 12 -- This report describes a full-term newborn with massive fetomaternal hemorrhage\n",
            "13 -- 17 -- The nonstress test was abnormal with low biophysical profile and decreased beat-to-beat variability\n",
            "52 -- 58 -- Omphalocele-Exstrophy-Imperforate anus-Spinal defects ( OEIS complex ) , a combination of omphalocele , exstrophy of the bladder , an imperforate anus and spinal defects , arises from a single localized defect in the early development of the mesoderm that will later contribute to infraumbilical mesenchyme , cloacal septum , and caudal vertebrae\n",
            "41 -- 43 -- Although long-term survival can be achieved by successful corrective surgery , the associated structural defects such as large meningomyelocele and severe limb aplasia or hypoplasia , as seen in our patient , can influence the patient 's quality of life .\n",
            "33 -- 37 -- As there have been few reports of the obstetrical care of affected patients , we wish to document two pregnancies in a woman with a Chronic Progressive External Ophthalmoplegia ( Kearns-Sayre-like syndrome )\n",
            "11 -- 13 -- OBJECTIVE : To identify additional genetic risk factors for late-onset AD\n",
            "34 -- 36 -- Critical values for chromosomal regional follow-up were a P value of .05 or less for affected relative pair analysis or sibpair analysis , a parametric lod score of 1.0 or greater , or both\n",
            "12 -- 14 -- Regional follow-up included analysis of additional markers and a second data set\n",
            "75 -- 80 -- PATIENTS : > From a series of multiplex families affected with late-onset ( > or =60 years ) AD ascertained during the last 14 years ( National Insititute of Neurological Disorders and Stroke-Alzheimer 's Disease and Related Disorders Association diagnostic criteria ) and for which DNA has been obtained , a subset of 16 families ( 135 total family members , 52 of whom were patients with AD ) was used for the genomic screen\n",
            "26 -- 28 -- A second subset of 38 families ( 216 total family members , 89 of whom were patients with AD ) was used for the follow-up analysis\n",
            "19 -- 23 -- MAIN OUTCOME MEASURES : Linkage analysis results generated using both genetic model-dependent ( lod score ) and model-independent methods\n",
            "8 -- 10 -- RESULTS : Fifteen chromosomal regions warranted initial follow-up\n",
            "26 -- 28 -- Follow-up analyses revealed 4 regions of continued interest on chromosomes 4 , 6 , 12 , and 20 , with the strongest results observed forchromosome 12\n",
            "46 -- 50 -- Peak 2-point affecteds-only lod scores ( n=54 ) were 1.3 , 1.6 , 2.7 , and 2.2 and affected relative pairs P values ( n=54 ) were .04 , .03 , .14 , and .04 for D12S373 , D12S1057 , D12S1042 , and D12S390 , respectively\n",
            "23 -- 25 -- OBJECTIVE : To investigate phenotypic characteristics of families potentially linked to the hereditary prostate cancer 1 ( HPC1 ) locus on chromosome 1q24-25\n",
            "38 -- 40 -- The age at diagnosis of prostate cancer , serum prostate-specific antigen levels , digital rectal examination status , stage , grade , primary treatment of prostate cancers , and occurrence of other cancers were compared between the groups\n",
            "51 -- 55 -- Higher-grade cancers ( grade 3 ) were more common in potentially linked families , and advanced-stage disease was found in 41 % of the case patients in potentially linked families compared with 31 % in both the potentially unlinked families and the reference groups ( P=.03 for the latter comparison )\n",
            "19 -- 23 -- However , 3 characteristics were observed : younger age at diagnosis , higher-grade tumors , and more advanced-stage disease\n",
            "32 -- 44 -- RESULTS : The HLA effect is due to the class II DR2 haplotype , DRB1*1501-DQA1*0102-DRB1*0602 ; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed\n",
            "27 -- 29 -- < TO_SEE > OBJECTIVE : To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development\n",
            "32 -- 36 -- DESIGN : Cohort incidence study of patients with retinoblastoma followed for a median of 20 years , and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas\n",
            "31 -- 33 -- SETTING/PARTICIPANTS : A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis , identified from hospital records in Massachusetts and New York during 1914 to 1984\n",
            "50 -- 52 -- RESULTS : Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma , in whom 190 cancers were diagnosed , vs 6.3 expected in the general population ( relative risk ( RR ) , 30 ( 95 % confidence interval , 26-47 ) )\n",
            "35 -- 38 -- Cumulative incidence ( +/-SE ) of a second cancer at 50 years after diagnosis was 51.0 % ( +/-6.2 % ) for hereditary retinoblastoma , and 5.0 % ( +/-3.0 % ) for nonhereditary retinoblastoma\n",
            "22 -- 24 -- A radiation dose-response relationship is demonstrated for all sarcomas and , for the first time in humans , for soft tissue sarcomas\n",
            "51 -- 53 -- The objective of this study was to determine the rate of recent cocaine use among a metropolitan population of predominantly Hispanic and African-American women with preterm premature rupture of the membranes ( PROM ) and to ascertain the impact of cocaine on the latency period between rupture of membranes and delivery\n",
            "28 -- 34 -- There was a higher rate of recent cocaine use among African-American women ( 20.4 % ) as compared to non-African-Americans ( 1.2 % , p = 0.0001 )\n",
            "18 -- 20 -- Responses to an interview at initial prenatal care enrollment were compared using Chi-square and Fisher 's exact tests\n",
            "19 -- 21 -- These inner-city , pregnant women disapproved of pregnancy if HIV infected and thought the risk of transmission was high\n",
            "19 -- 21 -- BACKGROUND : Cochlear implantation is nowadays a reliable and well-accepted method of auditory rehabilitation in selected adults and children\n",
            "18 -- 20 -- RESULTS : Results of first tune-up show an open set speech understanding in approximately 50 % of patients\n",
            "15 -- 17 -- Long-term results also reveal further improvement in patients who had no open set speech understanding\n",
            "17 -- 19 -- CONCLUSIONS : In adults , open set speech understanding can be achieved even at the first tune-up\n",
            "72 -- 74 -- Current pharmacovigilance is predominantly based on spontaneous reporting and is mainly helpful in detecting type B effects ( those effects that are often allergic or idiosyncratic reactions , characteristically occurring in only a minority of patients and usually unrelated to dosage and that are serious , unexpected and unpredictable ) and unusual type A effects ( those effects that are related to the pharmacological effects of the drug and are dosage-related )\n",
            "31 -- 35 -- Examples of other sources of signals are prescription event monitoring , large automated data resources on morbidity and drug use ( including record linkage ) , case-control surveillance and follow-up studies\n",
            "22 -- 24 -- STUDY DESIGN : Thirty children , aged 6.4 to 16.4 years , with epilepsy and ADHD were studied during a 4-month period\n",
            "38 -- 40 -- During the initial 2 months of the study , the children were treated with antiepileptic drugs ( AEDs ) only , and for the remaining 2 months , methylphenidate was added at a morning dose of 0.3 mg/kg\n",
            "24 -- 26 -- Electroencephalography , AED determinations , and the continuous-performance task ( CPT ) test were done at baseline and after 2 months of methylphenidate therapy\n",
            "22 -- 24 -- The temporal properties of semantic and phonological processes in speech production were investigated in a new experimental paradigm using movement-related brain potentials\n",
            "22 -- 28 -- In addition , a 2-choice reaction go/no-go procedure was included , involving a semantic and a phonological categorization of the picture name\n",
            "46 -- 48 -- Varying the position of the critical phoneme in the picture name did not affect the onset of the LRP but rather influenced when the LRP began to differ on go and no-go trials and allowed the duration of phonological encoding of a word to be estimated\n",
            "23 -- 33 -- Molecular dynamics in torsion-angle space was applied to nuclear magnetic resonance structure calculation using nuclear Overhauser effect-derived distances and J-coupling-constant-derived dihedral angle restraints\n",
            "46 -- 48 -- Compared to two other commonly used algorithms , molecular dynamics in Cartesian space and metric-matrix geometry combined with Cartesian molecular dynamics , the method shows increased computational efficiency and success rate for large proteins , and it shows a dramatically increased radius of convergence for DNA\n",
            "33 -- 43 -- The torsion-angle molecular dynamics algorithm starts from an extended strand conformation and proceeds in four stages : high-temperature torsion-angle molecular dynamics , slow-cooling torsion-angle molecular dynamics , Cartesian molecular dynamics , and minimization\n",
            "34 -- 37 -- Tests were carried out using experimental NMR data for protein G , interleukin-8 , villin 14T , and a 12 base-pair duplex of DNA , and simulated NMR data for bovine pancreatic trypsin inhibitor\n",
            "33 -- 36 -- For villin 14T , a monomer consisting of 126 residues , structure determination by torsion-angle molecular dynamics has a success rate of 85 % , a more than twofold improvement over other methods\n",
            "29 -- 31 -- The wavelet-transform method is used to quantify the magnetic resonance spectroscopy ( MRS ) parameters : chemical shift , apparent relaxation time T2 , resonance amplitude , and phase\n",
            "25 -- 27 -- Wavelet transformation is a time-frequency representation which separates each component from the FID , then successively quantifies it and subtracts it from the raw signal\n",
            "16 -- 18 -- The results indicate that the wavelet-transform method can provide efficient and accurate quantification of MRS data\n",
            "36 -- 40 -- In the Coumadin Aspirin Reinfarction Study ( CARS ) , we aimed to find out whether a combination of low-dose warfarin and low-dose aspirin would give superior results to standard aspirin monotherapy without excessive bleeding risk\n",
            "9 -- 11 -- METHODS : We used a randomised double-blind study design\n",
            "18 -- 20 -- FINDINGS : The primary event was first occurrence of reinfarction , non-fatal ischaemic stroke , or cardiovascular death\n",
            "8 -- 10 -- Primary comparisons were done with all follow-up data\n",
            "33 -- 35 -- The relative risk of the primary event for the 160 mg aspirin group compared with the 3 mg warfarin with 80 mg aspirin group was 0.95 ( 0.81-1.12 , p = 0.57 )\n",
            "58 -- 64 -- For the 3382 patients assigned 3 mg warfarin with 80 mg aspirin , the INR results were : at week 1 ( n = 2985 ) median 1.51 ( IQR 1.23-2.13 ) ; at week 4 ( n = 2701 ) 1.27 ( 1.13-1.64 ) ; at month 6 ( n = 2145 ) 1.19 ( 1.08-1.44 )\n",
            "41 -- 45 -- INTERPRETATION : Low , fixed-dose warfarin ( 1 mg or 3 mg ) combined with low-dose aspirin ( 80 mg ) in patients who have had myocardial infarction does not provide clinical benefit beyond that achievable with 160 mg aspirin monotherapy\n",
            "32 -- 36 -- We report the primary clinical endpoints ( cardiac ischaemic death , myocardial infarction , and severe recurrent ischaemia ) , assessed at day 31 , in 202 patients on an intention-to-treat basis\n",
            "7 -- 9 -- No major drug-related adverse effects were observed\n",
            "9 -- 11 -- Large-scale trials are needed to confirm these preliminary observations\n",
            "31 -- 33 -- In this prospective randomised trial of radiotherapy versus surgery , our aim was to assess the 5-year survival and the rate and pattern of complications and recurrences associated with each treatment\n",
            "29 -- 31 -- Adjuvant radiotherapy was delivered after surgery for women with surgical stage pT2b or greater , less than 3 mm of safe cervical stroma , cut-through , or positive nodes\n",
            "12 -- 14 -- The primary outcome measures were 5-year survival and the rate of complications\n",
            "58 -- 62 -- FINDINGS : 170 patients in the surgery group and 167 in the radiotherapy group were included in the intention-to-treat analysis ; scheduled treatment was delivered to 169 and 158 women , respectively , 62 of 114 women with cervical diameters of 4 cm or smaller and 46 of 55 with diameters larger than 4 cm received adjuvant therapy\n",
            "64 -- 72 -- After a median follow-up of 87 ( range 57-120 ) months , 5-year overall and disease-free survival were identical in the surgery and radiotherapy groups ( 83 % and 74 % , respectively , for both groups ) , 86 women developed recurrent disease : 42 ( 25 % ) in the surgery group and 44 ( 26 % ) in the radiotherapy group\n",
            "20 -- 22 -- Significant factors for survival in univariate and multivariate analyses were : cervical diameter , positive lymphangiography , and adeno-carcinomatous histotype\n",
            "24 -- 28 -- 48 ( 28 % ) surgery-group patients had severe morbidity compared with 19 ( 12 % ) radiotherapy-group patients ( p = 0.0004 )\n",
            "12 -- 14 -- Nursing across state lines poses complications : state-bound regulatory and licensure issues\n",
            "35 -- 41 -- PROBLEM : To compare the expression by T-lymphocytes of an immunomodulatory protein known as progesterone-induced blocking factor ( PIBF ) in conception versus non-conception cycles even when there has been definite fertilization and embryo formation\n",
            "18 -- 20 -- METHOD : PIBF expression on T lymphocytes was measured using an immunohistochemical method with a PIBF-specific polyclonal antibody\n",
            "18 -- 20 -- There were no differences in PIBF levels by therapy used in non-pregnant cases or in the pregnant group\n",
            "25 -- 27 -- CONCLUSION : These data are consistent with the hypothesis that maternal expression of PIBF in T-lymphocytes soon after trophoblast invasion may depend on successful implantation\n",
            "37 -- 39 -- It has been reported previously that amino acids in the Murchison meteorite exhibit an excess of L-enantiomers , raising the possibility that a similar excess was present in the initial inventory of organic compounds on the Earth\n",
            "28 -- 30 -- The stable carbon isotope compositions of individual amino acids in Murchison support an extraterrestrial origin -- rather than a terrestrial overprint of biological amino acids-although reservations have persisted\n",
            "47 -- 49 -- The miracidia of Fasciola hepatica and Trichobilharzia ocellata approach their host snails Lymnaea truncatula and L. stagnalis by increasing their rate of change of direction ( RCD ) in increasing gradients of snail-conditioned water ( SCW ) , and they perform a turnback swimming in decreasing gradients\n",
            "13 -- 17 -- Alkaline cleavage revealed that they contained carbohydrates linked O-glycosidically via serine and N-acetylgalactosamine\n",
            "32 -- 34 -- Differences in the chemical characteristics of SCW from the intermediate hosts L. truncatula and L. stagnalis could be shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis , blotting , and subsequent carbohydrate detection\n",
            "20 -- 22 -- The first step of purification of the effective signaling SCW components from both snail species was achieved by ion-exchange chromatography\n",
            "21 -- 23 -- Black patients with colon cancer in the Black/White Cancer Survival Study were found to have a poorer survival than white patients\n",
            "18 -- 20 -- More advanced-stage disease at diagnosis was the primary determinant , accounting for 60 % of the excess mortality\n",
            "48 -- 52 -- Blacks were less likely to have poorly differentiated ( grade 3 ) tumors ( odds ratio ( OR ) , 0.44 ; 95 % confidence interval , 0.22-0.88 ) and lymphoid reaction ( OR , 0.49 ; 95 % confidence interval , 0.26-0.90 ) when compared with whites\n",
            "35 -- 39 -- These black/white ( B/W ) differences remained statistically significant after adjusting for age , sex , metropolitan area , summary stage , socioeconomic status , body mass index , and health care access and utilization\n",
            "36 -- 38 -- In addition , blacks were less likely to have high-grade ( grade 3 ) nuclear atypia , mitotic activity , and tubule formation , although these ORs did not reach a statistical significance level of 0.05\n",
            "21 -- 23 -- Future studies should explore the B/W differences in tumor biology using molecular markers that precede the conventional histological parameters evaluated here\n",
            "27 -- 29 -- A new method is described for detection of mutations in the lysosomal alpha-glucosidase gene ( GAA ) leading to Glycogen Storage Disease type II ( GSDII )\n",
            "34 -- 35 -- A new splice site mutation in the GAA gene of this patient was identified , IVS16 ( +2T -- > C ) , resulting in the deletion of 16 base pairs of exon 16\n",
            "34 -- 36 -- The purpose of this study was to investigate the autonomic function in patients with cerebral palsy using two noninvasive tests : sympathetic skin response ( SSR ) and R-R interval variation ( RRIV )\n",
            "54 -- 56 -- A two-credits per semester clinical medicine course was established in the Department of Physical Medicine and Rehabilitation ( PM & # 38 ; R ) in cooperation with the Johns Hopkins University undergraduate Human Biology faculty to present the variety of inpatient consultation personnel , units , patient diagnostic groups , and functional problems\n",
            "98 -- 100 -- The results confirm student exposure to many ward settings ( surgery , 30 % ; neurology/neurosurgery , 28 % ; medicine , 24 % ; intensive care , 15 % ; oncology , 2 % ; and psychiatry , 1 % ) , patient complexity ( averaging 10 problems ) , and multiple ICD-9 diagnosis categories ( circulatory , 36 % ; neurologic , 22 % ; musculoskeletal , 17 % ; neoplasms , 10 % ; injury , 5 % ; endocrine , 4 % ; infections , 3 % ; and others , 3 % )\n",
            "38 -- 41 -- We performed a prospective study over a12-mo period on bone density at a spinal and peripheral measuring site in 28 female senior members ( mean age : 67 +/- 2 yr ) of a dancing group in Vienna\n",
            "31 -- 33 -- Changes of the biochemical parameters were observed in the bone-specific isoenzyme of alkaline phosphatase , a marker of osteoblastic activity , in group I giving additional evidence of increased bone formation\n",
            "28 -- 31 -- SUBJECTS : 890 women aged 18-35 years attending general practice for a cervical smear or a `` young well woman '' check between October 1994 and January 1996\n",
            "29 -- 31 -- MAIN OUTCOME MEASURES : Prevalence of C trachomatis infection in women aged 18-35 on the basis of each test ; sensitivity and specificity of both tests in this population\n",
            "57 -- 64 -- DATA SOURCES : Archival articles and reviews identified through a computerized search of MEDLINE from 1966 to April 1997 using `` fenfluramine ( s ) , '' `` serotonin , '' `` neurotoxicity , '' `` behavior , '' `` anorexigens , '' `` weight loss , '' and `` primary pulmonary hypertension '' as index terms\n",
            "25 -- 27 -- STUDY SELECTION : Reports dealing with long-term effects of fenfluramines on brain serotonin neurons , body weight , and pulmonary function in animals and humans\n",
            "28 -- 32 -- DATA SYNTHESIS : Fenfluramines cause dose-related , long-lasting reductions in serotonin axonal markers in all the animal species tested and with all the routes of drug administration used\n",
            "25 -- 29 -- Moxonidine ( Physiotens-Solvay ) was introduced last year as the first of a new class of centrally-acting antihypertensive agents , the selective imidazoline receptor agonists\n",
            "19 -- 21 -- Other claims suggest that it causes fewer unwanted effects than older centrally-acting antihypertensive drugs such as clonidine and methyldopa\n",
            "32 -- 36 -- After six baiting campaigns ( 15-20 baits/km2 ) over a period of 14 months , the prevalence of the cestode in foxes , initially 32 % , had fallen to 4 %\n",
            "24 -- 26 -- In patients with chronic myeloid leukemia ( CML ) , the neoplastic ( BCR-ABL+ ) progenitor cells are characterized by an increased proliferative activity\n",
            "25 -- 33 -- Nevertheless , both primary CML cells and BCR-ABL+ BAF3 cells show the same dose-dependent sensitivity to TNF-alpha or ceramide-induced apoptosis as their respective normal counterparts\n",
            "53 -- 57 -- However , in the first case , activation of apoptosis is blocked by the basal activity of p210 ( BCR-ABL ) , whereas in the second , the presence of p210 ( BCR-ABL ) appears to accelerate the onset of apoptosis by a mechanism that may involve an activation of its kinase function\n",
            "21 -- 22 -- Altered calcium ( Ca2+ ) homeostasis is thought to play a key role in aging and neuropathology resulting in memory deficits\n",
            "25 -- 27 -- Several forms of hippocampal synaptic plasticity are dependent on Ca2+ , providing a potential link between altered Ca2+ homeostasis and memory deficits associated with aging\n",
            "21 -- 23 -- The current study reviews evidence for Ca2+ dysregulation during aging which could interact with Ca ( 2+ ) -dependent synaptic plasticity\n",
            "25 -- 26 -- The authors suggest that changes in Ca2+ regulation could adjust the thresholds for synaptic modification , favoring processes for depression of synaptic strength during aging\n",
            "38 -- 40 -- The ability of PRL to activate the promoter of the beta-casein gene or the lactogenic hormone responsive element fused to the luciferase reporter was assessed in Chinese hamster ovary cells or 293 fibroblasts transiently transfected with PRLR cDNAs\n",
            "73 -- 77 -- This approach has allowed us to show that delta-19 , lacking expression at the plasma membrane , can transduce the hormonal message , at least to a limited extent ( up to 30 % of wild type efficiency ) , providing that association/activation occurs with a PRL-PRLR complex initiated at the cell surface level ; box 1 of the cytoplasmic form is necessary to rescue this partial transcriptional activity of the inactive mutant\n",
            "37 -- 41 -- Bone mineral density was measured by dual-energy x-ray absorptiometry , blood and urine were analyzed every six months , and cases of nonvertebral fracture were ascertained by means of interviews and verified with use of hospital records\n",
            "62 -- 65 -- RESULTS : The mean ( +/-SD ) changes in bone mineral density in the calcium-vitamin D and placebo groups were as follows : femoral neck , +0.50+/-4.80 and -0.70+/-5.03 percent , respectively ( P=0.02 ) ; spine , +2.12+/-4.06 and +1.22+/-4.25 percent ( P=0.04 ) ; and total body , +0.06+/-1.83 and -1.09+/-1.71 percent ( P & # 60 ; 0.001 )\n",
            "35 -- 39 -- The difference between the calcium-vitamin D and placebo groups was significant at all skeletal sites after one year , but it was significant only for total-body bone mineral density in the second and third years\n",
            "25 -- 27 -- Of 37 subjects who had nonvertebral fractures , 26 were in the placebo group and 11 were in the calcium-vitamin D group ( P=0.02 )\n",
            "53 -- 55 -- CONCLUSIONS : In men and women 65 years of age or older who are living in the community , dietary supplementation with calcium and vitamin D moderately reduced bone loss measured in the femoral neck , spine , and total body over the three-year study period and reduced the incidence of nonvertebral fractures\n",
            "28 -- 30 -- Misinterpretation of `` safe and adequate '' to mean `` safety limit '' would impose restrictions on vitamin and mineral intakes that are not needed to ensure safety\n",
            "15 -- 17 -- There is no evidence of adverse effects from beta-carotene supplements except in current heavy smokers\n",
            "24 -- 26 -- Mutations in one of these MMR genes , hMSH2 , account for about half of all cases of genetically linked hereditary non-polyposis colorectal cancer\n",
            "12 -- 14 -- Both Msh2- and p53-targeted knockout mice are viable and susceptible to cancer\n",
            "27 -- 29 -- In contrast , male Msh2-/-p53-/- mice are viable , but succumb to tumours significantly earlier ( t1-2 is 73 days ) than either Msh2-/- or p53-/- littermates\n",
            "42 -- 48 -- 141 , 252-258 , 1995 ) on the kinetics of the repair of potentially lethal damage in log-phase Chinese hamster V79 cells are used to test some predictions which arise from the different assumptions of the repair-misrepair ( RMR ) ( C\n",
            "15 -- 19 -- 104 , S77-S95 , 1985 ) , lethal-potentially lethal ( LPL ) ( S. B\n",
            "7 -- 9 -- 118 , 437-466 , 1989 ) models\n",
            "30 -- 32 -- The LPL model defines the time available for repair of PLD ( t ( rep ) ) as the time taken to reach maximal survival in a delayed-plating recovery experiment\n",
            "34 -- 39 -- Second , data for split-dose recovery are used to predict the first-order kinetics time constant for DSB repair ( tau ( DSBR ) ) using the DSB model ( 24 +/- 1.5 min )\n",
            "32 -- 35 -- This value is nearly identical to the value of 27 +/- 1 min determined from the data obtained by Cheong et al . using pulsed-field gel electrophoresis ( PFGE ) ( Mutat\n",
            "6 -- 8 -- 274 , 111-122 , 1992 )\n",
            "66 -- 69 -- The value based on PFGE is used to calculate the value of t ( rep ) predicted by the DSB model ( 2.6 +/- 0.1 h ) , which agrees with the value determined experimentally as the time when changing the delayed-plating medium from growth medium to conditioned medium no longer gives the full recovery seen with delayed plating in conditioned medium ( 2.5 h )\n",
            "110 -- 111 -- The early t ( rep ) , associated with tau ( fast ) , is predicted to be 1.7 +/- 0.7 h , and the late t ( rep ) , associated with tau ( slow ) , is predicted to be about 5 h. Both values are in excellent agreement with the times at which changing from growth medium to conditioned medium no longer gives the full recovery seen in conditioned medium only ( the early t ( rep ) ) , and the time when changing from growth medium to conditioned medium produces no further increase in survival ( the late t ( rep ) ) , respectively\n",
            "16 -- 18 -- We assessed G-CSF as adjuvant therapy for the treatment of severe foot infections in diabetic patients\n",
            "20 -- 24 -- No G-CSF-treated patient needed surgery , whereas two placebo recipients underwent to amputation and two had extensive debridement under anaesthesia\n",
            "6 -- 8 -- G-CSF therapy was generally well tolerated\n",
            "28 -- 32 -- BACKGROUND : Accelerated infusion of alteplase ( tissue plasminogen activator ) over a period of 90 minutes induces more rapid lysis of coronary-artery thrombi than a 3-hour infusion\n",
            "15 -- 17 -- We tested the hypothesis that double-bolus alteplase is at least as effective as accelerated infusion\n",
            "66 -- 68 -- METHODS : In 398 hospitals , 7169 patients with acute myocardial infarction were randomly assigned to weight-adjusted , accelerated infusion of 100 mg of alteplase or to a bolus of 50 mg of alteplase over a period of 1 to 3 minutes followed 30 minutes later by a second bolus of 50 mg ( or 40 mg for patients who weighed less than 60 kg )\n",
            "15 -- 17 -- The trial was stopped prematurely because of concern about the safety of the double-bolus injection\n",
            "23 -- 29 -- RESULTS : Thirty-day mortality was higher in the double-bolus group than in the accelerated-infusion group : 7.98 percent as compared with 7.53 percent\n",
            "25 -- 27 -- As increasing numbers of these patients with similar clinical features were identified , there appeared to be an association between these features and fenfluramine-phentermine therapy\n",
            "24 -- 29 -- RESULTS : Twenty-four women ( mean ( +/-SD ) age , 44+/-8 years ) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy\n",
            "14 -- 16 -- The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease\n",
            "16 -- 18 -- CONCLUSIONS : These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease\n",
            "20 -- 22 -- Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects , including pulmonary hypertension and valvular heart disease\n",
            "28 -- 32 -- Internal fixation was achieved with either dual intrameduilary threaded Steinmann pins or an obliquely placed AO compression screw and a three- or four-hole one-third tubular dorsal neutralization plate\n",
            "23 -- 25 -- Although technically demanding , it provides long-term stability to the hallux , restores weightbearing , and allows for maintenance of a propulsive gait\n",
            "5 -- 7 -- DESIGN : Prospective community-based study\n",
            "28 -- 30 -- RESULTS : The crude incidence rate was estimated to be 30.7 per 100000 ( 95 % confidence interval 27.1-34.4 ) and the standardised rate was 68 per 100000\n",
            "34 -- 36 -- CONCLUSION : With a standardised rate of 68 per 100000 and a first-week mortality rate of 35 % , stroke must now be considered an important cause of morbidity and mortality in the population\n",
            "20 -- 22 -- OBJECTIVE : To explore the long-term effect of calcium supplementation during pregnancy on the offspring 's blood pressure during childhood\n",
            "37 -- 39 -- SUBJECTS : 591 children at a mean age of 7 years whose mothers were randomly assigned during pregnancy to receive 2 g/day of elemental calcium ( n = 298 ) or placebo ( n = 293 )\n",
            "56 -- 66 -- A prospective , randomized , placebo-controlled , double-blind , parallel-group , 6-month study assessed the efficacy and safety of ropinirole , a nonergoline D2-dopamine agonist , in patients with early Parkinson 's disease ( n = 241 ; Hoehn & # 38 ; Yahr stages I to III ) with limited or no prior dopaminergic therapy\n",
            "28 -- 30 -- Starfish oocytes can be fertilized after germinal vesicle breakdown ( GVBD ) and artificial parthenogenesis can be induced by activating the oocytes after GVBD ( post-GVBD activation )\n",
            "16 -- 20 -- Most of the caffeine-treated eggs developed as tetraploids , as parthenogenotes produced by the post-GVBD activation\n",
            "29 -- 33 -- Eggs derived from immature oocytes activated by A23187 , treated with 1-MeAde and post-treated with cytochalasin B failed to extrude polar bodies , and eventually developed into parthenogenetic embryos\n",
            "18 -- 20 -- We hypothesized that fluoride partly acts by changing the levels of circulating calcium-regulating hormones and skeletal growth factors\n",
            "16 -- 18 -- The effects of oral fluoride on 24 female , Dutch-Belted , young adult rabbits were studied\n",
            "23 -- 27 -- The rabbits were divided into two study groups , one control and the other receiving about 16 mg fluoride/rabbit/day in their drinking water\n",
            "42 -- 46 -- X-ray diffraction showed altered mineral crystal thickness in fluoride-treated bones ( P & # 60 ; 0.001 ) , and there was a negative association between crystal width and fracture stress of the femur ( P & # 60 ; 0.02 )\n",
            "13 -- 15 -- The follow-up ranged from 1 to 4.5 years ( mean 2 years )\n",
            "34 -- 46 -- In the present study the potent 5-HT1A receptor agonist , 8-hydroxy-2- ( di-n-propylamino ) -tetralin ( 8-OH-DPAT ) was tested for its effect on plasma cortisol concentrations in rainbow trout ( Oncorhynchus mykiss )\n",
            "13 -- 17 -- Blood was sampled and 8-OH-DPAT administered through a catheter in the dorsal aorta\n",
            "44 -- 62 -- Thirty minutes after the injection of 40 microg of 8-OH-DPAT/kg , plasma cortisol levels had increased from 12 to 149 ng/ml , whereupon they fell , reaching baseline levels after 4 h. The effect of 1-40 microg 8-OH-DPAT/kg on plasma cortisol concentrations was dose-dependent\n",
            "56 -- 58 -- The results lends further support to the hypothesis that the brain serotonergic system plays a key role in integrating autonomic , behavioral and neuroendocrine stress-responses in fish as well as mammals , suggesting that not only the structural and biochemical organization , but also the function of the serotonergic system has been conserved during vertebrate evolution\n",
            "71 -- 75 -- < TO_SEE > Eighty women undergoing cesarean section ( C/S ) with epidural 2 % lidocaine with epinephrine ( 1 : 200 , 000 ) were randomly assigned to receive double-blind epidural administration of F ( 25 , 50 , 100 , or 200 microg ) or S ( 5 , 10 , 20 , or 30 microg ) ( n = 10 per group ) upon complaint of pain postoperatively\n",
            "51 -- 53 -- Visual analog scales ( VAS , 0-100 mm ) were used to assess pain and sedation at baseline ; at 3 , 6 , 9 , 12 , 15 , 20 , 25 , 30 , 45 , and 60 min ; and every 30 min until further analgesia was requested\n",
            "52 -- 56 -- < TO_SEE > Granulocyte colony-stimulating factor ( G-CSF ) has been used to improve granulocyte count in chronic neutropenia and myelodysplasia , to minimize the incidence and duration of neutropenia during conventional chemotherapy , and to mobilize peripheral blood stem cells prior to leukapheresis for use in autologous and allogeneic marrow transplantation\n",
            "16 -- 18 -- However , thus far , no life-threatening sequelae of these effects are found in the literature\n",
            "27 -- 31 -- We now describe a case of spontaneous splenic rupture four days following a six-day course of G-CSF therapy in an allogeneic donor of peripheral blood stem cells\n",
            "18 -- 20 -- Evidence-based medicine ( EBM ) aids clinical decision making in all fields of medicine , including primary care\n",
            "21 -- 23 -- General practice is characterized by particular emphasis on the doctor-patient relationship and on biomedical , personal and contextual perspectives in diagnosis\n",
            "32 -- 34 -- Most evidence available to general practitioners ( GPs ) addresses only the bio-medical perspective and is often not directly applicable to primary care , as it derives from secondary or tertiary care\n",
            "13 -- 15 -- The data were then meta-analyzed to produce outcome estimates for alternative surgical procedures\n",
            "39 -- 43 -- CONCLUSIONS : The panel found sufficient acceptable long-term outcomes data ( longer than 48 months ) to conclude that surgical treatment of female stress urinary incontinence is effective , offering a long-term cure in a significant percentage of women\n",
            "18 -- 22 -- Retropubic suspensions and slings are the most efficacious procedures for long-term success ( based on cure/dry rates )\n",
            "13 -- 19 -- A 55-year-old lady underwent repeat aortic valve replacement using a 16-mm Carbomedics prosthesis\n",
            "12 -- 14 -- Doppler echocardiography reveals a 21-mm Hg gradient across the valve at rest\n",
            "17 -- 19 -- We therefore evaluated the effect of cure of Helicobacter pylori infection on basal and pentagastrin-stimulated acid secretion\n",
            "43 -- 47 -- RESULTS : The gastritis index was significantly lower after therapy and was associated with an increase in both BAO and MAO after cure of the H. pylori infection ( BAO from 0.3 mmol/h and MAO from 4.8 mmol/h to 19 mmol/ h )\n",
            "52 -- 60 -- Basal and stimulated acid concentrations also increased ( 29.1 +/- 36.6 to 54 +/- 31 mmol/l and 72.5 +/- 46 to 120.1 +/- 30 mmol/l , respectively , for basal and stimulated acid concentrations ; P & # 60 ; 0.05 for peak and MAO , P = 0.07 for BAO )\n",
            "23 -- 25 -- RESULTS : Forty-four patients in the partner intrauterine insemination group and 37 in the donor insemination group were identified as having primary infertility\n",
            "26 -- 30 -- Chromosomally integrated retroviral switch ( S ) substrates have been developed to reveal switch recombinase-like activities ( SRLA ) in pre-B and mature B cell lines\n",
            "41 -- 45 -- By initially selecting for proviral integrants in hygromycin followed by shifting into neomycin + ganciclovir to select for S sequence-mediated deletions , switch recombinations can be specifically forestalled in B cell lines whilst most switch-incompetent cells do not survive secondary selection\n",
            "23 -- 29 -- A semi-quantitative DC-PCR assay detects a significant recombinase activity only in a restricted set of late stage pre-B and mature B cell lines\n",
            "30 -- 34 -- BCL1B1 mature B cells have the highest level of recombinase activity with 25 % or more of proviral integrants accumulating S mu/S gamma 2b substrate recombinations within 10-14 cell generations\n",
            "29 -- 31 -- The SSR recombinase assay can be performed in a transient fashion wherein extensive , B cell-specific recombination can be visualized within only a few cell divisions post proviral integration\n",
            "40 -- 42 -- We propose that switch recombinase activity becomes activated during B cell ontogeny independent of or prior to the acquisition of CH locus accessibility and that endogenous S segment targeting to pre-existing recombinase requires a level of accessibility beyond transcriptional activation\n",
            "30 -- 31 -- DESIGN : A prospective study consisting of anonymous , unlinked urine testing of 504 'first visit ' antenatal patients and a separate group of 515 patients six weeks after delivery\n",
            "21 -- 23 -- METHODS & # 38 ; OUTCOME MEASURES : Toxicological screening using enzyme-linked immunoassay techniques , with all positive samples being reanalysed\n",
            "15 -- 17 -- None of the women yielding positive samples had been pre-identified on the basis of history\n",
            "19 -- 21 -- A significant proportion of the women were in the high risk categories with regard to age and socio-economic status\n",
            "73 -- 75 -- Given that the predisposition ( which presumably is genetic ) is associated with a procreative disadvantage why do such illnesses persist ? Here it is suggested that these conditions are a manifestation of genetic diversity in the evolution of the specifically human characteristic of language , an innovation that has occurred by a process of progressive hemispheric specialization-the establishment of dominance for some critical component of language in one or the other hemisphere\n",
            "27 -- 28 -- Individuals who develop schizophrenic symptoms show lesser anatomical and functional asymmetries than the population as a whole ; such symptoms may reflect 'dominance failure ' for language\n",
            "33 -- 34 -- OBJECTIVE : To examine the relationship between plasma plasminogen activator inhibitor 1 ( PAI-1 ) activity and PAI-1 gene ( 4G/5G ) polymorphism and diabetic retinopathy in Pima Indians with type 2 diabetes\n",
            "25 -- 29 -- RESEARCH DESIGN AND METHODS : We studied 171 Pima Indians with type 2 diabetes between the ages of 30-70 years in a population-based epidemiological survey\n",
            "25 -- 28 -- Plasma PAI-1 activity was measured by a spectrophotometric assay and PAI-1 4G/5G promoter genotype by the polymerase chain reaction ( PCR ) using allele-specific primers\n",
            "31 -- 33 -- Plasma PAI-1 activity was not significantly different among subjects with and without retinopathy ( 17.1 +/- vs. 19.7 +/- 9.1 arbitrary units ( AU ) /ml , P = 0.09 )\n",
            "64 -- 66 -- In a logistic regression analysis controlled for age , sex , BMI , and duration of diabetes , any retinopathy was significantly associated with fasting plasma glucose concentrations ( P & # 60 ; 0.05 ) , 2-h postload glucose ( P = 0.02 ) , and HbA1c ( P = 0.008 ) , but not with PAI-1 activity ( P = 0.48 )\n",
            "70 -- 77 -- The prevalence of retinopathy in the three genotype groups differed significantly ( 4G/4G , 4G/5G , and 5G/5G were 44 , 49 , and 24 % , respectively ; chi 2 = 8.22 , df = 2 , P = 0.016 ) and remained significant after controlling for age , sex , BMI , duration of diabetes , glycated hemoglobin , and urine albumin-to-creatine ratio in a logistic regression analysis\n",
            "24 -- 27 -- The odds ratios for retinopathy in subjects with 4G/4G and 4G/5G , compared with the 5G/5G genotype , were 2.0 and 3.1 , respectively\n",
            "36 -- 39 -- CONCLUSIONS : Although diabetic retinopathy in Pima Indians with type 2 diabetes is not associated with PAI-1 activity , subjects with the 4G/4G and 4G/5G genotype had a higher prevalence of retinopathy compared with 5G/5G PAI-1genotype\n",
            "31 -- 32 -- These preliminary findings indicate that in Pima Indians with type 2 diabetes , presence of the 4G allele of the PAI-1 gene was associated with a higher risk of diabetic retinopathy\n",
            "22 -- 24 -- BACKGROUND : Diagnostic peritoneal lavage ( DPL ) is used to diagnose intra-abdominal injury in patients with stab wounds and blunt trauma\n",
            "24 -- 26 -- OBJECTIVE : To evaluate the performance of DPL in the diagnosis of intra-abdominal injury in hemodynamically stable patients with gunshot wounds to the abdomen\n",
            "23 -- 25 -- INTERVENTIONS : Clinical predication of intra-abdominal injury in the emergency department and DPL performed in the operating room before the initiation of celiotomy\n",
            "9 -- 11 -- RESULTS : Forty-four patients were enrolled into the study\n",
            "47 -- 49 -- Diagnostic peritoneal lavage correctly identified the presence or absence of intra-abdominal injury in 40 ( 91 % ) of the patients ( positive predictive value = 96.7 % , negative predictive value = 78.6 % , phi = 0.79 , P & # 60 ; .01 )\n",
            "32 -- 34 -- Diagnostic peritoneal lavage is an objective test that may augment clinical judgment in selecting hemodynamically stable patients with potential tangential gunshot wounds for observation and is especially useful in identifying intra-abdominal hemorrhage\n",
            "12 -- 14 -- In the group C the presence of non-parasitic enteropathogens was also investigated\n",
            "36 -- 38 -- Breastfed infants also showed greater catch-up growth in head circumference ( SD score ( SDS ) 0.53 higher at 3 months ) , and greater body length gain ( SDS 0.68 higher at 6 months )\n",
            "21 -- 23 -- Critical care nurses routinely teach patients about using healthy practices such as low-fat diets , exercise , and routine screening examinations\n",
            "94 -- 98 -- OBJECTIVES : The purpose of this descriptive exploratory study was to examine critical care nurses ' responses to three questions about health practices in their daily lives : ( 1 ) What are critical care nurses doing currently to stay healthy ? ( 2 ) Do they anticipate making any changes in their lifestyle in the future ? ( 3 ) Would they recommend their lifestyle to their patients ? METHODS : One hundred twenty-seven critical care nurses attending a midwestern critical care conference completed a two-part questionnaire designed to produce a health profile\n",
            "14 -- 20 -- In a man-on-the-street approach , 23 nurses participated in an interview via video camera\n",
            "16 -- 18 -- Five themes emerged from the videotaped interviews : ( 1 ) Heart-healthy practices predominated the responses\n",
            "39 -- 41 -- Cytochrome P450 1A1 ( CYP1A1 ) and glutathione S-transferase M1 ( GSTM1 ) genetic polymorphisms are involved in the activation and detoxification of chemical carcinogens found in tobacco smoke ; thus they may influence host susceptibility to lung cancer\n",
            "65 -- 69 -- After adjusting for age , gender , pack-years of smoking , and years since quitting smoking , while neither the CYP1A1 MspI heterozygous genotype alone nor the GSTM1 null genotype alone were associated with a significant increase in lung cancer risk , having both genetic traits was associated with a twofold increase in risk ( 95 percent confidence interval ( CI ) = 1.0-3.4 )\n",
            "27 -- 29 -- Our data did not provide enough evidence for a substantial modification of the effect of pack-years on lung cancer risk by the CYP1A1 MspI and GSTM1 genotypes\n",
            "21 -- 23 -- Overall 30-day mortality was significantly lower in the patients who received thrombolytic agents ( 4.7 versus 11.1 % , P=.016 )\n",
            "26 -- 28 -- The authors report the postoperative magnetic resonance ( MR ) imaging findings in 36 patients with advanced Parkinson 's disease who underwent unilateral microelectrode-guided posteroventral pallidotomy\n",
            "16 -- 20 -- Sequential MR studies were obtained within 1 to 3 days postoperatively and at 6-month follow-up examination\n",
            "44 -- 46 -- The mean volume of the middle zone , corresponding to the area of hemorrhagic coagulation necrosis , was 44.4 +/- 17.6 mm3 ; the mean lesion volume as defined by the outer zone , corresponding to perilesional edema , was 262.2 +/- 111.6 mm3\n",
            "15 -- 18 -- The mean volume of late-phase ( 6 months ) lesions was 22 +/- 28.8 mm3\n",
            "27 -- 29 -- A commercially available health food product of cold-pressed hemp seed oil ingested by one volunteer twice a day for 4 1/2 days ( 135 mL total )\n",
            "125 -- 153 -- Urine specimens collected from the volunteer were subjected to standard workplace urine drug testing procedures , and the following concentrations of 11-nor-delta9- tetrahydrocannabinol carboxylic acid ( 9-THCA ) were detected : 41 ng/mL 9-THCA at 45 h , 49 ng/mL at 69 h , and 55 ng/mL at 93 h. Ingestion was discontinued after 93 h , and the following concentrations were detected : 68 ng/mL at 108 h , 57 ng/mL at 117 h , 31 ng/mL at 126 h , and 20 ng/mL at 142 h. The first specimen that tested negative ( 50 ng/mL initial immunoassay test , 15 ng/mL confirmatory gas chromatographic-mass spectrometric test ) was at 146 h , which was 53 h after the last hemp seed oil ingestion\n",
            "24 -- 26 -- This study indicates that a workplace urine drug test positive for cannabinoids may arise from the consumption of commercially available cold-pressed hemp seed oil\n",
            "45 -- 49 -- RESULTS : Test results for 46 ECMO-treated infants ( 57.5 % ) were normal , and those for 34 infants ( 42.5 % ) were abnormal , with either elevated wave V threshold , prolonged wave I-V interval , or both on neonatal BAEP recordings\n",
            "24 -- 28 -- The guide situates general internal medicine as the primary care profession that focuses on preventive , short-term , and long-term care of adult patients\n",
            "18 -- 20 -- It also describes a process that program directors and local program committees can use to develop competency-based curricula\n",
            "14 -- 16 -- We report 4 new cases of localized Darier disease and review the English-language literature\n",
            "34 -- 38 -- UV radiation induces two major DNA damage products , the cyclobutane pyrimidine dimer ( CPD ) and , at a lower frequency , the pyrimidine ( 6-4 ) pyrimidinone dimer ( 6-4 product )\n",
            "41 -- 45 -- Although Escherichia coli and Saccharomyes cerevisiae produce a CPD-specific photolyase that eliminates only this class of dimer , Arabidopsis thaliana , Drosphila melanogaster , Crotalus atrox , and Xenopus laevis have recently been shown to photoreactivate both CPDs and 6-4 products\n",
            "33 -- 35 -- We describe the isolation and characterization of two new classes of mutants of Arabidopsis , termed uvr2 and uvr3 , that are defective in the photoreactivation of CPDs and 6-4 products , respectively\n",
            "25 -- 27 -- This provides us with a unique opportunity to study the biological consequences of each of these two major UV-induced photoproducts in an intact living system\n",
            "16 -- 20 -- We present the case of a 15-month-old girl with TSS , but without erythroderma or desquamation\n",
            "28 -- 30 -- After 7 days , a TSS toxin 1-producing strain of Staphylococcus aureus was cultured from an inguinal lymph node , where inflammation had already been noticed on admission\n",
            "32 -- 34 -- Without the evidence implicating a TSS toxin 1-producing strain of S. aureus as the cause of her disease , a diagnosis of syndrome of hemorrhagic shock and encephalopathy would have been made\n",
            "48 -- 54 -- RESULTS : Two male patients are presented , 1 with a metastatic germ cell tumor of both the retroperitoneum and mediastinum ( with elevated alpha-fetoprotein level ) and 1 with a primary germ cell tumor of the mediastinum ( with elevated alpha-fetoprotein and beta-human chorionic gonadotropin levels )\n",
            "31 -- 36 -- Our results demonstrate that the `` multigene-one-protein '' principle of CaM synthesis is not only applicable to mammals whose CaM is encoded by three different genes , but also to chickens\n",
            "36 -- 42 -- METHODS AND RESULTS : In 1994 , 24 months after enrollment in a longitudinal study , 326 high-risk adults underwent both 3- and 6-mm image-slice thickness EBCT scanning and were followed up for 32.0+/-4.0 additional months\n",
            "21 -- 23 -- We monitored these subjects for the 32-month postscanning period with yearly phone calls and acquisition of records for all hospital admissions\n",
            "29 -- 31 -- At the time of scanning , 11 subjects ( 3 % ) had already suffered 12 events ( 5 infarctions and 7 revascularizations ) during the 24-month prescanning period\n",
            "13 -- 14 -- The very motivation for seeking an `` origin '' of homosexuality reveals homophobia\n",
            "44 -- 46 -- Cyclin D1 , the regulatory subunit of certain protein kinases thought to advance the G1 phase of the cell cycle , is now established as a proto-oncogene , with evidence indicating that its derangement may contribute to the uncontrolled cell growth characteristic of tumors\n",
            "21 -- 23 -- Recent studies demonstrated that immunohistochemical detection in paraffin-embedded material , using a monoclonal antibody , is very useful for routine diagnosis\n",
            "33 -- 37 -- In the mammalian central nervous system , a diverse group of basic helix-loop-helix ( bHLH ) proteins is involved in the determination of progenitor cells and , subsequently , in regulating neuronal differentiation\n",
            "26 -- 32 -- Here we report the identification of a novel subfamily of bHLH proteins , defined by two mammalian enhancer-of-split- and hairy-related proteins , termed SHARP-1 and SHARP-2\n",
            "25 -- 26 -- This suggests that neuronal bHLH proteins are also involved in the `` adaptive '' changes of mature CNS neurons which are coupled to glutamatergic stimulation\n",
            "15 -- 17 -- Successful patterning was demonstrated by challenging surfaces with goat anti-mouse antibody conjugated to tetramethylrhodamine isothiocyanate\n",
            "35 -- 39 -- It was found that with appropriate enzymes , peak outputs occurred within approximately 5 min ( 4-20 times faster than without enzymes ) and peak response magnitudes were up to nine-fold greater than without enzymes\n",
            "20 -- 24 -- An easy-to-use technique for detection of antibodies specific for the parasite L. donovani in human serum sample has been developed\n",
            "15 -- 19 -- These biosensors are fabricated by site-selective photodeposition of analyte-sensitive polymer matrices on optical imaging fibres\n",
            "19 -- 21 -- These dual-analyte arrays allow for the simultaneous , independent measurement of the analyte of interest and the transducing analyte\n",
            "52 -- 54 -- The first integrated optical-biosensors using this design have been prepared that allow both the dependent and independent analytes to be measured simultaneously , for example penicillin and pH ( Healey & # 38 ; Walt , 1995 ) or glucose and O2 ( Li & # 38 ; Walt , 1995 )\n",
            "14 -- 18 -- Penicillin can be measured in the range 0.25-10.0 mM in the pH range 6.2-7.5\n",
            "15 -- 19 -- Glucose can be measured in the range 0.6-20.0 mM in the O2 range 20-100 %\n",
            "22 -- 26 -- The utility of the sensor design was demonstrated by using the penicillin-dual-analyte biosensor to quantitate penicillin produced during a Penicillium chrysogenum fermentation\n",
            "19 -- 21 -- We report on the investigation of the binding of low molecular weight ligands to immobilized receptors by label-free detection\n",
            "26 -- 30 -- High affinity binding of biotin to immobilized streptavidin was clearly detectable at receptor surface concentrations as low as 1-2 x 10 ( 10 ) binding sites/mm2\n",
            "14 -- 16 -- Bi-exponential increase and decrease of intercalator loading was observed , indicating complex interaction kinetics\n",
            "16 -- 18 -- An amperometric lactate oxidase catheter has been developed for in vivo application to real-time lactate monitoring\n",
            "21 -- 27 -- The electrochemical behaviour of the 1 x 3 mm Pt-Ag/AgCl thin film electrode is not significantly influenced by lactate oxidase-polyurethane covering\n",
            "11 -- 13 -- Gamma-irradiation ( 25 kGy ) is suitable for the sterilization procedure\n",
            "26 -- 28 -- The final lactate catheter is characterized by a linear concentration range between 0.5 and 20 mmol/l lactate with a sensitivity around 2 nA mmol-1 l-1 lactate\n",
            "37 -- 39 -- Ex vivo whole blood measurements using the lactate catheter ( y ) give a correlation with the BIOSEN Med L ( x ) of y = ( 1.010x + 0.513 ) mmol/l ( r = 0.9748 )\n",
            "31 -- 33 -- The diffusion-limited binding kinetics of antigen ( or antibody ) in solution to antibody ( or antigen ) immobilized on a biosensor and other surfaces is analyzed within a fractal framework\n",
            "19 -- 23 -- Then , for these cases , the dual-fractal analysis provides an improved fit when compared with a single-fractal analysis\n",
            "44 -- 46 -- The different examples analyzed and presented together provide a means by which the antigen-antibody reactions may be better controlled by noting the magnitude of the changes in the fractal dimension and in the binding rate coefficient as the reaction progresses on the biosensor surface\n",
            "27 -- 29 -- The ability to detect UTI by dipstick only and by complete urinalysis was the same , however microscopic evaluation added many false-positive results without detecting additional UTIs\n",
            "27 -- 33 -- Using video-intensified fluorescence microscopy and a pseudocolor display of fluorescence intensity , we analyzed the distribution of microinjected molecules within the nurse-cell/oocyte syncytium of Drosophila ovarian follicles\n",
            "27 -- 29 -- As culture solutions , we used four simple salines ( IMADS ) and a complex tissue-culture medium ( R-14 ) that matched the osmolarity of adult hemolymph\n",
            "44 -- 47 -- Small amounts of two anionic dyes ( Lucifer Yellow CH and Lucifer Yellow dextran ) as well as of two cationic dyes ( rhodamine 6G and tetramethylrhodamine dextran-lysine ) were iontophoretically microinjected either into a nurse cell or into the oocyte of stage-10 follicles\n",
            "49 -- 51 -- In the tissue-culture medium , within a few seconds following microinjection , all tested dyes passed through the intercellular bridges in both the anterior direction ( to the nurse cells ) and the posterior direction ( to the oocyte ) , independent of their electrical charge or molecular mass\n",
            "16 -- 18 -- In mitogen-stimulated human peripheral blood mononuclear cells the AF-4 antigen was predominantly located in the nucleus\n",
            "14 -- 18 -- The members of this family encode serine-proline-rich proteins with properties of nuclear transcription factors\n",
            "28 -- 32 -- To identify novel members of this superfamily in the chick nervous system , we developed a polymerase chain reaction-based approach making use of sequence motifs of immunoglobulin-like domains\n",
            "35 -- 37 -- This molecule has 91 % sequence identity with the limbic system-associated membrane protein ( LAMP ) characterized in the rat and is therefore referred to as the chicken homologue of the latter ( chLAMP )\n",
            "18 -- 26 -- The molecule is a glycosylphosphatidyl-inositol-anchored 60 kDa protein with three immunoglobulin-like domains and contains 40 % N-linked carbohydrate\n",
            "28 -- 30 -- The protein was found on a subset of axons in the central and peripheral nervous system and is likely to be involved in specific cell-cell interactions in neurohistogenesis\n",
            "27 -- 29 -- DNAS1L2 is located on a 16p13.3 cosmid , while DNAS1L3 maps to 3p14.3-p21.1 by fluorescence in situ hybridization and by PCR analysis of a radiation hybrid panel\n",
            "50 -- 54 -- A comparison of DNAS1L1 , DNAS1L2 , and DNAS1L3 with the well-characterized DNase I suggests that the DNAS1L proteins are unlikely to be glycosylated or bind actin ; however , catalytic and calcium- and DNA-binding residues are conserved , and potentially cleavable signal peptides are present among all these proteins\n",
            "33 -- 35 -- In one , suppression of virus replication occurred and has persisted for 90 weeks ( bDNA , & # 60 ; 500 human immunodeficiency virus type 1 ( HIV-1 ) RNA copies/ml )\n",
            "22 -- 24 -- In the six patients in this group , there was also an identical mutation in the gag p7/p1 gag protease cleavage site\n",
            "29 -- 33 -- In one patient , a second mutation occurred at the gag p1/p6 cleavage site , but it appeared 18 weeks after the time of appearance of the p7/p1 mutation\n",
            "31 -- 33 -- When recombinant HIV-1-containing protease mutations at 46 and 82 was grown in MT2 cells , there was a 68 % reduction in its rate of replication compared to the WT virus\n",
            "43 -- 49 -- Similarly , rates of replication of viruses with mutations M46L/I , I54V , and V82A in protease were enhanced both in the presence and in the absence of Indinavir when combined with mutations in the gag p7/p1 and the gag p1/p6 cleavage sites\n",
            "39 -- 41 -- This is the first report of the emergence of mutations in the gag p7/p1 protease cleavage sites in patients receiving protease therapy and identifies this change as an important determinant of HIV-1 resistance to protease inhibitors in patient populations\n",
            "13 -- 15 -- A novel intracellular calcium-binding protein from Echinococcus granulosus is described in this work\n",
            "41 -- 47 -- A cDNA was isolated from a lambdagt11 protoscolex expression library and the deduced amino acid sequence has at least fifteen sequentially repeated twelve-residue repeats that resemble the calcium-binding loop of EF-hands ; however , the dodecamer motif has no flanking helices\n",
            "22 -- 24 -- The cDNA was expressed in Escherichia coli using the pGEX vector , and a recombinant fusion protein ( EgCaBP1-GST ) was obtained\n",
            "26 -- 28 -- It is possible that the calcium-binding motifs present a secondary structure similar to the parallel beta roll structure described for an alkaline protease from Pseudomonas aeruginosa\n",
            "18 -- 22 -- A native protein of more than 300 kDa was recognized by an anti-EgCaBP1 monoclonal antibody by Western-blot analysis\n",
            "18 -- 22 -- Immunohistochemistry using a pool of anti-EgCaBP1-GST mouse sera demonstrated a strong association of the protein with calcareous corpuscles\n",
            "32 -- 34 -- The enzyme activity of mitogen-activated protein kinase ( MAP kinase ) increases in response to agents acting on a variety of cell surface receptors , including receptors linked to heterotrimeric G proteins\n",
            "47 -- 49 -- To investigate the molecular nature underlying cellular responses to Raf-1 activation , we have stably transfected rat salivary epithelial Pa-4 cells with human Raf-1-estrogen receptor fusion gene ( DeltaRaf-1 : ER ) and used mRNA differential display in search of messages induced by DeltaRaf-1 : ER activation\n",
            "24 -- 28 -- Through this approach , the gene encoding non-histone chromosomal protein HMGI-C was identified as one of the target genes activated by oncogenic Raf-1 kinase\n",
            "42 -- 56 -- The role of the extracellular signal-related kinase ( ERK ) signaling pathway in the HMGI-C induction was highlighted by the result that the MAP kinase kinase ( MEK ) inhibitor , PD 98059 , blocked DeltaRaf-1 : ER- and 12-O-tetradecanoylphorbol-13-acetate-stimulated HMGI-C induction\n",
            "27 -- 33 -- Altogether , these findings support the notion that the Raf/MEK/ERK signaling module , at least in part , regulates transcriptional activation of the chromosomal architectural protein HMGI-C\n",
            "15 -- 17 -- Previous genetic linkage studies localized the gene to a broad interval on human chromosome 7q22-31.1\n",
            "26 -- 28 -- We report the cDNA cloning , partial genomic organization , and expression pattern of Stra10 , a novel retinoic acid-inducible gene in P19 embryonal carcinoma cells\n",
            "53 -- 57 -- The predicted protein sequences exhibit approximately 85 % identity with the Pbx-related Meis1 homeobox gene products , which are involved in myeloid leukemia in BXH-2 mice , and one of the Stra10 isoforms corresponds to the recently published Meis2 sequence ( Nakamura et al . ( 1996 ) Oncogene 13 : 2235-2242 )\n",
            "23 -- 25 -- The Meis2 homeodomain is identical to that of Meis1 , and is most closely related to those of the Pbx/TGIF homeobox gene products\n",
            "15 -- 17 -- With this approach , a library specific to the BTA 6q21-31 chromosomal region was constructed\n",
            "19 -- 25 -- Eleven unique microsatellite-containing sequences were isolated , converted into sequence-tagged microsatellite sites , and characterized concerning their species-specific origin\n",
            "23 -- 25 -- Seven primer pairs generated bovine-specific PCR products and provided a set of microsatellite markers that generally revealed high informativity in the HF breed\n",
            "33 -- 35 -- The results underline the usefulness of the BTA 6q21-31 library for targeted isolation of unique sequences that are specific for the dissected chromosomal region as demonstrated here by the isolation of microsatellite markers\n",
            "42 -- 44 -- An analysis of molecular variance ( AMOVA ) revealed no correspondence between mtDNA phylogeography and subspecies delimitation , nor between matrilines and areas characterized by a high incidence of the viverrid-type rabies , of which the yellow mongoose is the principal vector\n",
            "23 -- 25 -- The lack of structure was also shown by control region sequences although four of the maternal lineages shared a near-perfect 81 bp repeat\n",
            "29 -- 33 -- Dioxins are a family of chlorinated aromatic hydrocarbons that are produced during combustion processes in the presence of a chlorine donor and as by-products of the chlorine-processing chemical industries\n",
            "22 -- 28 -- Certain dioxins , particularly 2 , 3 , 7 , 8-tetrachlorodibenzo-p-dioxin , are very toxic and able to induce numerous clinical conditions\n",
            "29 -- 30 -- This presentation summarizes the debate on the suggested progressive impairment of semen quality ( the `` sperm fall '' ) in the last forty years in the developed countries\n",
            "32 -- 33 -- The various available data strongly suggesting an environmental toxic origin for the `` sperm fall '' will be presented as well as the most frequently suspected class of substances , the xenoestrogens\n",
            "51 -- 53 -- < TO_SEE > Despite Beta-blockade therapy has been considered as an absolute contraindication in the treatment of heart failure , it has been shown that they could have a beneficial effect , provided that they were introduced at very low dose , and very progressively in addition of the traditional treatment\n",
            "65 -- 69 -- The advances in the understanding of the neuro-hormonal mechanisms of heart failure have modified the therapeutic strategy : the deleterious effect of the activation of the sympathetic nervous system on the myocardium has served as the rationale for randomized clinical trials comparing beta-blockade to placebo : the current data are promising , suggesting a beneficial effect on survival as well as on quality of life\n",
            "23 -- 25 -- Several recent retrospective studies have suggested that chronic treatment with short-acting dihydropyridines increased the incidence of cardiac events , cancer and gastrointestinal bleedings\n",
            "26 -- 28 -- In addition , well-conducted studies using verapamil and diltiazem have suggested that these calcium antagonists may even improve cardiovascular mortality and morbidity of the hypertensive patient\n",
            "40 -- 44 -- < TO_SEE > There is therefore no reason to believe that the questionable results derived from retrospective studies of the effects of short-acting calcium antagonists on cardiac and noncardiac events may apply to the newer generation of long-acting calcium antagonists\n",
            "17 -- 19 -- However , psychological testing may reveal early-warning signs more readily than the various physiological or immunological markers\n",
            "19 -- 21 -- Furthermore , directing attention to psychophysiological cues serves the same purpose as in RPE , i.e . increasing self-awareness\n",
            "32 -- 33 -- Beyond a certain intensity of exercise , and coinciding with the accumulation of blood lactate ( anaerobic threshold or AT ) , a 'saliva threshold ' ( Tsa ) does indeed exist\n",
            "43 -- 44 -- The mobilisation of FFA is primarily a function of sympathetic nervous activity directed towards the adipocytes , or the 'fat pad ' . This nervous activity can be direct or may be an effect of circulating catecholamines such as adrenaline ( epinephrine )\n",
            "24 -- 26 -- As the clinical availability of glycohaemoglobin/GHb measurement increases , so does the need for comparable and accurate values among different laboratories and different methods\n",
            "20 -- 24 -- Data on the actual state of inter-laboratory and inter-assay differences of observed values were useful for comparing results among facilities\n",
            "26 -- 28 -- Inter-method differences among 11 available assay methods were great even after correction and depended on not only the methods but the samples used for the determination\n",
            "18 -- 20 -- An urgent and worldwide problem to remove inter-laboratory differences in the measurement of GHb needs to be solved\n",
            "9 -- 11 -- Social class and premarital sexual permissiveness : a re-examination\n",
            "6 -- 7 -- A comment on `` anomy ''\n",
            "9 -- 11 -- `` Chronic pancreatitis `` and carcinoma of the pancreas\n",
            "11 -- 13 -- Control of post-haemorrhoidectomy bleeding with a Foley catheter and a pack\n",
            "8 -- 10 -- Urologic complications in non-recurrent cancer of the cervix\n",
            "20 -- 21 -- Supportive role of nurse in first stage of labor `` can not be emphasized enough '' , according to patient\n",
            "6 -- 7 -- Purposeful `` heroic '' heart treatment\n",
            "8 -- 12 -- Synthesis and fragmentation behavior of deuterium-labeled 12-keto steroids\n",
            "8 -- 10 -- A three-year comparison of day and residental treatment\n",
            "11 -- 13 -- Beta-propiolactone as used in sterilization of homografts not carcinogenic for mice\n",
            "18 -- 20 -- Comparative fates of intravenously and orally administered aldosterone : evidence for extrahepatic formation of acid-hydrolyzable conjugate in man\n",
            "19 -- 21 -- Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells of mice to vinblastine administered in vivo\n",
            "15 -- 17 -- Hyperbaric oxygen , whole-body X irradiation , and cyclophosphamide combination therapy in mouse leukemia L1210\n",
            "14 -- 16 -- Effects of tryptophan mustard on incorporation of amino acids into proteins in tumor-bearing rats\n",
            "6 -- 8 -- Community clinic treatment for back-ward patients\n",
            "14 -- 15 -- `` Return the joy of home delivery '' with fathers in the delivery room\n",
            "17 -- 19 -- Comparison of neutral fat and free fatty acids in high lipid-low carbohydrate diets for the growing chicken\n",
            "5 -- 7 -- Sequential estrogen-progestogen therapy in gynecology\n",
            "16 -- 18 -- Congenital heart disease , deaf-mutism and associated somatic malformations occurring in several members of one family\n",
            "9 -- 11 -- On the official inspection of coal-tar dyes in 1969\n",
            "12 -- 14 -- Application of infra-red absorption spectroscopy to examination of drugs and their preparation\n",
            "10 -- 12 -- Ultramicro-analysis of cyclohexylamine and low fatty amines by gas chromatography\n",
            "6 -- 8 -- Identification of tranquillizers by thin-layer chromatography\n",
            "10 -- 12 -- Studies on the anti-microbial activity of nonionic and anionic surfactants\n",
            "12 -- 13 -- On the National Institute of Hygienic Sciences Standard `` lysozyme standard ''\n",
            "9 -- 11 -- Various aspects of water-salt metabolism in heart congestive failure\n",
            "20 -- 22 -- Changes in the mechanism of renal acidification in congestive heart failure : effects of diuretic treatment on the acid-base equilibrium\n",
            "18 -- 54 -- Neuraminic acid-containing oligosaccharides of human urine : isolation and identification of di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine , 6-2-Nacetylneuraminyl-lactose , 6-2-N-acetylneuraminyl-N-acetyllactosamine and 3-2-N-acetylneuraminyl-lactose\n",
            "8 -- 12 -- Determination of serum oxytocinase ( 1-cystine-aminopeptidase ) activity\n",
            "13 -- 15 -- Antenatally detectable markers for the diagnosis of autosomally trisomic fetuses in at-risk pregnancies\n",
            "18 -- 24 -- Perinatal features of omphalocele-exstrophy-imperforate anus-spinal defects ( OEIS complex ) associated with large meningomyeloceles and severe limb defects\n",
            "12 -- 14 -- Intrapartum sonography of the lower uterine segment in patients with breech-presenting fetuses\n",
            "14 -- 16 -- Isolated persistent fetal bradycardia in complete A-V block : a conservative approach is appropriate\n",
            "11 -- 13 -- Amnioinfusion for prevention of pulmonary hypoplasia in second-trimester rupture of membranes\n",
            "10 -- 12 -- Laerdal infant resuscitators are unreliable as free-flow oxygen delivery devices\n",
            "14 -- 16 -- Low prenatal weight gain among low-income women : what are the risk factors ?\n",
            "11 -- 15 -- A randomized trial of one-to-one nurse support of women in labor\n",
            "8 -- 10 -- Detection of differentially expressed genes in head-neck carcinomas\n",
            "4 -- 5 -- A 'normal ' practice\n",
            "8 -- 10 -- Predisposition genetic testing for late-onset disorders in adults\n",
            "16 -- 18 -- Gonorrhea among men who have sex with men -- selected sexually transmitted diseases clinics , 1993-1996\n",
            "8 -- 10 -- Complete genomic screen in late-onset familial Alzheimer disease\n",
            "10 -- 12 -- Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis\n",
            "11 -- 13 -- Early and long-term results of rehabilitation of cochlear implant patients )\n",
            "19 -- 21 -- Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method\n",
            "21 -- 23 -- Ribosomal S6 kinase p90rsk and mRNA cap-binding protein eIF4E phosphorylations correlate with MAP kinase activation during meiotic reinitiation of mouse oocytes\n",
            "15 -- 19 -- Platelet-derived growth factor activates a mammalian Ste20 coupled mitogen-activated protein kinase in airway smooth muscle\n",
            "26 -- 32 -- Cyclic AMP inhibitors inhibits PDGF-stimulated mitogen-activated protein kinase activity in rat aortic smooth muscle cells via inactivation of c-Raf-1 kinase and induction of MAP kinase phosphatase-1\n",
            "6 -- 8 -- A call for stepped-up melanoma screening\n",
            "22 -- 24 -- An efficient HN ( CA ) NH pluse scheme for triple-resonance 4D correlation of sequential amide protons and nitrogens-15 in deuterated proteins\n",
            "19 -- 23 -- Optimal detection of weak nJ ( 1H- 119Sn ) couplings by gradient-enhanced 1D and 2D heteronuclear multiple-quantum correlation spectroscopy\n",
            "23 -- 25 -- The 2D NMR experiments H ( C ) CO2 and HCCO2 for assignment and pH titration of carboxylate groups in uniformly 15N/13C-labeled proteins\n",
            "6 -- 10 -- Post-acquisition solvent suppression by singular-value decomposition\n",
            "12 -- 16 -- Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction\n",
            "12 -- 16 -- Randomised trial of roxithromycin in non-Q-wave coronary syndromes : ROXIS Pilot Study\n",
            "9 -- 11 -- Association between 5-HT2A gene promoter polymorphism and anorexia nervosa\n",
            "12 -- 14 -- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer\n",
            "10 -- 13 -- State regulation in a world of `` boundary-less '' technology\n",
            "4 -- 6 -- Physician-assisted suicide in Oregon\n",
            "11 -- 13 -- Clinical problem-solving -- where did good old clinical diagnosis go ?\n",
            "13 -- 14 -- Steps still being taken to undo damage of `` America 's Nuremberg ''\n",
            "5 -- 7 -- Patient-centered ethics reclaiming center stage\n",
            "16 -- 20 -- Evidence that the expression of progesterone-induced blocking factor by maternal T-lymphocytes is positively correlated with conception\n",
            "3 -- 5 -- Sports-related ocular injuries\n",
            "7 -- 9 -- Long-term benefit of one thrombolytic over another\n",
            "8 -- 10 -- Verona , Italy , September 21-22 , 1995\n",
            "8 -- 10 -- Dose-volume histograms can be interpreted in different ways\n",
            "7 -- 9 -- Meta-analyses and large randomized , controlled trials\n",
            "2 -- 4 -- Low-fat diets\n",
            "12 -- 14 -- Are normal hearing thresholds a sufficient condition for click-evoked otoacoustic emissions ?\n",
            "12 -- 14 -- Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein\n",
            "14 -- 20 -- ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells\n",
            "31 -- 41 -- Tests of the double-strand break , lethal-potentially lethal and repair-misrepair models for mammalian cell survival using data for survival as a function of delayed-plating interval for log-phase Chinese hamster V79 cells\n",
            "11 -- 15 -- Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection\n",
            "14 -- 16 -- A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction\n",
            "7 -- 8 -- `` Children are not supposed to die\n",
            "17 -- 19 -- Structure-activity and mechanism studies on silicon phthalocyanines with Plasmodium falciparum in the dark and under red light\n",
            "18 -- 20 -- Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects\n",
            "6 -- 8 -- Valvular heart disease associated with fenfluramine-phentermine\n",
            "21 -- 23 -- Long-term effect of calcium supplementation during pregnancy on the blood pressure of offspring : follow up of a randomised controlled trial\n",
            "10 -- 14 -- Serotonin as a regulator of hypothalamic-pituitary-interrenal activity in teleost fish\n",
            "9 -- 11 -- Update : influenza activity -- worldwide , March-August 1997\n",
            "2 -- 4 -- DARTS/MEMO Collaboration\n",
            "16 -- 18 -- Vesico-uterine fistula -- a rare complication of vacuum extraction in a patient with previous caesarean section\n",
            "14 -- 16 -- Practice parameters for the psychiatric assessment of infants and toddlers ( 0-36 months )\n",
            "8 -- 9 -- Re : `` Biologic synergism and parallelism ''\n",
            "5 -- 7 -- Evidence-based medicine and general practice\n",
            "8 -- 10 -- Haemodynamic performance of a 16-mm Carbomedics aortic prosthesis\n",
            "2 -- 4 -- Case 30-1997\n",
            "11 -- 15 -- A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities\n",
            "25 -- 27 -- Palliative options of last resort : a comparison of voluntarily stopping eating and drinking , terminal sedation , physician-assisted suicide , and voluntary active euthanasia\n",
            "9 -- 11 -- Losing weight -- an ill-fated New Year 's resolution\n",
            "11 -- 13 -- Single-breath diffusing capacities for NO , CO and C18O2 in rabbits\n",
            "2 -- 6 -- Low-molecular-weight heparins\n",
            "8 -- 10 -- Case 30-1997 : pulmonary interstitial emphysema in infancy\n",
            "21 -- 22 -- Antibody class switch recombinase activity is B cell stage specific and functions stochastically in the absence of 'targeted accessibility ' control\n",
            "7 -- 9 -- The safety-net role of international medical graduates\n",
            "22 -- 23 -- Diabetic retinopathy , promoter ( 4G/5G ) polymorphism of PAI-1 gene , and PAI-1 activity in Pima Indians with type 2 diabetes\n",
            "15 -- 17 -- Cerebral abscesses in a patient with AIDS caused by methicillin-resistant Staphylococcus aureus ( MRSA )\n",
            "17 -- 19 -- More than 20 years second-look surgery in advanced epithelial ovarian cancer : what did we learn ?\n",
            "9 -- 11 -- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility\n",
            "5 -- 9 -- Management of life-threatening acid-base disorders\n",
            "19 -- 21 -- < TO_SEE > Freeze-dried cortical allograft in posterior spinal arthrodesis : use with segmental instrumentation for idiopathic adolescent scoliosis\n",
            "10 -- 12 -- Effect of HAART on natural history of AIDS-related opportunistic disorders\n",
            "11 -- 13 -- Breastfeeding and catch-up growth in infants born small for gestational age\n",
            "12 -- 13 -- Ilych : a critical look at the `` philosophy of hospice ''\n",
            "21 -- 23 -- Sensitivity and specificity of the neonatal brain-stem auditory evoked potential for hearing and language deficits in survivors of extracorporeal membrane oxygenation\n",
            "7 -- 9 -- Vancomycin-resistant Staphylococcus aureus : apocalypse now ?\n",
            "27 -- 31 -- In vitro interactions of oxidatively modified LDL with type I , II , III , IV , and V collagen , laminin , fibronectin , and poly-D-lysine\n",
            "27 -- 31 -- Mutations of the Drosophila dDP , dE2F , and cyclin E genes reveal distinct roles for the E2F-DP transcription factor and cyclin E during the G1-S transition\n",
            "27 -- 29 -- A rapid molecular method ( polymerase chain reaction with sequence-specific primers ) to genotype for ABO blood group and secretor status and its potential for organ transplants\n",
            "8 -- 10 -- A population-based registry on paraproteinaemia in The Netherlands\n",
            "7 -- 9 -- Intra- and inter-individual biological variability data bank\n",
            "15 -- 17 -- Run-in periods in randomized trials : implications for the application of results in clinical practice\n",
            "9 -- 11 -- Human fetal pituitary expresses functional growth hormone-releasing peptide receptors\n",
            "22 -- 24 -- Testicular sperm retrieval by percutaneous fine needle sperm aspiration compared with testicular sperm extraction by open biopsy in men with non-obstructive azoospermia\n",
            "11 -- 17 -- SHARPs : mammalian enhancer-of-split- and hairy-related proteins coupled to neuronal stimulation\n",
            "3 -- 5 -- Human cervico-facial morphogenesis\n",
            "7 -- 9 -- X inactivation in females with X-linked disease\n",
            "6 -- 8 -- Pressure- and Volume-Limited Ventilation Strategy Group\n",
            "12 -- 16 -- Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone\n",
            "17 -- 18 -- The `` H '' graft : an alternative approach for performing minimally invasive direct coronary artery bypass\n",
            "6 -- 8 -- Fascioloidiasis in game-ranched elk from Montana\n",
            "10 -- 12 -- Preoperative thromboxane A2/prostaglandin H2 receptor activity predicts early graft thrombosis\n",
            "5 -- 7 -- Needle-exchange programmes in the USA\n",
            "20 -- 22 -- A discriminant function for preeclampsia : case-control study of minor hemoglobins , red cell enzymes , and clinical laboratory values\n",
            "14 -- 16 -- A cell-based immunobiosensor with engineered molecular recognition -- Part II : Enzyme amplification systems\n",
            "13 -- 15 -- Amperometric lactate oxidase catheter for real-time lactate monitoring based on thin film technology\n",
            "18 -- 20 -- Molecular distances from dipolar coupled spin-labels : the global analysis of multifrequency continuous wave electron paramagnetic resonance data\n",
            "15 -- 18 -- Surface plasmon resonance analysis of topoisomerase I-DNA binding : effect of Mg2+ and DNA sequence\n",
            "13 -- 17 -- Biobehavioral pain research : a multi-institute assessment of cross-cutting issues and research needs\n",
            "8 -- 10 -- Urogynaecology proceedings of the joint RCOG/BAUS urogynaecology meeting\n",
            "12 -- 16 -- Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B\n",
            "15 -- 19 -- Growth hormone secretion in HIV-positive versus HIV-negative hemophilic males with abnormal growth and pubertal development\n",
            "21 -- 23 -- Trends in HIV counseling and testing of clients attending a public sexually transmitted disease clinic in Portland , Oregon , 1989-1995\n",
            "6 -- 8 -- Epidemiology and association with extra-gastrointestinal diseases\n",
            "5 -- 7 -- Extra-gastrointestinal diseases and Helicobacter pylori\n",
            "15 -- 17 -- Sequence analysis of the 36-kb region between gntZ and trnY genes of Bacillus subtilis genome\n",
            "11 -- 13 -- Truncated-gene reporter system for studying the regulation of manganese peroxidase expression\n",
            "4 -- 6 -- hordei glyceraldehyde-3-phosphate dehydrogenase gene\n",
            "4 -- 6 -- February 3-6 , 1996\n",
            "8 -- 10 -- Verona , Italy , September 21-22 , 1995\n",
            "4 -- 6 -- September 7-10 , 1996\n",
            "8 -- 10 -- Athens , Greece , December 6-9 , 1995\n",
            "9 -- 11 -- Lake Como , Italy , September 9-12 , 1996\n",
            "26 -- 32 -- Exon/intron structure of the human AF-4 gene , a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia\n",
            "14 -- 16 -- A protein with a novel calcium-binding domain associated with calcareous corpuscles in Echinococcus granulosus\n",
            "19 -- 21 -- Meis2 , a novel mouse Pbx-related homeobox gene induced by retinoic acid during differentiation of P19 embryonal carcinoma cells\n",
            "10 -- 12 -- Mar del Plata , Argentina , August 26-30 , 1996\n",
            "13 -- 15 -- Targeted development of microsatellite markers from the defined region of bovine chromosome 6q21-31\n",
            "13 -- 15 -- Characterization of the orf31-petG gene cluster from the plastid genome of Populus deltoides\n",
            "8 -- 10 -- Tokyo , Japan , November 11-13 , 1996\n",
            "7 -- 9 -- Marseille , France , 28-30 April 1998\n",
            "8 -- 10 -- Budapest , Hungary , August 24-27 , 1997\n",
            "40 -- 42 -- Proceedings of the 6th Congress of the Soci ( c ) t ( c ) de Pharmaco-Toxicologie Cellulaire and the Soci ( c ) t ( c ) Franaise de Toxicologie G ( c ) n ( c ) tique\n",
            "7 -- 9 -- Rapallo , Italy , 14-15 March 1997\n",
            "20 -- 22 -- Report of the 61st National Scientific Meeting of the American College of Rheumatology , Washington DC , 8-12 November 1997\n",
            "5 -- 7 -- Kiel , 20-21 February 1998\n",
            "8 -- 10 -- Cologne , Germany , March 14-15 , 1998\n",
            "7 -- 9 -- Strasbourg , France , 3-6 September 1997\n",
            "8 -- 10 -- Catania , Italy , May 27-31 , 1998\n",
            "6 -- 8 -- Psychosexual care in a multi-ethnic society\n",
            "8 -- 10 -- Brandon/Hill selected list of nursing books and journals\n",
            "10 -- 12 -- Are academic medicine-alternative medicine incompatible , compatible , complementary ?\n",
            "6 -- 8 -- Mononucleosis infectiosa ( Epstein-Barr virus infection\n",
            "14 -- 17 -- Diseases transmitted by non-conventional agents ( `` prions '' ) : nosology and diagnosis\n",
            "8 -- 10 -- A note on the epidemiology of Creutzfeldt-Jakob syndrome\n",
            "7 -- 9 -- Biology of non-conventional transmissible agents or prions\n",
            "7 -- 9 -- Pneumosinus dilatans : a little-known diagnostic tool\n",
            "23 -- 25 -- Survey and assessment of the actual state of routine measurement of glycohaemoglobin/GHb by commercial methods : warning to the users and the providers\n",
            "7 -- 9 -- p53 mutations in BRCA1-associated familial breast cancer\n",
            "9 -- 11 -- A major non-LTR retrotransposon of Bombyx mori , L1Bm\n",
            "13 -- 17 -- Use of protein-C concentrate , heparin , and haemodiafiltration in meningococcus-induced purpura fulminans\n",
            "9 -- 11 -- Dose-dependent effects of recombinant human interleukin-6 on glucose regulation\n",
            "5 -- 7 -- Equine dinucleotide repeat loci LEX049-LEX063\n",
            "21 -- 22 -- A family of highly repetitive DNAs from `` ginbuna '' ( Carassius auratus langsdorfi ) genome common to Carassius auratus populations\n",
            "11 -- 13 -- Characterization of cDNA clones in size-fractionated cDNA libraries from human brain\n",
            "19 -- 23 -- Mouse LIM-kinase 2 gene : cDNA cloning , genomic organization , and tissue-specific expression of two alternatively initiated transcripts\n",
            "12 -- 14 -- A national survey of physician-assisted suicide and euthanasia in the United States\n",
            "23 -- 29 -- Alterations in the developing immune system of the F344 rat after perinatal exposure to 2 , 3 , 7 , 8-tetrachlorodibenzo-p-dioxin : II\n",
            "3 -- 5 -- College-age drinking problems\n",
            "6 -- 8 -- Early identification of variant Creutzfeldt-Jakob disease\n",
            "15 -- 17 -- Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir\n",
            "17 -- 19 -- `` Pull '' or `` push '' PEG : the reinsertion of the gastroscope is often unnecessary\n",
            "8 -- 10 -- Isolated internal ophthalmoplegia associated with IgG anti-GQ1b antibody\n",
            "11 -- 13 -- Enthesopathy in a case of primary biliary cirrhosis with positive HLA-B27\n",
            "7 -- 9 -- Aarhus , Denmark , 21-24 May 1997\n",
            "2 -- 6 -- Intravascular-catheter-related infections\n",
            "12 -- 14 -- US-guided puncture of the internal jugular vein : complications and anatomic considerations\n",
            "11 -- 13 -- The effect of melatonin administration on ethanol-induced lipid peroxidation in rats\n",
            "5 -- 7 -- Physicians disciplined for sex-related offenses\n",
            "15 -- 19 -- Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin 's lymphoma\n",
            "11 -- 13 -- Occupation : the keystone of a curriculum for a self-defined profession\n",
            "12 -- 14 -- Endoscopic hemostasis of bleeding duodenal ulcer in a child with Henoch-Schnlein purpura\n",
            "4 -- 6 -- Evidence-Based Medicine Working Group\n",
            "17 -- 19 -- Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response\n",
            "6 -- 8 -- Brain-gut axis in health and disease\n",
            "11 -- 13 -- Voluntary death : a comparison of terminal dehydration and physician-assisted suicide\n",
            "11 -- 13 -- Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor\n",
            "16 -- 18 -- Interleukin-8 participates in angiogenesis in non-small cell , but not small cell carcinoma of the lung\n",
            "19 -- 21 -- Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line ( NPC-BM1 ) derived from a bone marrow metastatic lesion\n",
            "10 -- 12 -- Relation between intellectual dysfunctioning and mortality in community-residing older people\n",
            "19 -- 21 -- Cross-reactivity of specific antibodies directed to heat shock proteins from periodontopathogenic bacteria and of human origin ( corrected )\n",
            "31 -- 33 -- Missense mutation in exon 11 ( Codon 378 ) of the presenilin-1 gene in a French family with early-onset Alzheimer 's disease and transmission study by mismatch enhanced allele specific amplification\n",
            "20 -- 22 -- Novel acceptor splice site mutation in the invariant AG of intron 6 of alpha-galactosidase A gene , causing Fabry disease\n",
            "8 -- 10 -- Meta-analysis of trials comparing antidepressants with active placebos\n",
            "14 -- 16 -- Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada\n",
            "29 -- 31 -- < TO_SEE > Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome\n",
            "14 -- 16 -- Isolated axial lateral pulse as a sign of latero-bulbar ischemia : clinical topographic correlation\n",
            "11 -- 13 -- Endoscopic ultrasound miniprobe-guided steroid injection for treatment of refractory esophageal strictures\n",
            "12 -- 14 -- Renal trauma and the risk of long-term complications in shock wave lithotripsy\n",
            "7 -- 9 -- An under-recognised cause of idiopathic learning disability\n",
            "9 -- 11 -- Detection of four novel mutations in the iduronate-2-sulfatase gene\n",
            "16 -- 18 -- Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces : a magnetic resonance imaging and pathological study\n",
            "12 -- 14 -- Role of a p53 polymorphism in the development of human papillomavirus-associated cancer\n",
            "8 -- 10 -- The psychological profiles of patients with whiplash-associated headache\n",
            "7 -- 8 -- Quo vadis `` suprema lex '' ?\n",
            "13 -- 15 -- Nonanesthetic volatile drugs obey the Meyer-Overton correlation in two molecular protein site models\n",
            "27 -- 33 -- Filter paper blood spot assay of human insulin-like growth factor I ( IGF-I ) and IGF-binding protein-3 and preliminary application in the evaluation of growth hormone status\n",
            "12 -- 14 -- Is prevaccination screening for hepatitis B among sexually active adolescents cost-effective ?\n",
            "32 -- 38 -- < TO_SEE > in conclusion , 3d computer-assisted analysis of the internal structure of small pulmonary nodules using contrast-enhanced dh-ct was found to be effective for differentiating between benign and malignant nodules\n",
            "33 -- 37 -- the patient was a 62-year-old man with squamous cell lung cancer , which was first successfully treated by a combination of radiation therapy and chemotherapy , but showed local recurrence after 8 months\n",
            "31 -- 35 -- the combination of txt , gem and cddp may be effective for recurrent non-small-cell lung carcinoma , even in patients that have failed to respond to more than one chemotherapy regimen\n",
            "15 -- 17 -- carboplatin and ifosfamide performed well and safe , in the treatment of non-bulky metastatic seminoma\n",
            "37 -- 39 -- we further developed a vaccine model based on s.c.injection of infected , irradiated rm-9 cells and found that both admil-12 and admil-12/b7 are effective at suppressing the development and growth of challenge orthotopic tumors using this protocol\n",
            "32 -- 34 -- despite the marked toxicity of the initial intensive chemotherapy , the treatments are tolerable and effective in the control of extra-thoracic micrometastases , whereas they are less effective for thoracic primary tumor\n",
            "28 -- 32 -- a phase ii study of fractionated administration of irinotecan ( cpt-11 ) and cisplatin ( cddp ) in patients with non-small-cell lung cancer ( nsclc ) was conducted\n",
            "42 -- 46 -- intravenous injection of pb2-as , as a complex with dmrie-c , a cationic liposome , was most effective for prolonging the mean survival time in days ( msds ) and increasing the survival rates of mice infected with the influenza a virus\n",
            "31 -- 33 -- conclusion : mr-guided rfa using single cooled tip electrodes is safe and technically effective for treatment of hepatic neoplasms up to 3 cm in size , however further improvements are necessary\n",
            "10 -- 14 -- a 68-year-old man underwent curative pancreaticoduodenectomy for bile duct cancer\n",
            "28 -- 30 -- corticosteroids can be considered for cases of drug-induced hepatitis , especially those with evidence of immune hypersensitivity , if no improvement is seen in 8 to 12 weeks\n",
            "15 -- 17 -- our conclusion was that the covered-ems can be effective for the palliation of esophagorespiratory fistulas\n",
            "29 -- 31 -- the food and drug administration ( fda ) recently approved the first protein-polysaccharide conjugate vaccine to prevent invasive pneumococcal diseases in infants and toddlers < 2 years of age\n",
            "48 -- 50 -- based on the results of three well-designed studies demonstrating the vaccine 's safety , immunogenicity , and efficacy , the vaccine is safe and effective for active immunization of children < 2 years of age against invasive disease caused by seven streptococcus pneumoniae serotypes included in the vaccine\n",
            "27 -- 31 -- < TO_SEE > i concluded that 6-month regimen containing pyrazinamide was effective for the patients with isoniazid-rifampicin susceptible tuberculosis patients except the patients complicated with diabetes mellitus\n",
            "60 -- 64 -- only the combination of a cell wall-active antibiotic to which the enterococcus is susceptible ( ie , certain beta-lactams or vancomycin ) plus an aminoglycoside ( ie , gentamicin or streptomycin ) is bactericidal , and is required for cure of endocarditis , meningitis and probably infection in neutropenic patients ; bacteriostatic activity is sufficient to treat most other infections\n",
            "51 -- 61 -- d-penicillamine ( 2-amino-3-mercapto-3-methylbutanoic acid ) , a well-known heavy metal chelator , is the drug of choice in the treatment of wilson 's disease and is also effective for the treatment of several disorders including rheumatoid arthritis , primary biliary cirrhosis , scleroderma , fibrotic lung diseases and progressive systemic sclerosis\n",
            "45 -- 53 -- stages of non-small cell lung cancer ( nsclc ) that are potential candidates for surgical resection have been treated in several ways : surgery alone is curative in only two-thirds of cases and post-operative radiotherapy ( rt ) provides only weak control of advanced-stage disease\n",
            "54 -- 56 -- among these , the gemcitabine/cisplatin study protocol ( gc ) , set up in a phase ii study for patients with stage iiia n2 nsclc , was very effective ( objective response ( or ) : 70.2 % ; median survival : 19 months ) and should be promising for stages ib and ii\n",
            "44 -- 46 -- several studies have suggested that non-small cell lung cancer ( nsclc ) patients whose tumors have neuroendocrine ( ne ) features may be more responsive to chemotherapy in addition , increased expression of p53 and her2 may confer relative chemotherapy resistance and shortened survival\n",
            "28 -- 34 -- this london lung cancer group trial of gemcitabine/carboplatin may define an active , safe , and acceptable treatment for patients with extensive-stage and poor-prognosis small cell lung cancer\n",
            "11 -- 13 -- gemcitabine and carboplatin for patients with advanced non-small cell lung cancer\n",
            "25 -- 27 -- an aggressive surgical approach is justified in patients with mplc and offers the greatest chance for long-term survival even in the case of limited resection\n",
            "66 -- 70 -- < TO_SEE > the standard care for patients with non-small-cell lung cancer is chemotherapy of supportive care , with surgery being reserved for palliation of symptoms ; however , there is a small group of patients with a finite number of extrathoracic metastases ( oligometastases ) who may experience improved survival by resection of their metastases and the primary site , with or without systemic treatment\n",
            "19 -- 21 -- conclusions : this constitutes one of the largest single-institution reports on carinal resection for bronchogenic carcinoma involving the carina\n",
            "32 -- 34 -- < TO_SEE > purpose : the benefit of whole-lung irradiation ( wli ) for patients who have pulmonary metastases ( pm ) of ewing sarcoma family tumors ( esft ) is unclear\n",
            "13 -- 15 -- therefore , patients with radiation-induced spinal cord injury may benefit from anticoagulant therapy\n",
            "16 -- 18 -- conclusions : heparin and/or enoxaparin may be considered as potential treatments for patients with radiation-induced myelopathy\n",
            "19 -- 21 -- thus , we should recognize this immanent risk and perform peri- and postoperative management for patients with gh-producing tumors\n",
            "49 -- 51 -- we conducted a phase ii study of etoposide ( vp-16 ) -ifosfamide-cisplatin ( vip ) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity\n",
            "18 -- 24 -- methods : forty-four patients with limited small cell lung cancer were treated with etoposide-ifosfamide-cisplatin and concurrent thoracic irradiation\n",
            "26 -- 28 -- inhaled corticosteroid therapy is recommended for patients with persistent disease , and careful instruction in the use of metered-dose inhalers is particularly important for the elderly\n",
            "20 -- 22 -- background : the role of surgical staging of patients with non-small cell lung cancer ( nsclc ) continues to evolve\n",
            "50 -- 56 -- purpose : given the cisplatin-related myelotoxicity and nonhematologic toxicities , we were prompted to undertake a study of the noncisplatin combination of paclitaxel plus gemcitabine to evaluate the efficacy , tolerance , and survival of this combination in patients with locally advanced and metastatic non-small-cell lung cancer ( nsclc )\n",
            "48 -- 50 -- methods : we analyzed 34 patients who were found to have malignant pleural effusions in the course of diagnosis of 118 patients enrolled in three consecutive clinical trials on advanced nsclc assessing combination chemotherapy of cisplatin , ifosfamide , and irinotecan with recombinant human granulocyte colony-stimulating factor support\n",
            "19 -- 21 -- the administration of mitomycin c in addition to cisplatin-based regimens for patients with lung cancer should be carefully considered\n",
            "72 -- 74 -- patients : during this period , a total of 77 patients underwent lung resection for the following neuroendocrine neoplasms : typical carcinoid ( tc ) , 50 patients ; atypical carcinoid ( ac ) , 5 patients ; large cell neuroendocrine carcinoma ( lcnec ) , 9 patients ; mixed large-small cell neuroendocrine carcinoma ( lsnec ) , 4 patients ; or small cell neuroendocrine carcinoma ( scc ) , 9 patients\n",
            "25 -- 27 -- despite the poor overall prognosis in high-grade neuroendocrine tumors of the lung , surgery remains a viable adjunct in the early stages of this disease\n",
            "19 -- 27 -- urpose : to assess results with twice-daily high-dose radiotherapy ( rt ) for non-small-cell lung cancer ( nsclc )\n",
            "16 -- 18 -- we treated 27 nsclcm patients with concomitant daily low-dose cisplatin and radiotherapy between 1993 and 1995\n",
            "33 -- 35 -- these data suggest that her2/erbb-2 should be evaluated prospectively as a prognostic indicator and clinical trials using antibodies that target this receptor should be considered for the treatment of patients with osteogenic sarcoma\n",
            "39 -- 48 -- objective : to examine the effectiveness of ninjin yoei to ( nyt ; ren-shen-yang-rong-tang in chinese medicine ; kotaro pharmaceutical co. , ltd. , osaka , japan ) , one of the traditional herbal medicines , against lung carcinoma\n",
            "34 -- 36 -- setting : the nursing center himawari design , patient , and preparation : the regular dosage of nyt ( 15 g/d ) was prescribed for 7 weeks to one elderly patient with lung carcinoma\n",
            "33 -- 35 -- object : the purpose of this retrospective study was to compare the effectiveness of gamma knife radiosurgery ( gks ) for multiple cerebral metastases with that of whole-brain radiation therapy ( wbrt )\n",
            "18 -- 20 -- the notable exception has been docetaxel , which has been extensively studied as a second-line therapy for nsclc\n",
            "33 -- 35 -- object : the purpose of this retrospective study was to compare the effectiveness of gamma knife radiosurgery ( gks ) for multiple cerebral metastases with that of whole-brain radiation therapy ( wbrt )\n",
            "22 -- 24 -- objective : careful patient selection is vital when video-assisted thoracoscopic surgical ( vats ) therapeutic pulmonary metastasectomy of colorectal carcinoma is considered\n",
            "45 -- 49 -- objectives : to review the spectrum of presentation and the surgical management of non small cell lung cancer ( nsclc ) and the role of various diagnostic modalities in predicting the post-operative stage and the correlation of the post-operative stage with the chances of recurrence\n",
            "26 -- 28 -- in the past several years , new chemotherapeutic agents , including the taxanes and the topoisomerase i inhibitors , have demonstrated substantial activity against small-cell carcinoma\n",
            "33 -- 35 -- the aim of this study was the evaluation of both the antitumour activity and toxicity of an immunochemotherapeutic regimen consisting of interferon-alpha2b and interleukin-2 in combination with fotemustine for patients with metastatic melanoma\n",
            "17 -- 21 -- neoadjuvant therapy with oxaliplatin/fluorouracil/folinic acid has proven beneficial in enabling surgical removal of previously unresectable liver metastases\n",
            "38 -- 44 -- in 2 studies , surgery with curative intent was performed in 16 and 51 % of patients with initially unresectable liver metastases following oxaliplatin/fluorouracil/folinic acid therapy ; the 5-year survival rates were 40 and 50 % , respectively\n",
            "31 -- 37 -- in patients with advanced ovarian cancer , first-line therapy with oxaliplatin/cyclophosphamide achieved an objective response rate which did not differ significantly from that of cisplatin/cyclophosphamide ( 33 vs 42 % )\n",
            "32 -- 36 -- conclusion : oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer , both as a first-line therapy and in patients refractory to previous chemotherapy\n",
            "28 -- 29 -- combined modality treatment has 'come out of age ' and increasingly represents standard of care for a rapidly growing number of patients in locally advanced stages of nsclc\n",
            "19 -- 23 -- standard treatment of sclc consists of platinum-based combination chemotherapy , with thoracic irradiation added for patients with limited-stage disease\n",
            "26 -- 30 -- we recently performed completion pneumonectomy of the left lung in a 70-year-old man with hemophilia a , for squamous cell carcinoma in the residual left lung\n",
            "22 -- 24 -- objective : several reports emphasize the importance of en-bloc resection as the optimal surgical treatment of lung cancer with chest wall invasion\n",
            "44 -- 50 -- methods : between 1981 and 1998 , 100 patients ( 90 male ; ten female ) , with a median age of 60 years ( 36-84 ) , underwent radical en-bloc resection of non-small cell lung cancer ( nsclc ) with chest wall involvement\n",
            "37 -- 43 -- a growing body of evidence suggests that postoperative irradiation for non-small cell lung cancer may cause life-threatening toxicity and , when the risk of local-regional recurrence is low , the toxicity of irradiation may outweight the benefit\n",
            "19 -- 23 -- as a best-case scenario , postoperative irradiation may improve the chance for long-term survival in patients with n2 tumors\n",
            "23 -- 25 -- for patients with stage i or ii non-small cell lung cancer ( nsclc ) , surgical resection is considered the standard of care\n",
            "31 -- 33 -- efforts at improving survival for early-stage nsclc patients have focused on the use of chemotherapy administered postoperatively ( adjuvant ) or preoperatively ( neoadjuvant or induction ) to eradicate micrometastatic disease\n",
            "23 -- 25 -- reviewer 's conclusions : prophylactic cranial irradiation significantly improves survival and disease-free survival for patients with small cell lung cancer in complete remission\n",
            "27 -- 31 -- methods : non-small cell lung cancer cells were treated with gemcitabine , harvested , and nuclear extracts analyzed for nf-kappab dna binding by electrophoretic mobility shift assays\n",
            "18 -- 24 -- novel treatment strategies for patients with advanced nsclc may involve chemotherapy combined with inhibition of nf-kappab-dependent cell-survival pathways\n",
            "24 -- 28 -- in single-agent phase ii studies , irinotecan yielded response rates between 16 % and 47 % in patients with previously treated small-cell lung cancer\n",
            "35 -- 39 -- a phase ii study of irinotecan in combination with cisplatin ( platinol ) resulted in a response rate of 86 % and a median survival of 13.0 months in patients with extensive-disease small-cell lung cancer\n",
            "23 -- 27 -- based on these results , the irinotecan and cisplatin combination is a new standard regimen in the treatment of extensive-disease small-cell lung cancer\n",
            "26 -- 28 -- background : both gemcitabine and etoposide are active in the treatment of small-cell lung cancer ( sclc ) , and are characterised by mild toxicity profiles\n",
            "40 -- 50 -- patients and methods : forty-two chemo-naive extensive disease sclc patients were enrolled to receive gemcitabine 1000 mg/m2 , days 1 , 8 and 15 , and etoposide 80 mg/m2 , days 8 , 9 and 10 of a 28-day cycle\n",
            "37 -- 39 -- background : to find the maximum tolerated dose for ifosfamide in combination with paclitaxel and carboplatin in small-cell lung cancer patients ( sclc ) , who are resistant to cyclophosphamide , doxorubicin and etoposide ( cde )\n",
            "39 -- 47 -- conclusions : the maximum tolerated dose of this combination for patients with resistant sclc is ifosfamide 2000 mg/m2 in combination with paclitaxel 175 mg/m2 and carboplatin auc 6 mg/ml min administered on the first day of a 21-day cycle\n",
            "18 -- 20 -- small cell lung cancer is a frequently relapsing tumor despite a high rate of response after first-line chemotherapy\n",
            "23 -- 25 -- an anti-idiotypic monoclonal antibody against the gd3 ganglioside , bec-2 , is being evaluated after chemotherapy in sclc patients in a european study\n",
            "25 -- 29 -- we attempted a new regimen of intermittent administration of 5-fu and low-dose isovorin ( f.i ) to four patients with advanced and recurrent colon cancer\n",
            "19 -- 21 -- purpose/objectives : to describe the relationship between fatigue and nutritional status in patients receiving radiation therapy for lung cancer\n",
            "23 -- 27 -- patients who benefit from a surgical resection for non-small-cell lung cancer with aneuploid dna content prove to have a higher risk of death\n",
            "49 -- 51 -- purpose : a prospective randomized trial in small-cell lung cancer ( sclc ) was performed to determine if intensification of the platinum dose by giving cisplatin and carboplatin in combination to patients with sclc yields higher response rates and survival , than carboplatin alone in a combination chemotherapy regimen\n",
            "21 -- 23 -- tc-tf chest scintigraphy correlated well with pgp or mrp1 expression and accurately predicted the response to chemotherapy in patients with sclc\n",
            "34 -- 36 -- prophylactic cranial irradiation ( pci ) has been demonstrated to significantly reduce the incidence of brain relapse from limited disease small-cell lung cancer ( ld sclc ) , but concerns about neurologic toxicity remain\n",
            "19 -- 21 -- thus , twice-daily pci should be considered for patients with ld sclc who achieve a complete response to chemoirradiation\n",
            "38 -- 44 -- in a pivotal phase iii trial , 242 patients with advanced ovarian cancer were randomised to receive treatment with cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2 every 3 weeks with or without pretreatment with intravenous amifostine 910 mg/m2\n",
            "35 -- 37 -- amifostine ( 340 mg/m2 ) also provided significant protection against pneumonitis and oesophagitis in patients with lung cancer receiving thoracic irradiation in a preliminary report from a phase iii trial ( n = 144 )\n",
            "64 -- 66 -- < TO_SEE > conclusion : the results of phase iii trials have confirmed the safety and efficacy of amifostine as a cytoprotectant to ameliorate cisplatin-induced cumulative renal toxicity , for which it is the only agent proven to be effective , and neutropenia in patients with advanced ovarian cancer , and to reduce xerostomia in patients with head and neck cancer receiving irradiation therapy\n",
            "29 -- 31 -- to perform a curative operation for the lung cancer without myocardial infarction , minimally invasive direct coronary artery bypass and left lower lobectomy with video-endoscopic assistance were performed simultaneously\n",
            "12 -- 16 -- Continuous arterio-venous hemofiltration in a wearable device to treat end-stage renal disease\n",
            "38 -- 44 -- Antagonism of atracurium-induced neuromuscular blockade by neostigmine or edrophonium has been studied using the tetanic ( 50 Hz ) and train-of-four ( 2 Hz ) or single twitch responses of the adductor pollicis muscle in 22 anaesthetized patients\n",
            "94 -- 112 -- Active forms of vitamin D3 , 1 alpha-hydroxyvitamin D3 and 1 alpha , 25-dihydroxyvitamin D3 , were administered in an open-design study to 40 patients with psoriasis vulgaris in three ways : to 17 patients 1 alpha-hydroxyvitamin D3 was given orally at a dose of 1.0 micrograms/day for 6 months , to four patients 1 alpha , 25-dihydroxyvitamin D3 was given orally at a dose of 0.5 microgram/day for 6 months , and 19 patients were given 1 alpha , 25-dihydroxyvitamin D3 applied topically at concentration of 0.5 microgram/g of base for 8 weeks\n",
            "38 -- 42 -- When indomethacin was applied immediately after irradiation , UVR ( ultraviolet radiation ) dose-dependent suppression of erythema was demonstrated for both wavelengths until 36 h after irradiation when both indomethacin and control gel base-treated sites were equally erythematous\n",
            "34 -- 38 -- Significant inhibition of monocyte SA output stimulated with IgG-treated zymosan ( ITZ ) and fluoride ion ( F ) , but not serum-treated zymosan ( STZ ) was demonstrated following steroid therapy in RA\n",
            "28 -- 30 -- Methotrexate ( MTX ) appears to be useful in patients with rheumatoid arthritis ( RA ) refractory to other drugs but its long-term toxicity and efficacy are uncertain\n",
            "16 -- 20 -- MTX in a low-dose regimen is useful in refractory RA and superior to low-dose purine analogues\n",
            "17 -- 19 -- Over a 1-year period , rigid ureteroscopy has been used to retrieve ureteric calculi in 120 patients\n",
            "16 -- 18 -- Two hundred and seventy-seven patients with advanced prostatic cancer were treated by either orchiectomy or oestrogen\n",
            "26 -- 28 -- A patient with a vesico-enteric fistula was successfully treated with resection of the small intestine and dome of the bladder and drainage of the intervening abscess\n",
            "11 -- 13 -- Steroid therapy was also used in two patients with NSAID-induced proteinuria\n",
            "15 -- 17 -- Recombinant leukocyte A interferon ( rIFN-alpha A ) in the treatment of disseminated malignant melanoma\n",
            "29 -- 31 -- As noted previously , using chemotherapy , a small proportion of patients with advanced malignant melanoma , despite prior therapy , may achieve prolonged objective regression with rIFN-alpha A\n",
            "18 -- 20 -- Between July 1973 and December 1979 , 1171 patients with metastatic breast cancer were treated with doxorubicin-containing chemotherapy\n",
            "17 -- 21 -- Long-term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy\n",
            "20 -- 22 -- Treatment of advanced stage mycosis fungoides with bleomycin , doxorubicin , and methotrexate with topical nitrogen mustard ( BAM-M )\n",
            "25 -- 27 -- This study indicates that BAM-M is effective therapy for advanced stage mycosis fungoides and suggests that the therapeutic role of splenectomy should be evaluated further\n",
            "39 -- 43 -- For refractory right ventricular failure following the surgical repair of congenital cardiac defects in which the placement of right atrial and pulmonary artery cannulae is not technically feasible , use of high-frequency high-volume ventilation appears to be quite promising\n",
            "35 -- 37 -- At 6 months follow-up 26 % ( 14/53 ) of all the patients who underwent angioplasty had recurrence of angina , which was successfully treated with repeat angioplasty , bypass surgery , or medical therapy\n",
            "23 -- 27 -- A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis\n",
            "39 -- 45 -- Initial empiric therapy for community-acquired bacterial meningitis should be based on the possibility that penicillin-resistant pneumococci may be the etiologic organisms and , hence , should include a combination of third-generation cephalosporin ( cefotaxime or ceftriaxone ) and vancomycin\n",
            "18 -- 20 -- Results of clinical trials and meta-analysis suggest that dexamethasone therapy improves the outcome for patients with bacterial meningitis\n",
            "17 -- 19 -- Placebo-controlled trials have shown that vitamin C supplementation decreases the duration and severity of common cold infections\n",
            "15 -- 19 -- Levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanate in the treatment of community-acquired pneumonia that require hospitalization\n",
            "27 -- 31 -- The results of this study show that resection of extrahepatic bile duct carcinomas , particularly in an upper-third localization , is often associated with worthwhile long-term survival\n",
            "25 -- 27 -- Background : N-acetylcysteine ( NAC ) and ambroxol ( AMB ) have recently been proposed as possible therapeutic agents in the treatment of pulmonary disorders\n",
            "28 -- 30 -- The present study evaluated the effects of TJ-135 on concanavalin A ( con A ) -induced hepatitis in mice in vivo and con A-induced cytokine production in vitro\n",
            "13 -- 15 -- These results suggest that con A-induced hepatitis was ameliorated by pretreatment with TJ-135\n",
            "7 -- 11 -- T-helper type 2 cell-directed therapy for asthma\n",
            "17 -- 22 -- Effects of the Japanese herbal medicine 'Inchinko-to ' ( TJ-135 ) on concanavalin A-induced hepatitis in mice\n",
            "20 -- 22 -- Presumed cavernomas have been documented following radiation for malignancy ( 5-6 ) , and sterotactic cerebral biopsy ( 7 )\n",
            "16 -- 18 -- Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy\n",
            "20 -- 22 -- Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon\n",
            "29 -- 33 -- A 65-year-old woman , who had been undergoing immunotherapy for inoperably disseminated renal carcinoma and lung metastases , presented with severe abdominal pain in a state of hypovolemic shock\n",
            "18 -- 24 -- Novel treatment strategies for patients with advanced NSCLC may involve chemotherapy combined with inhibition of NF-kappaB-dependent cell-survival pathways\n",
            "25 -- 27 -- OBJECTIVE : This retrospective study was designed to confirm that aggressive pulmonary resection can provide effective long-term palliation of disease for patients with pulmonary aspergilloma\n",
            "33 -- 35 -- The authors monitored clinical outcome and lung function of 43 children with acute lymphoblastic leukemia and non-Hodgkin lymphoma who received chemotherapy at the University Children 's Hospital of Greifswald between 1993 and 1998\n",
            "21 -- 23 -- An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation\n",
            "19 -- 21 -- Neutralization of hepatitis A virus ( HAV ) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1\n",
            "57 -- 61 -- To ascertain the results of standard ABVD chemotherapy ( doxorubicin , bleomycin , vinblastine , dacarbazine ) in HIV-infected patients with newly diagnosed Hodgkin 's disease ( HD ) , a nonrandomized , prospective , multiinstitutional clinical trial was conducted by the AIDS Clinical Trials Group ( ACTG ) , in HIV-infected patients with Hodgkin 's disease\n",
            "13 -- 15 -- The effectiveness of glucocorticoids in treating croup : meta-analysis ( see comments )\n",
            "31 -- 37 -- Thus , s-ECP appears to be a useful marker for determining when a step-down in iBDP therapy is indicated , and thus may contribute to successful long-term management of chronic asthma\n",
            "19 -- 21 -- Twinrix ( SmithKline Beecham Biologicals ) is a combined hepatitis A and B vaccine licensed with a three-dose schedule\n",
            "12 -- 14 -- A two-dose combined hepatitis A and B vaccine would facilitate immunisation programs\n",
            "44 -- 46 -- Therefore , it can be concluded that with two injections of the high-dose hepatitis A and B vaccine , 6 months apart , a similar immune response can be obtained as induced with three doses of Twinrix at months 0 , 1 and 6\n",
            "18 -- 20 -- We treated two children with influenza-associated acute encephalopathy by a combination of mild hypothermia and steroid pulse therapy\n",
            "15 -- 19 -- Treatment of spontaneous carotid-cavernous fistula in Ehlers-Danlos syndrome by transvenous occlusion with Guglielmi detachable coils\n",
            "20 -- 22 -- When bleeding is stopped via surgical or radiological methods , the clinical course of hemobilia-associated pancreatitis appears to be benign\n",
            "19 -- 21 -- Therapy designed to control the efferent phase of established asthma by augmenting down-regulatory Th1 counterbalancing mechanisms should be effective\n",
            "34 -- 38 -- A field study was carried out to evaluate the effect of vaccination against swine enzootic pneumonia in different production systems ( closed or one-site , and open , two- or three-site , systems )\n",
            "26 -- 30 -- From these results Gingyo-san was shown to be an antiviral agent in mice infected with a lethal amount of a mouse-adopted strain of influenza A2 virus\n",
            "37 -- 39 -- Treatment with omeprazole , amoxicillin , and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 ( 80 % ) of 19 patients who had a follow-up examination\n",
            "29 -- 31 -- BACKGROUND : The administration of salbutamol is permitted only by inhalation by the International Olympic Committee ( IOC ) for the management of asthma and exercise-induced asthma in athletes\n",
            "45 -- 47 -- Urine was also obtained from subjects who had received the maximum dosage of inhaled salbutamol advisable for competing athletes to provide protection from exercise-induced asthma and treatment of asthma ( 1600 microg in 24 h , 800 microg being in the last 4 h )\n",
            "29 -- 35 -- OBJECTIVE : to evaluate the possible existence of the so-called < Roux-en-Y syndrome > in a group of 21 patients who underwent surgery to correct postoperative alkaline reflux gastritis\n",
            "21 -- 25 -- CONCLUSIONS : we found no evidence of disturbances in gastric remnant emptying after Roux-en-Y gastrojejunostomy to treat postoperative alkaline gastric reflux\n",
            "48 -- 52 -- Quality-of-life assessments in patients with mild to moderate disease show that inhaled fluticasone propionate achieved improvements which were deemed to be clinically meaningful in patients with mild to moderate asthma ; these changes were significantly greater than those achieved with oral zafirlukast , inhaled triamcinolone acetonide or placebo\n",
            "51 -- 53 -- CONCLUSIONS : In addition to the considerable body of clinical evidence supporting the use of inhaled fluticasone propionate in patients with asthma , accumulating short term cost-effectiveness data also suggest that this agent can be administered for a similar or lower cost per outcome than other inhaled corticosteroids or oral zafirlukast\n",
            "27 -- 29 -- OBJECTIVE : To describe the effect of influenza vaccination on long-term change in CD4 count and HIV RNA level , and on progression to AIDS or death\n",
            "22 -- 26 -- Ribavirin in combination with IFN alpha exerts an additional anti-viral/immunmodulatory effect which manifests itself in phase 2 of hepatitis C viremia decline\n",
            "13 -- 15 -- Minimally invasive treatment of abscesses by CT-controlled drainage with a basket catheter system\n",
            "33 -- 37 -- A 72-year old man who had been prescribed amiodarone for more than one year before for arrhythmogenic right ventricular dystrophy , repeatedly took PL granules at one-week intervals because of sneezing and fever\n",
            "32 -- 38 -- In a follow-up study operative risk , postoperative functional disorders and incidence of anastomotic ( recurrent ) ulcer after partial gastrectomy with Roux-en-Y gastrojejunostomy for gastroduodenal ulcer were evaluated in 52 patients\n",
            "33 -- 37 -- < TO_SEE > With regard to the high rate of recurrent ulcer Roux-en-Y reconstruction after partial gastrectomy for primary ulcer surgery should be avoided and reconstruction procedures preferred , which guarantee duodenogastric reflux\n",
            "38 -- 42 -- OBJECTIVE : The aim of these studies was to compare the pharmacokinetics of inhaled fluticasone propionate ( FP ) after repeated administration via the Diskus or Diskhaler dry powder inhalers ( DPIs ) to patients with mild-to-moderate asthma\n",
            "52 -- 64 -- A three-step treatment algorithm for refractory AOM that employs amoxicillin , trimethoprim/sulfamethoxazole ( TMP/SMX ) , or high-dose amoxicillin/clavulanate ( depending on the prior dose of and adherence to amoxicillin therapy ) , and ceftriaxone or tympanocentesis at steps 1 , 2 , and 3 , respectively , appears rational and cost-effective\n",
            "22 -- 24 -- The recent introduction of ribavirin , given in combination , has led to a re-appraisal of the management of chronic hepatitis C\n",
            "23 -- 25 -- OBJECTIVE : To review the clinical effectiveness and cost-effectiveness of combination therapy with interferon alfa and ribavirin in patients with chronic hepatitis C\n",
            "16 -- 22 -- Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu , South Africa , 1991-97\n",
            "32 -- 36 -- OBJECTIVE : To evaluate the efficacy of oral tacrolimus as an induction agent in steroid-refractory severe colitis .Study design : Open-label , multicenter trial of oral tacrolimus in patients with severe colitis\n",
            "29 -- 31 -- CONCLUSION : Although tacrolimus is effective induction therapy for severe ulcerative or Crohn 's colitis , fewer than 50 % of patients treated will successfully achieve a long-term remission\n",
            "43 -- 45 -- Cytomegalovirus ( CMV ) infection was one of the most common opportunistic infections in AIDS patients , leading to blindness or life-threatening disease in about 40 % of patients in the later stages of AIDS before highly active antiretroviral therapy ( HAART )\n",
            "25 -- 31 -- OBJECTIVE : To study the relationship between interleukin-2 ( IL-2 ) , soluble interleukin-2 receptor ( sIL-2R ) and the non-and-hypo-responsiveness to hepatitis B vaccine\n",
            "21 -- 25 -- We assessed the effects of early replacement therapy with protein-C concentrate together with continuous veno-venous haemodiafiltration and conventional treatment in meningococcaemia\n",
            "60 -- 72 -- METHODS : Thirty-seven children with a history of constipation ( i.e . , pain and difficulty or delay in defecation for > 3 months ) were recruited and randomly assigned to 8 weeks of treatment with either cisapride , 0.2 mg/kg three times daily , or matching placebo after a 2-week run-in period in a double-blind , parallel-group study design\n",
            "30 -- 32 -- Patient 1 demonstrated dramatic clearing of his MCV lesions when intravenous cidofovir therapy was started for his treatment-resistant bilateral CMV retinitis and because of cidofovir 's possible activity against MCV\n",
            "33 -- 35 -- Although improved glycemic control , maintenance of normal blood pressure , and use of angiotensin-converting enzyme inhibitors are important strategies to avoid developing microalbuminuria , dietary macronutrient intake may also play a role\n",
            "40 -- 47 -- < TO_SEE > Intrapleural injection of irradiated LLC-IL2 cured pre-existing lung LLC tumors and extended the survival of the mice but did not affect survival of mice with pre-existing peritoneal tumors nor did it affect the growth of s.c. tumors\n",
            "39 -- 44 -- < TO_SEE > Intraperitoneal injection of irradiated LLC-IL2 cured pre-existing LLC peritoneal tumors and extended the survival of the mice but did not affect survival of mice bearing lung tumors nor did it affect the growth of s.c. tumors\n",
            "33 -- 45 -- After a 2- to 9-day placebo lead-in , 79 inpatients with schizophrenia according to DSM-III-R criteria were placed on an olanzapine dosage of 10 mg/day or 1 mg/day for up to 6 weeks\n",
            "29 -- 35 -- Fludarabine and ara-C successfully eradicated bone marrow disease in 16 of 27 patients ( 59 % ) , 23 patients of which had been treated previously with high-dose ara-C\n",
            "27 -- 29 -- These results verified the synergistic effect fludarabine exhibited in augmenting ara-CTP concentrations in patients ' leukemic blasts , thus improving the clinical response in relapsed pediatric leukemias\n",
            "47 -- 53 -- METHODS AND RESULTS : Platelet P-selectin ( CD62 ) and activated GP IIb/IIIa ( PAC-1 ) expression on platelet membrane was quantified in whole blood as well as platelet aggregation in platelet-rich plasma in 43 patients with unstable angina before and during treatment with UFH or enoxaparin\n",
            "17 -- 21 -- Women randomised to screen-and-treat received appropriate antibiotics only if screening proved positive for one or more infection\n",
            "24 -- 28 -- < TO_SEE > A 71-year-old woman with autoimmune hemolytic anemia underwent an emergency endocardial patch repair for ventricular septal perforation after acute myocardial infarction\n",
            "42 -- 50 -- < TO_SEE > We report a case of a 29-year-old male chronic HBV carrier who developed fulminant reactivated HBV infection following intensive chemotherapy for stage IVB large cell B-cell non-Hodgkin 's lymphoma associated with extensive central nervous system and bone marrow involvement\n",
            "43 -- 45 -- The results of several clinical investigations showed the efficacy and safety of artichoke extracts ( Cynara scolymus L. ) in the treatment of hepato-biliary dysfunction and digestive complaints , such as sensation of fullness , loss of appetite , nausea and abdominal pain\n",
            "34 -- 36 -- The growing use of automated night-time dialysis ( APD ) in peritoneal dialysis over the last few years shows that this method represents a valid alternative to continuous ambulatory peritoneal dialysis ( CAPD )\n",
            "31 -- 37 -- Treatment for low-grade NHL during the past 30 yr has consisted of high-dose radiation and cytotoxic agents , administered alone or in combination , and high-dose therapy with stem cell transplant\n",
            "43 -- 47 -- However , recent clinical use of monoclonal antibodies ( mAbs ) in patients with low-grade or transformed low-grade NHL has resulted in less toxicity than conventional treatments , as well as response rates that are comparable or superior to those achieved with chemotherapy\n",
            "21 -- 23 -- CONCLUSION : Adrenal-sparing surgery is safe and effective , and may become the treatment of choice in patients with hereditary phaeochromocytoma\n",
            "49 -- 51 -- < TO_SEE > PURPOSE : The purposes of this descriptive , longitudinal study were to evaluate the MacDibbs Mouth Assessment instrument for the assessment of mucositis in the radiation therapy patient being treated for head and neck cancer and to describe the course of radiation-induced mucositis in these patients\n",
            "46 -- 48 -- < TO_SEE > For a subset of patients with Kaposi 's sarcoma who were treated with recombinant interferon alfa-2a , the disease is in complete remission , without opportunistic infection , and they appear to be culture-negative for the etiologic retrovirus that causes their immune deficiency\n",
            "39 -- 43 -- In three consecutive Phase II trials of recombinant interferon alfa-2a ( rIFN alfa-2a ; Roferon-A Hoffmann-La Roche , Nutley , NJ ) involving 96 patients with advanced malignant melanoma , an overall response rate of 22 % was observed\n",
            "36 -- 40 -- This approach is being extended to the clinic , and trials are now underway evaluating combinations of interferon and various cytotoxic drugs known from previous studies to be active in patients with low-grade non-Hodgkin 's lymphomas\n",
            "29 -- 33 -- The data resulting from these clinical trials indicate that interferon alfa-2a is effective in inducing hematologic remissions in the majority of minimally treated , benign-phase CML , Ph1-positive patients\n",
            "31 -- 35 -- More than 1600 patients with neoplastic disorders have received recombinant human interferon alfa-2a ( Roferon-A , Hoffmann-La Roche , Nutley , NJ ) as part of ongoing or completed clinical trials\n",
            "39 -- 43 -- PURPOSE : A phase I/II trial of docetaxel , cisplatin , fluorouracil ( 5-FU ) , and leucovorin ( TPFL5 ) induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck ( SCCHN )\n",
            "31 -- 33 -- PATIENTS AND METHODS : Twenty-three previously untreated patients with stage III or IV SCCHN and Eastern Cooperative Oncology Group functional status less than or equal to 2 were treated with TPFL5\n",
            "18 -- 20 -- BACKGROUND : The effectiveness of LTG as add-on therapy for partial seizures in adults has previously been established\n",
            "18 -- 20 -- The present study was performed to examine whether omega3 fatty acids also exhibit mood-stabilizing properties in bipolar disorder\n",
            "24 -- 26 -- CONCLUSION : Omega3 fatty acids were well tolerated and improved the short-term course of illness in this preliminary study of patients with bipolar disorder\n",
            "22 -- 24 -- Several large-scale trials have firmly established the effectiveness of thrombolytic therapy , beta blockers , and aspirin in the treatment of AMI\n",
            "36 -- 38 -- < TO_SEE > While diastolic left ventricular ( LV ) dysfunction is frequent and associated with cardiovascular complications in end-stage renal disease treated with dialysis , controversial information exists on diastolic LV function after renal transplantation\n",
            "44 -- 46 -- Three patients with FAP and two patients with multiple ( more than 30 ) colorectal polyps were administered DHA-concentrated fish oil capsules_Hlk427554600 ( 2.2 g of DHA and 0.6 g of eicosapentanoic acid ( EPA ) per day ) for one or two years\n",
            "110 -- 114 -- < TO_SEE > In this article , evidence of effectiveness and cost-effectiveness of the following procedures is reviewed : ( 1 ) laser treatment of bladder tumors ; ( 2 ) extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy ; ( 3 ) laparoscopic treatment of endometriosis ; ( 4 ) laparoscopic removal of ovarian cysts ; ( 5 ) laparoscopic cholecystectomy ; ( 6 ) laparoscopic appendectomy ; ( 7 ) catheter treatment of coronary artery disease ; ( 8 ) palliation of colon cancer by endoscopic intervention ; ( 9 ) treatment of upper gastrointestinal ( UGI ) bleeding by endoscopic intervention ; and ( 10 ) arthroscopic knee surgery\n",
            "10 -- 14 -- Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy\n",
            "11 -- 13 -- Comprehensive modified diet simplifies nutrition management of adults with short-bowel syndrome\n",
            "14 -- 16 -- Spinal manipulation in the treatment of episodic tension-type headache : a randomized controlled trial\n",
            "18 -- 22 -- Successful treatment with lamivudine for fulminant reactivated hepatitis B infectioN following intensive therapy for high-grade non-Hodgkin 's lymphoma\n",
            "12 -- 14 -- Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation\n",
            "15 -- 17 -- Treatment strategy for mucin-producing intrahepatic cholangiocarcinoma : value of percutaneous transhepatic biliary drainage and cholangioscopy\n",
            "7 -- 9 -- One-lung ventilation in patients with difficult airways\n",
            "4 -- 6 -- Adrenal-sparing surgery for phaeochromocytoma\n",
            "12 -- 18 -- Laugier-Hunziker syndrome : case report and treatment with the Q-switched Nd-Yag laser\n",
            "13 -- 15 -- Thoracoscopic operation for secondary pneumothorax under local and epidural anesthesia in high-risk patients\n",
            "7 -- 9 -- Troglitazone-induced hepatic failure leading to liver transplantation\n",
            "16 -- 20 -- Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin 's lymphoma\n",
            "25 -- 27 -- Induction chemotherapy with docetaxel , cisplatin , fluorouracil , and leucovorin for squamous cell carcinoma of the head and neck : a phase I/II trial\n",
            "13 -- 19 -- Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS\n",
            "21 -- 25 -- Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil , leucovorin , oxaliplatin and surgery\n",
            "15 -- 17 -- Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors\n",
            "14 -- 16 -- Long-term mortality in patients after a British trial of anticoagulants in acute myocardial infarction\n",
            "9 -- 11 -- The single-place caisson in the treatment of decompression accidents\n",
            "13 -- 15 -- Interferon-alpha-2b in the management of patients with relapsed and/or refractory Hodgkin 's disease\n",
            "22 -- 28 -- In vitro radiation-induced apoptosis and tumour response to radiotherapy : a prospective study in patients with non-Hodgkin lymphomas treated by low-dose irradiation\n",
            "13 -- 17 -- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America\n",
            "8 -- 11 -- Standard versus high-dose therapy in 10+ breast cancer\n",
            "10 -- 12 -- Dosing of amoxicillin/clavulanate for treatment of lower respiratory tract infection\n",
            "12 -- 14 -- Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections\n",
            "18 -- 20 -- The effect of an endothelin-receptor antagonist , bosentan , on blood pressure in patients with essential hypertension .\n",
            "13 -- 19 -- Long-term therapy with long-acting octreotide ( Sandostatin-LAR ) for the management of acromegaly\n",
            "15 -- 19 -- Montelukast , a leukotriene-receptor antagonist , for the treatment of mild asthma and exercise-induced bronchoconstriction\n",
            "16 -- 18 -- A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure\n",
            "12 -- 16 -- Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major\n",
            "13 -- 17 -- Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer\n",
            "17 -- 19 -- Reconstruction of thoracic wall defects after tumor resection using a polytetrafluoroethylene soft tissue ( Gore-Tex ) patch\n",
            "8 -- 12 -- Effect of long-term salmeterol treatment on exercise-induced asthma\n",
            "26 -- 28 -- Randomized trial of intensive cyclophosphamide , epirubicin , and fluorouracil chemotherapy compared with cyclophosphamide , methotrexate , and fluorouracil in premenopausal women with node-positive breast cancer\n",
            "8 -- 12 -- Low-molecular-weight heparins in the treatment of venous thromboembolism\n",
            "35 -- 43 -- IDA-FLAG ( idarubicin , fludarabine , cytarabine , G-CSF ) , an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation : experiences of a phase II trial\n",
            "32 -- 38 -- Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized , low to high Gleason grade prostate carcinoma\n",
            "12 -- 14 -- The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma\n",
            "12 -- 16 -- Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson 's disease\n",
            "7 -- 9 -- Cost-effectiveness of interferon treatment for hepatitis C\n",
            "18 -- 26 -- Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C\n",
            "26 -- 28 -- Meta-analysis of typhoid vaccine efficacy trials showed that whole cell vaccines are more effective than either the oral , attenuated vaccine or the Vi polysaccharide vaccine\n",
            "8 -- 10 -- Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy\n",
            "18 -- 20 -- < TO_SEE > Surgical-site complications associated with a morphine nerve paste used for postoperative pain control after laminectomy\n",
            "10 -- 12 -- Melatonin treatment of sleep-wake cycle disorders in children and adolescents\n",
            "19 -- 21 -- Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11 , 974 in the control of cisplatin-induced emesis\n",
            "17 -- 19 -- Evaluation of clomipramine as an adjunct to behavioural therapy in the treatment of separation-related problems in dogs\n",
            "20 -- 24 -- Mitomycin , ifosfamide , and cisplatin in unresectable non-small-cell lung cancer : effects on survival and quality of life .\n",
            "12 -- 16 -- Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism\n",
            "20 -- 22 -- Radiotherapy in breast-conserving treatment for ductal carcinoma in situ : first results of the EORTC randomised phase III trial 10853\n",
            "17 -- 19 -- Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence : a randomized controlled trial\n",
            "12 -- 14 -- Cell-based vaccination against melanoma -- background , preliminary results , and perspective\n",
            "14 -- 18 -- Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis\n",
            "18 -- 20 -- Special report : pressure-reducing support surfaces in the prevention and treatment of pressure ulcers : group 1 technologies\n",
            "10 -- 12 -- Intra-articular hyaluronan injections for treatment of osteoarthritis of the knee\n",
            "\n",
            "\n",
            "\n",
            "No. of mismatches (spacy)= 796\n"
          ]
        }
      ],
      "source": [
        "count = 0\n",
        "for i in train_sentences:\n",
        "    split_len = len(i.split())\n",
        "    spacy_len = len(model(i))\n",
        "    if split_len != spacy_len:\n",
        "        print(split_len, \"--\",  spacy_len, \"--\", i)\n",
        "        count+=1\n",
        "print(\"\\n\\n\\nNo. of mismatches (spacy)=\", count)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### from the above, it can be seen that there are 796 mismatches and spacy tokenizer is out of question, proved again"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "YrIAz8gqN_Js"
      },
      "source": [
        "## Build the CRF Model"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### various algorithms are used for CRF, the f1 score are compared and the best one is chosen"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 877,
      "metadata": {
        "id": "k2oGSiqQ8Otd"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9185340918118996"
            ]
          },
          "execution_count": 877,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'pa'\n",
        "crf_pa = sklearn_crfsuite.CRF(max_iterations=100, algorithm='pa')\n",
        "crf_pa.fit(X_train, y_train)\n",
        "y_pred = crf_pa.predict(X_test)\n",
        "f1_pa = flat_f1_score(y_test, y_pred, average='weighted')\n",
        "f1_pa"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 878,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9182284625896802"
            ]
          },
          "execution_count": 878,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'ap'\n",
        "crf = sklearn_crfsuite.CRF(max_iterations=100, algorithm='ap')\n",
        "crf.fit(X_train, y_train)\n",
        "y_pred = crf.predict(X_test)\n",
        "f1_ap = flat_f1_score(y_test, y_pred, average='weighted')\n",
        "f1_ap"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 879,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.903275052568046"
            ]
          },
          "execution_count": 879,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'lbfgs'\n",
        "crf = sklearn_crfsuite.CRF(max_iterations=100, algorithm='lbfgs')\n",
        "crf.fit(X_train, y_train)\n",
        "y_pred = crf.predict(X_test)\n",
        "f1_lbfgs = flat_f1_score(y_test, y_pred, average='weighted')\n",
        "f1_lbfgs"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 880,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9041202880091156"
            ]
          },
          "execution_count": 880,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'l2sgd'\n",
        "crf = sklearn_crfsuite.CRF(max_iterations=100, algorithm='l2sgd')\n",
        "crf.fit(X_train, y_train)\n",
        "y_pred = crf.predict(X_test)\n",
        "f1_l2sgd = flat_f1_score(y_test, y_pred, average='weighted')\n",
        "f1_l2sgd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 881,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9027557948801219"
            ]
          },
          "execution_count": 881,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'arow'\n",
        "crf = sklearn_crfsuite.CRF(max_iterations=100, algorithm='arow')\n",
        "crf.fit(X_train, y_train)\n",
        "y_pred = crf.predict(X_test)\n",
        "f1_arow = flat_f1_score(y_test, y_pred, average='weighted')\n",
        "f1_arow"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 883,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "<Axes: xlabel='Algorithms', ylabel='F1-Score'>"
            ]
          },
          "execution_count": 883,
          "metadata": {},
          "output_type": "execute_result"
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "import pandas as pd\n",
        "import seaborn as sns\n",
        "\n",
        "df = pd.DataFrame({'Algorithms': ['pa', 'ap', 'lbfgs', 'l2sgd','arow'], 'F1-Score': [f1_pa, f1_ap, f1_lbfgs, f1_l2sgd, f1_arow]})\n",
        "sns.barplot(data=df, x='Algorithms', y='F1-Score', hue='F1-Score')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### It can be seen from the above that algorithm 'pa' has the maximum f1-score of 0.9185"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Checking the F1-Score with only previous word as the feature together with PoS. No next word is used, just for comparison. Informatively, the final model has next word also in the list of features, therefore giving more accuracy"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 884,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9158301781030854"
            ]
          },
          "execution_count": 884,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "# Build the CRF model with algorithm 'pa'\n",
        "crf_prev = sklearn_crfsuite.CRF(max_iterations=100, algorithm='pa')\n",
        "crf_prev.fit(X_train_prev, y_train)\n",
        "y_pred_prev = crf_prev.predict(X_test_prev)\n",
        "flat_f1_score(y_test, y_pred_prev, average='weighted')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "5VPFrPZJOJMq"
      },
      "source": [
        "## Evaluation"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "84gUagMZOP9B"
      },
      "source": [
        "### Predict the labels of each of the tokens in each sentence of the test dataset that has been pre processed earlier.\n",
        "### Using 'pa' algorithm found to be giving more accuracy"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 885,
      "metadata": {
        "id": "D_sDJs1n8-sI"
      },
      "outputs": [],
      "source": [
        "y_pred = crf_pa.predict(X_test)\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "qIneYrqZOUiJ"
      },
      "source": [
        "### Calculate the f1 score using the actual labels and the predicted labels of the test dataset."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 886,
      "metadata": {
        "id": "Lr_JNIgrOTcr"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "0.9185340918118996"
            ]
          },
          "execution_count": 886,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "flat_f1_score(y_test, y_pred, average='weighted')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Informatively, from above, there is marginal increase in the F1-Score when using both previous word and next word as features together with PoS"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ORDyDw6sYHf5"
      },
      "source": [
        "##Identifying Diseases and Treatments using Custom NER\n",
        "\n",
        "We now use the CRF model's prediction to prepare a record of diseases identified in the corpus and treatments used for the diseases.\n",
        "\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "V9aOa7LEOcWu"
      },
      "source": [
        "### Create the logic to get all the predicted treatments (T) labels corresponding to each disease (D) label in the test dataset."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "sWxZ2TaOqN-u"
      },
      "source": [
        "![image.png](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAk4AAAECCAYAAAAIK1h/AAAgAElEQVR4Ae2dfahlZ3X/r3+LUFIQ/UsoLRKjDFKskhJfUGYEpSooiVVTX2JHNFhUgiRUxWmxojgNtY2NhhmxU6UlmSQEjUnUGDNTjRNM0rxN1Lw5Khon0UQdI3F8fny3/d7fuuvut/N+9jmfDWf22ft5nvWs9VnPWft79z73zkZhgwAEIAABCEAAAhDoRWCjVy86QQACEIAABCAAAQgUhBOLAAIQgAAEIAABCPQkgHDqCYpuEIAABCAAAQhAAOHEGoAABCAAAQhAAAI9CUwknPbs2VM2Nja2vZ773OeWv//7vy/333//NjeOHz9edu3aVY05dOjQtvbHH3+8HDx4sLzuda8rp5xyStVP9t773veWu+66q/zsZz/bHF83dzwn++PO9w//8A/lwQcf3OafYn7KU55S/vM//7P8/ve/39Z+4sSJsnv37sb4NOCSSy6p2mWnjoH61LF9xjOeUd72treVW2+9dXPuRx55pGKluD/2sY+V3/3ud9t8uu2228qOHTsqv6+55poixmwQgAAEIAABCIxOYCrCSRf0l73sZWXnzp3VXse6kEv4fPazny1PPPHEpmdtQua73/1ueeUrX1mN1fgXvOAFW+xJaHzuc58r55xzTjWX5nvJS16yKbDUX+f8uvnmm1uF0wMPPFBe85rXNM6nOC677LJNkaIgLGjUVid6uoTTr371q/LmN795c84PfOADtWInzmO2z3zmM6txWbhJDOmcxNHRo0c3WeuN2F9wwQXVOAk6+Vcn+LYM4gACEIAABCAAgVoCUxFOviB7Bt3R+I//+I8icZEv8k3C6Sc/+Ul51ateVV3gX//612+5W2V7Ov/QQw95mmrfZM+dmtrjfG9605vKsWPHPKS6I7Nv375KkCmGr3/965ttFjQSdvJXduLWJZx09+fP/uzPikTQ05/+9EoY/vjHP44mqveeJ7IVh4985CMVo9NPP71I+GmLc6o93nXSfKeeemqViyNHjmybhxMQgAAEIAABCPQnMBPhpOl1V0PiSQLjL//yLzeFUJ2Q0YXegqBOjLSFU2cv9q9rl28XXnhh5VvTfOrz6U9/uurzV3/1V+WnP/1pZdaCRnHp9c53vrPoLpK3KGLyHSnZ/MQnPlGNe//731/e/va3V++vvPJKD9/ce54onNT4ox/9qLz4xS+uxkX7EkUSefGuU7zbpLtO8c7f5kS8gQAEIAABCECgN4GZCSd5oO8jvfzlL68u8gcOHKicqhMyUQzo0dgoW529OL6uPfrVNl/0y+LGgsbCSfuPfvSjm6KkTTjp+0h6NKi7cBI9/q7Tu9/97m3fO/I8WTjVxaN4o0jy4z/fbYpiKrLhPQQgAAEIQAACoxGYqXDSnaTzzz+/Ek7vec97ym9/+9va7xx985vfrMTEc57znHL33XePFEGTkLCRunZ990mPybrmiyJIQkabBY3uGD3/+c+vYpOtr371q1V7HBPvCKlRxxJNEpMSb3fccUf1GE127rvvvmq8//E8WTh5TJ0Ycpsezd1yyy2b323SXS7d7WKDAAQgAAEIQGAyAjMVTnItC4A6IaO7Obpzo9+2U/soW529OL6uXQJG88XvCcUx8X3238e6g6bvPunxmGxJ/Oi3/pqEk0Sk7gSpr35jT0ImflFcd5/i5nksnNT/3nvvLfqel2y8733v23aXKj7yfMtb3lL5FB+TRvu8hwAEIAABCEBgdAIIp//7gnUTuixgfCzhJDHj70pJzOj7UrpzJLGj43jHyY/9/JjO8/lxnX7TLn5XyvPITn699a1v3fYledvTn4CQWPIYfU+Lu02mwx4CEIAABCAwGYGZCqdVflTn72xJ7OgL4hYq+sL3G9/4xm3CSd+lUh8/pnPa9OcD9NhNv2mn7yR5s3DSHS39OQL/KQLN9dhjj7nbtr1E0kUXXVTNpS+RS7CxQQACEIAABCAwHQIzFU7xS9gWGnWPzvRr9XpsJmHR9mXtupDr7MV+de3Rr7b5fJdIfuUvhzsezRX/tIEFlPa+46Q/I6AvgMe2uvfxu0gWTn5UF+8kdd1Fkm+yP86jz8iO9xCAAAQgAAEIbCUwM+GkOx+j/DkCf/9Hv3WW/1aTXJa9kydPbvW+lNovm8dOdcJJtvyIbdw/RxCFk+bT95v8ZXGLIgsn31XSY7ozzjhj8w90+g916g93aoxi12/eacvCSee+8IUvVF8u15e/492pakD4B+EUYPAWAhCAAAQgMEUCMxFO/oOVeswksRD/e5I6IaN49FfDLTz0uCuKJ33hWkJHwiL/wckme2bU1B7vEo3zBzCzcJIYU5yKNwsnf48pCiP7p72+F6XY4/ef6oSTOJx77rmV/bPPPrs8+uij0czme4TTJgreQAACEIAABKZKYCrCyd/D0R0UfR/Hv2k26n+58j//8z/V930kPHx3Jv6XKvou0Le//e0tAJqEkTu1tU/yX65k4aT59LeU9DedonDS95EkzHRu7969dmvLPj7K899gqhNOGqQ7W+Ige02P7BBOW/ByAAEIQAACEJgagakIJwsF7yf5T34ldD75yU+WF73oRZsCRO91Tm15axNG6tvVLtFS958Kt/0nv4qzTjhpvvhlcT2qu+mmm6q/GaU7Srqr1rR97Wtfq/6LFz3K03//0iSc4p2tpkd2CKcmypyHAAQgAAEITEZgIuE02dSMhgAEIAABCEAAAsMigHAaVr7wFgIQgAAEIACBBRJAOC0QPlNDAAIQgAAEIDAsAginYeULbyEAAQhAAAIQWCABhNMC4TM1BCAAAQhAAALDIoBwGla+8BYCEIAABCAAgQUSQDgtED5TQwACEIAABCAwLAIIp2HlC28hAAEIQAACEFggAYTTAuEzNQQgAAEIQAACwyKAcBpWvvAWAhCAAAQgAIEFEkA4LRA+U0MAAhCAAAQgMCwCCKdh5QtvIQABCEAAAhBYIAGE0wLhMzUEIAABCEAAAsMi0Cqcrr766qLXLbfcwgsGrAHWwNzWwDXXXFPVnm9+85tzm5M6R51nDbAGbrjhhqr2HDlypFHNtQqngwcPln379vGCAWuANcAaYA2wBlgDa7MGxhZOUl779+8v99xzDy8YsAZYA3NbA9dff31VoG+99da5zUmdo86zBlgDN910U1V7tBaattY7TocPH66E0wMPPFB4wYA1wBqY1xq48cYbq+J11113UXuov6wB1sDc1sB3vvOdqvao1jVtCCcW5NwW5LwuuswzfIGHcBp+DvkcksMhrgGEE6IIUcQaGOQaQDhx0R3iRRefh79uEU5cNAd50aT4DL/4TJpDhBNrYNI1xHjW0DhrAOGEcEI4sQYGuQYQTlz0xrnoMYZ1M+kaQDhx0RzkRXPShc/44RdPhNPwc8jnkBwOcQ0gnBBOCCfWwCDXAMKJi+4QL7r4PPx1i3Diojm1i+Z73/vesrGxUS699NJNm/oruy984Qur82pX0bjwwgurY/XNL/XVGNvyGBcb2dYY97v33ns353If9sMvTH1yiHBa/Tz78/7Xf/3X5ejRo1s+664jsUa4bpx66qnla1/72pb+rkWuHXVrTGM0Ns+Xx/o41y8fy7c777xzy/x183FumGsY4YRwmtqH20XLwikWl1jcXPBcZOLeRS2OtT0VThU09fc5Cs8wC8808oZwWv3cuw5kIeRaEM+7r+uJ6kxcZ253jYltfo9wWv015VxPskc4IZy2FJdJFlMUTi5SKmJRNMm+hVMubHnu/NOmx2V7eRzH61H8EE7rkWfXlVgv6gSO68Pu3bt73TWqqxN1dtXP9cyiKx/X2eLc6q5PhBPCaerC6TOf+cy2x3OxiLjAxUIY2/3eP1VKfNmmC5f7sF/d4tSVW4TTeuTeYiZ+9rOYcq3QHagvfelL1Z3peDdKa6mP2PFcfR/VRZ+61ivtq7NeEU4Ip6kLJ98q176usFg4xX5+n+8muZC5vUtsUZxWpzh15RLhtB65tihSDdBdaAugKIxcJyx4XGNivfC4uprktZbt+Hwe62PXpbi3X9/73vemVlvtB/vlWPMIJ4TT1D7c/ilQRUQFy8dZDLmoxWLj97mvCoX7uyhSPJajeCw6Dwin9VkHrgGqD36EH2uF27XXuqwTQBY7CKf1WTezqlEIJ4TT1IWTi5cLlURR/DJ3LnJdi7uuUHaNoX31iyPCafVz7M+xhZBET/4FkXhHyj+Axb1rj+vRNIVTmy37zn711inCCeE0deHkQqWCYZEU7xb5nAVWV2FBOK1e4enKeZ92hNP6rIssjqJgcX2IYim+952pPsLJfTS+rY65X/Sjz5qlz2qsWYQTwmmmwskFRoXIQsnCKRY3v/f3A2KBcWF0AYxtvF+NQjROHhFO65V714FYS7RuVBfyOZ2Pd6lUh2Itcr3xPgog23Nb3LuGtdlSf9m49dZbp1Zbx/l8MGZ2nw+EE8Jpah9uF5z4k5o+vC54FkUIp9l9oNepWCKc1msdWay4jmit153zZyDepVINct8ohPw+CieNr6tRsa612UI4rf66RDghnKYmnFyw2K9+4ViGHCOcWGfLsA7xYf3WIcIJ4YRwYg0Mcg0gnNbvgoVIIefLsAYQTlw0B3nRXIYPDz4stogjnBbLn/UP/3VdAwgnhBPCiTUwyDWAcOLCva4XbuJe7NpHOHHRHORFk8Kx2MKxDPwRTqyBZViH+LB+6xDhhHBCOLEGBrkGEE7rd8FCpJDzZVgDCCcumoO8aC7DhwcfFlvEEU6L5c/6h/+6roGJhdN1111X9u/fX/2NDP1tC14wYA2wBuaxBq655pqyb9++8q1vfYu6Q+1lDbAG5rYGvvGNb1S1R3WuadtoatD5gwcPVgZUwHjBgDXAGmANsAZYA6yBdVgDR44caZRHrcLp6quvrgTTfffdV3jBgDXAGpjXGvBPfXfccQe1h/rLGmANzG0N3HzzzZXuGVs4HT58uHpU1yi7aIAABCAwAwISTPqp9he/+MUMrGMSAhCAQD2BH/7wh1Xt0Xe8mrbWO04IpyZsnIcABGZJAOE0S7rYhgAEmgggnJrIcB4CEFhqAginpU4PzkFgZQkgnFY2tQQGgdUmgHBa7fwSHQSWlQDCaVkzg18QgEArAYRTKx4aIQCBGRFAOM0ILGYhAIHZEkA4zZYv1iEAgXoCCKd6LpyFAASWnADCackThHsQWFECMxVOBw4cKBsbG9tee/bs2YJT/Xbv3l1OnDix5fxQDw4dOrRS8Qw1D/i92gTahNOsP4OqVapZmmcR2yTxqd7mGtwWwzxinSSeNt/7tI0T39GjR8uOHTs2r21i2nebdazjxNPX9z79xokvaoUhaIGZC6f8AXVS8/k+CRlCHy0aicUhJH8IPPERAk0EEE6j/7DpC9Qo9dc1W7VtVts4F9tp+TJqfBZN5nH8+PGya9eu3iJ61rGOGs+0ONrOqPFpTYqfOGrT2hxlfXreee7modelwUXF5oAheFhqD5TlUEGse6PQNW0tymfRzved2ex3a1tyXGY/VTyHnnnbclnrZxtEEAAuMRaBJO999//2YN8OdfNWbv3r1VPdDnX3XCFxjXg1iD5JEvkG7XZ1vn8jjZ1vmzzjqrXHHFFZtzq75EG/bF0bpm2H6sR7LpOuJ2ndMWa1y2adt5bz/UX3HGuXLfeFwXq/yWDfGUb+bWFo9sak7Hor19qItHsao9jlE/nbcNj7e/sc25Upv8Um4uvvjizbHmVhef7TXtNY9jdh/76+OmfVOseW1qfFM8ast+i4n65/M65/i1Nn2XTP4fO3Zs8/MQecl+Wy691p1/zW0edfE1sYhxyE9vsuH8+Nyy7RcinARBi96wtDf4+F794rGTKbDavEhsR+fjAnB/zZX75mP3bbJdTdjyj8Zfe+21VY/oc8sQmiAAgQkINAknmdTn2DVFx/pMxtqQP//qozrhi7GFRq4Htunxbnf/PN4XAPd3reqqN+qnC5Ltax/917F96YNQ/vk/JI1x9hlr3+2LfXessuFz7uMxjld9o7/ql+OL7Tl+H3tOxbNz585KmGp+tcfxsm/29s3t9s22fGzf+zDJfWTL9nJbPtY89kVt8j3m1udinxiP/Y3zRRtudzw5fh/HOaP/bvd429Mc2vJad3+35/iqQSP8E30ZYdhcuy5MOAmyE6/3XiTxfSYRx7hNSdRPE0pe3eYk5OTnvuPYzjZ83BaD+7CHAAQmIzCqcHKN0ax1xV01RLVENaVui59r1xNfXPKF3O0a4y3WmPje7bGWxbnU7ouT56vz33a69q6JXf3c7lg8d/ZF/brisS3vs40cT46/ia/GNeVNccpOnsv+ej3k+Oxj3332rWtcV6xd8dTZjz7keOriz2sg+tSVyziXfYn2oi2399lrXolpC94+YxbVZ+mEk5MsgFERC5CSo/P5lUErsRrrfhqnTQn1OX9oDL6vbfdv2+cPfVtf2iAAgfEITCKcXKRdD7zPNSfWI/Vx3cgXp3wxye2KMF6QuupNriH2QzVM27gXJ43V3K6JlbGOf3Is2RfbNMO4z7U5c2+KJ8cvvvEH5OhTrvdxftmp8zfaj7Y6UGxr9tyy13fLuYu+yIZtxjj8Ps8T15HXbo6nLn6Ni7aiT9Gm59XeuZR/8W6ffNYYvbRFW9WJEf+psz+iiZl3X5hwionLC0dRO/kxYTE5dWTigvMHsm5M7Odk1/Wrm6PPubp4+oyjDwQg0J/ApMLJIqhuRl9sVH98gYmfa9cn15lc7HO75tD4vvUmzqWx9sfzTXJxGrXW5ViyL/Kvy6biibU828jx5PjFt0045Qt5zGmey7lw/nN8cWzbe19H5OsoW59Y2+LRXOItno4hrr8cT138Gh/9jj515TLO5bjjmGjL7aPs7X/0b5Tx8+i7EOGUE5k/JDHw2Letn8aoXQmMW0xoPK/3SrBVdJftPLbteJq22uahDQLrTGAS4RQ/+3UM64p//Fy7uKuftnwxye3qE+tTtFU3f26PdVD96/yrs1N3rq0m1vXPsWRfNCb7G+3k8WrLNnI82Z74NgmnbCvOXTeXzkX7df5lG/lY/kq4OP+5ve24K9Y+8eRHynH95Xjq7GkNiIG36FNk4/a4j3P5fFxT0Zbbm/Z1vtn/6F/T+EWdn7twMhSB9hYTFd+rXUmwuDHkCDT2j+81Vsda3JrL88axMdldtu1rn332o88Y+kAAAqMRmEQ4uR7EOhRrTXwvr3Qcf8L3eJ3Xli8muV19VBc8X1e9yTXE/T2f9r7bUDkwwj+x7vUZlmPJvsiGz8X66hgefvjhyle32V4UHjkej1VfbW3CSe3q7+tE9Ed27ZvZub/52Z/Yrj5Nm3zRY7G+/bMdjfPcasux+lzfeBzftB7V2Z7zZX/sc17rao9rKsen9rYtx59z2TZ2UW0zF076cORXTIgCj+C8iD3Gi8GAvGjd7mSqPY9VMmMS2sZqfFe7fejax3i6+tIOAQiMR6BNOLn4u37UfSbdx7UkXqjkkeqH21Rn9Fuztqd22VS7+uWLiWtRvLiqv/p6a6s32V/7ans+jv7YbtdePkQ/1D/Pl23EWD23fXHftnhym1iKqf2wTceT/dH4pjtOnl+2nC/t7Z9t+7gu3hif7TXt8zye09eiuvmiLbc3xeq+eZ7ov957XtnRsdav4tAW4/F8cbxsu6/6q83+6zjnK7flR4myp5c2z+f4qpMd/8RY8+dQfsb5245PnjzZMdN0mmcqnKbjIlYgAAEIbCfQJpy29+ZMGwEJPf2dI+3ZJicgIRKFyuQWsbBMBBBOy5QNfIEABHoTQDj1RtXZURf5eAeicwAdGglIfOoOiu68sK0mAYRTj7zG24i+PRr3FJweEOkCgSkTQDht/3pCrEt+z52P/gsvP6IyQ+/zY6T+ltez56peOxFO67meiRoCgyeAcBp8CgkAAoMkgHAaZNpwGgIQQDixBiAAgUUQQDgtgjpzQgACExNAOE2MEAMQgMAYBBBOY0BjCAQgsHgCCKfF5wAPILCOBCYWTvri4f79+4v+fgIvGLAGWAPzWgO333572bdvX3nkkUeoPdRf1gBrYG5r4NixY1Xtuf/++xt140ZjSynl4MGDlQEVMF4wYA2wBlgDrAHWAGtgHdbAkSNHGuVRp3DSHadvfetbvGDAGmANzG0NfPGLX6x+WLvhhhvmNid1jjrPGmANXHfddVXtGVs4HT58uHpU1yi7aIAABCAwAwJ8x2kGUDEJAQh0Epj4O04Ip07GdIAABGZAAOE0A6iYhAAEOgkgnDoR0QECEFhGAginZcwKPkFg9QkgnFY/x0QIgZUkgHBaybQSFASWngDCaelThIMQgEAdAYRTHRXOQQACsyaAcJo1YexDAAIzIYBwmglWjEIAAh0EEE4dgGiGAASWkwDCaTnzglcQWHUCMxVOBw4cKBsbG9tee/bs2cJV/Xbv3l1OnDix5fzQDmK8O3bsKEePHh1aCPgLgcEQaBNO+h8NZllTVKtkX/MsYpskvuPHj5ddu3b19n0esU4Sz6T8J4lPLM8666yRav2sY50knklZavyo8dnfqBW0PsV2WbeZC6cskgwpn19WQH39kmiKydbiicd97dAPAhDoRwDhNN4Pm6q9ukipRvXZXLP79u9jM/cZ9WKbx09yPG58FqCj/pA861jHjWcShnHsqPHpBsN55503qBsncxdOAuwF5w9ivuPkD7Y+3Fl8eKzVaRZgsum2PL5rbFd7XBzxvReq4vDmc47R59lDAALTIdAknPT/R7kGuH7os7l3796qnqhNn0t/Rt0336FSQddF0e2+QOZxsq2+uvNwxRVXbPZXbYo27Iujb6s3sqmLiXzy/K4vscZlm7bdtNdY2dS4PrWpLlb5LRviKd/MrS0e+RPrusa5dtfFo1jVHseon86bh8c71tjmXKlNfik3F1988eZYc6uLz/ba9vZLOdq5c2fvO05Nsea1qbmb4lFb9ltM1D+f1znHr7Xp9ayc6f9bEweNjbxkvy2XXuvOv8Z7DdTF18ZRbRqTc9k1ZtHtCxFOClqglFRt2ht8fJ/bnEyB1uZFYjs6HxeA+2uu3Dcfu2+T7WrCEf7J9kYYSlcIQKAHgSbhpKH6HLum6Fg1ItaG/PlXH9UJF3ALnlwPbNPj3e7+eXy+QLtW5fpge27XXhck29c++q9j+9IDVdVFc2rMPffc01s4aaB9sy/23bGqj8+5j8c4HvWN/qpfji+25/h97DnFOwoWtcfxsm/29s3t9s22fGzf+/CUCNG47EefsZrHvqi/fI+59bnYJ8Zjf+2/+9uG2x1Pjt/H7q/xsmV7bvd425Of2vJad3+35/iqQS3/aNyZZ565TdS2DFl408KEk2A5UXrvRRLfZzpxjNuURP00oeTVbV4QOfm57zi2s4143BZH7Md7CEBgPAKjCifXGM1WV9xVQ9q+rxI/064nvrjkC6jbNcZbrDHxvdtjLYtzqd0XJ89X57/tNO1lU69sq6m/zzsWz103vise2/I+28jx5Pib+GqcbNXlTbW/Kd5oP8dnH/vss199xnTF2hVP3RzRjxxPZq3xvi7aVvSpK5dxLo+P9qItt7ftNTZ+NjW/RW/buEW2LZ1wcpLrbh8KsM7nV4asxEpNu5/GaVNCfS4mSm19bfdJlhIf1XyfMfSBAARGIzCJcNJn1LUg7vPnNtYj9XPdyBenfDHJ7YosXpC66o36ei6NtR+qYdpGvTjJP3+PJNuqDLb8k2OpG98Vj81n7k3x5Pjlf/wBOfqU633Mp+zU+RvtR1v2s+8+573PuJy76IvGd8UT54jcvXZzPHXxa5zm9RZ9ijYjS19n62LWGL20RVu2P8re/kf/Rhk/j74LE04xcXnhKHDDU+KcsJicOjhxwfkDWTcm9nOy6/rVzdF1TrF4AXf1pR0CEBifwKTCKQqT7IUvNqo/LuCxTrk+uc7ki0lul32N71tv4lwaa3883ygXJ/ki0SQf62xVJ1v+ybFkXzS0q34qnljLs40cT45fvrcJp/jYLoeS51J7tJ/jy+PbjnPe2/q6rU+sbfHIjniLp9dw9CPHUxe/xouBt+hTVy7jXB4fx0Rbbh91n/0bdfys+y9EOOVExkWcA4592/ppnNoFPG4xofG83ivBFmVdtvPYumPNZXt17ZyDAASmR2AS4RQ/+3Ue1RX/WCPyxSlfTHK75oj1Kdqqmz+3xzqo/nX+1dnROfmmH+Z0oc0vzdO15ViyLxqf/Y0283i1ZRs5nmxPMTQJp2wrzl03l85F+3X+ZRtNxznvTf3i+a5Y+8STH01GP3I8dfayMIk+RTbRb7+Pc/lcvM5GW25v2tf5lv1vGrvI83MXToYi0N5iouJ7tSsJFiOGrD7eYv/4Xu06VqHQXJ43jo3J7rLt+Zr2sms/m/pwHgIQmB6BSYST60GsQ7HWxPfyWMfxJ3yP13lt+WKS29VHNcLzddUb9fXdBI11f8+nfWyvnOj5T7bVNSzHUjfe52J9dQwPP/xw5avbbE88m+LxWPXVJr5Nwknt6h/rr/2R/fjesUb79se+uE+ffc57nzE5d9EXjx8lHsfnJx05HrfH+LQONYe36JP7x/boY13M8Voabdl+215j41qOc7WNW2TbzIVT/glHxzEhCj6CctI9zovBkJS0+NNTBJ7HenH4A9U2Vva72u1D3nuh2ee4z7HmsRxDAALjEWgTTv5Mun7EGuPZ3MefV9cJt6t+uE115tprr93yGF421a5++WLiWhQvVuqvvt7a6k32177ano8dn2322XusbWlMni/bibHWjVf/tnhym1iKqXnYpuPJ/mh8m3DS/DFfyovjs20f18Ub48uxtx3Lr/xYrW6+aMPtTbG6b1M8alcsXpuyo2OtX8WhLcbj+WL8su2+thevpTlfuS3HLHt6afN8jq862fFPjDV/DuVnnL/t+OTJkx0zTad5psJpOi5iBQIQgMB2Am3CaXtvzrQRkNDT3znSnm1yAhIpUahMbhELywZX4asAABnzSURBVEQA4bRM2cAXCECgNwGEU29UnR11kY93IDoH0KGRgMSn7qDozgvbahJAOPXIa7yN6NujcU/B6QGRLhCYMgGE09bfPo41Kb7nzkf/hZcfUUWOep8fI/W3vJ49V/XaiXBaz/VM1BAYPAGE0+BTSAAQGCQBhNMg04bTEIAAwok1AAEILIIAwmkR1JkTAhCYmADCaWKEGIAABMYggHAaAxpDIACBxRNAOC0+B3gAgXUkgHBax6wTMwRWgADCaQWSSAgQGCCBiYXTwYMHy759+8pVV13FCwasAdbA3NbAf/3Xf1W15/LLL5/bnNQ56jxrgDVw2WWXVbXnyJEjjbJvo7GllGLhdOWVVxZeMGANsAbmtQYsnFSD5jUn87C+WQOsgUsvvXQy4XT48OGyf//+Nm1FGwQgAIGpE+BR3dSRYhACEOhBYOJHdQinHpTpAgEITJ0AwmnqSDEIAQj0IIBw6gGJLhCAwPIRQDgtX07wCALrQADhtA5ZJkYIrCABhNMKJpWQIDAAAginASQJFyEAge0EEE7bmXAGAhCYPQGE0+wZMwMEIDADAginGUDFJAQg0EkA4dSJiA4QgMAyEkA4LWNW8AkCq08A4bT6OSZCCKwkAYTTSqaVoCCw9ARmKpwOHDhQNjY2tr327NmzBYz67d69u5w4cWLL+aEdHDp0aDPWXbt2lePHjw8tBPyFwGAItAknfRZnWVNUq2Rf8yxiGye+WI9HYTOPWMeJZ1rcJ41v1OvXrGOdNJ5JuY4Sn66RulbW6QRxXdZt5sIpiyQnNZ9fVkB9/dJi2bFjRzl69Gg1ZNQPU9956AcBCPyBAMKp/w+bqkfxhznV37412DVbNW5W2ygX22n7MEl8qveq+6MI0VnHOkk802A7aXx5rU7Dp2nbmLtwUgBWmf4gZpGhD7QVaPywx7Fuzx9+2XSb9nG853V7HtvV3gZftqI9faB27ty5KaTaxtIGAQiMTqBJON1///2bNcCff9WYvXv3bv50qzrhC4zrQb74+aLodv9glMfJtvqeddZZ5YorrticW/Ug2rAvjrSt3sjmeeedV12QPb/OaYs1Ltu07bi3vx5vG6OMjT7Ib7EST503t7Z4NKd42I72rpd18chXtccx6qfztuHxjjW2OVdqk1/KzcUXX7w51rGbjW1GRrbbtNdY5ch50nHX1hRrXpuy0xSP2rLf8l/983mdc/xam+KivsrZsWPHNj8PkZfst+XSa935tz3NXRdfF5PY7s+L7CzzthDhJCBa9F6k2vvDF9+rXzx2Mg3Vi8R2dD4uAPfXXLlvPnbfJtujJjH6PepY+kMAAt0EmoSTRupz7JqiY30eY23In3/1UZ3wxTgXcPe3TR+7Xrh/Hp8v0K5VXfVG/XRBsn3to/85vm5aW3vEWLe2bD/Ksdp3x6oRPmd/Pcbxqq/Zqb/65fhie47fx55TvOMPpmqP42Xf7O2b2+2bbfnYvm8nUH9Gc/pl2/U9t57VPLG/bMTcqndbPPbX/ru/bbjd8eT4fez+Gi9btud2j7c9+aQtr3X3d3uOrxrU85/oR88hC+m2MOEkyE5UXCTxfSYSx7hNSdRPE0pe3eZE5OTnvuPYzjZ0rEWjghAXZV0/zkEAApMRGFU4xYtVXXFXDVEtUU2p22Jtcj3xxSVfyN2uMd5ijYnv3R5rWZxL7b44eb46/22nbS+7qk8WFW193eZYPHf2Rf264rEt77ONHE+Ov4mvxjXlTbVfdvJc9tfrIcdnH9v2sqnx2mdf28aprSvWrnjq7Ec+OZ66+H1dtK3oU1cu41weH+1FW27vs6+z22fcIvosnXBykuvEh5Kj8/mVi4ASIOHifhqnTQn1OX9oDL2vbffv2jsOzckGAQhMn8AkwkkXB9eCuM8/8Phz7D6uG/nilIt+blf08YLUVW/yxdh+uJ6Me3FyFrK/Pl+3z7FkXzSmKx7bzdyb4snxy9/4A3L0Kdd750p72anzN9qPtuxn117x2vdoq2uc2nPu8viueOIckbvXbo6nLn6N07zeok/RZmTp62zd2tEYvbRFW7bfZ5859BmzqD4LE04xcXXAnHwlzgmLyakDFhecF3XdmNjPya7rVzfHKOdmYXOU+ekLgVUmMKlwsgiqY+SLjS++6hPrlOuT60y+mOR2j+9bb+JcGmt/PN+4FyfHav80T9fmvp47+6LxXbVO88Ranm3keHL84tsmnOJjuxxPnkvt0X6OL4/Px/LVecy2ct+64z6xtsUjm5pfPL2G4/rL8dTFr/Ex99GnrlzGuRxfHBNtub1rb5+jT11jFtm+EOGUExkXcYYR+7b10zi1K4FxiwmN5/VeCbYo67Kdx8bjpqS3zR3H8x4CEBidwCTCKX7262auK/6xRvgzr37a8sUkt6tPrE/RVt38uT3WQfWv86/Ojs7lsTpn/zRP1+a+jrXOXvY32szj1ZZt5HiyvTbhlG3Fuevm0rlov86/bCMeq65LtOSXryWxb937rlj7xJMfKcf1l+Ops6cYYu6jT5FNnf9xLrfHa1205faufZ3NrjGLbJ+7cHJSBdpbTFR8r3YlwQvSCyAmPPaP7zVWx1rcmsvzxrEx2V227WvTPvppv33rtGkM5yEAgfEJTCKcXA9iHYqf4fheHuo4/oTv8TqvLRf+3K4+qj2er6ve5Frm/p5Pe99tqBzo+Cfb07HrasfQzdrpubMvGu9zsuvNcz788MOVr24zG/G0zRyPx6qvNvFtuuOkdvWP8dgf2Y3vs2+yb3/si/v03Wdfu8Z1xarxo8Tj+Hy9yfG4Pcandag5vEWf3D+2xxjzWpeNeC2Ntmy/a68xMX9d/RfdPnPhlFW5jmNCBCAmxUn3OC8Gg1LSdM7tsXjksV4cTkjbWNnvarcPTXvFYb+y301jOA8BCIxHoE04ufj7cxhrjGdzH39mXSfcrvrhNtWZa6+9dssvffjzrn75YuJaFC9W6q++3trqTfbXvtqejx2fbbbtYzw51jxfthNj9dz2xX3b4sltYimm5mGbjif7o/Ftwkk+xPiUN/tn2z5W32w/xud4+u6zrbr5oi23N8Xqvk3xqF2xeG3Kjo6VU/miLcbj+WL8su2+thevpTlfuS0/SpQ9vbR5PsdXnez4JzOM3XNb2/HJkyfj0Jm9n6lwmpnXGIYABNaeQJtwWns4IwKQ0NPfOdKebXICEilRqExuEQvLRADhtEzZwBcIQKA3AYRTb1SdHXWRj3cgOgfQoZGAxKfuvujOC9tqEkA49cirPgS+LVq3p+D0gEgXCEyZAMLp/3/Ju64u+Rx3PvovvPyIygy9z484+1tez56reu1EOPVYzz/4wQ/K4cOHG18PPfRQDyt0gQAEpkkA4VSKvtPx/e9/v7E2qW49+uij08S+0rZ0t+iWW25p5HnnnXeWJ554YqUZTDO4Vb12IpymuUqwBQEIzI0AwmluqJkIAhAIBBBOAQZvIQCB4RBAOA0nV3gKgVUigHBapWwSCwTWiADCaY2STagQWCICEwunyy+/vOzfv798+9vf5gUD1gBrYG5r4Etf+lLZt29fufHGG+c2J3WOOs8aYA189atfrWrPkSNHGuXcRmNLKeXgwYOVARUwXjBgDbAGWAOsAdYAa2Ad1sDYwkk/7emOk37TgBcMWAOsgXmtgdtuu636YU3/pce85mQe1jdrgDXw4IMPVrXn3nvvbbyv1HrHSb/uKuHEBgEIQGCeBPiO0zxpMxcEIGACE3/HCeFklOwhAIF5EkA4zZM2c0EAAiaAcDIJ9hCAwKAIIJwGlS6chcDKEEA4rUwqCQQC60UA4bRe+SZaCCwLAYTTsmQCPyAAgZEIIJxGwkVnCEBgSgQQTlMCiRkIQGC+BBBO8+XNbBCAwB8IIJxYCRCAwCAJIJwGmTachsDgCSCcBp9CAoDAehJAOK1n3okaAosmgHBadAaYHwIQGIsAwmksbAyCAAQmJIBwmhAgwyEAgcUQQDgthjuzQmDdCSCc1n0FED8EBkoA4TTQxOE2BAZOAOE08ATiPgTWlQDCaV0zT9wQWCwBhNNi+TM7BCAwJgGE05jgGAYBCExEAOE0ET4GQwACiyKAcFoUeeaFwHoTQDitd/6JHgKDJYBwGmzqcBwCgyaAcBp0+nAeAutLAOG0vrkncggsksBMhdOBAwfK7t27y4kTJ6oYu44XCYK5IQCBYRFoE06HDh0qu3btKsePH6+Cyse5Fg0rcryFAAQWSWCmwmmRgTE3BCCw2gTahNNqR050EIDAIgkgnBZJn7khAIGxCSCcxkbHQAhAYAICCKcJ4DEUAhBYHAGE0+LYMzME1pkAwmmds0/sEBgwAYTTgJOH6xAYMAGE04CTh+sQWGcCCKd1zj6xQ2BxBBBOi2PPzBCAwAQEEE4TwGMoBCAwNgGE09joGDgLAvrTFY899tgsTGNzxQggnFYsoYQDgYEQmFg4ffnLXy779u0rDzzwAC8YTLwGrr/++nLVVVdNbIf1uPqfxxtvvLGqPXfddRfrhdrDGmANzG0NfOc736lqz5EjRxql3kZjSynl4MGDlQGJJ14wmGQNXHLJJeXcc88tf/M3f8Na4vPEGmANsAZYA0u9BsYWTrfeemvRS7eueMFgkjUgFf+ud72rnH322UWPYSaxxdjVX4uuPffccw9rhfrLGmANzG0NuPZo37S13nFqGsR5CIxK4IYbbigvfOELyxlnnFH0yI4NAhCAAAQgMEQCCKchZm1gPv/mN78pF110UfnjP/7j8rSnPa18/OMfLydPnhxYFLgLAQhAAAIQKAXhxCqYOYHvf//75ZxzzikbGxvlSU96UnnDG95QfvSjH818XiaAAAQgAAEITJsAwmnaRLG3jcDVV19dnvvc51bCSeLpec97XvXbdds6cgICEIAABCCw5AQQTkueoKG798tf/rJ6NPfkJz95Uzidcsop5UMf+lB5/PHHhx4e/kMAAhCAwJoRQDitWcLnHe7tt99ezjzzzE3RpDtOer361a8uR48enbc7zAcBCEAAAhCYiADCaSJ8DO4icNlll5U//dM/3SacTjvttPL5z3++azjtEIAABCAAgaUigHBaqnSsljM///nPy7/927+Vv/iLvyjPetazih7R/dEf/VF59rOfXf1pggsvvJD/gmW1Uk40EIAABFaeAMJp5VO8uAB/+tOflq9//evliiuuKP/6r/9aXvziF5fTTz+9XHzxxdW5w4cPl0ceeWRxDjIzBCAAAQhAYEQCCKcRgdF9PAJ33313eeMb31he+9rXlvvuu288I4yCAAQgAAEILJgAwmnBCViX6RFO65Jp4oQABCCw2gQQTqud36WJDuG0NKnAEQhAAAIQmIAAwmkCeAztTwDh1J8VPSEAAQhAYHkJIJyWNzcr5RnCaaXSSTAQgAAE1pYAwmltUz/fwBFO8+XNbBCAAAQgMBsCCKfZcMVqIoBwSkA4hAAEIACBQRJAOA0ybcNzGuE0vJzhMQQgAAEIbCeAcNrOhDMzIIBwmgFUTEIAAhCAwNwJIJzmjnw9J0Q4rWfeiRoCEIDAqhFAOK1aRpc0HoTTkiYGtyAAAQhAYCQCCKeRcNF5XAIIp3HJMQ4CEIAABJaJAMJpmbKxwr4gnFY4uYQGAQhAYI0IIJzWKNmLDBXhtEj6zA0BCEAAAtMigHCaFknstBJAOLXioRECEIAABAZCAOE0kEQN3U2E09AziP8QgAAEICACCCfWwVwIIJzmgplJIAABCEBgxgQQTjMGjPk/EEA4sRIgAAEIQGAVCCCcViGLA4gB4TSAJOEiBCAAAQh0EkA4dSKiwzQIIJymQREbEIAABCCwaAIIp0VnYE3mRzitSaIJEwIQgMCKE0A4rXiClyU8hNOyZAI/IAABCEBgEgIIp0noMbY3AYRTb1R0hAAEIACBJSaAcFri5KySawinVcomsUAAAhBYXwIIp/XN/VwjRzjNFTeTQQACEIDAjAggnGYEFrNbCSCctvLgCAIQgAAEhkkA4TTMvA3Oa4TT4FKGwxCAAAQgUEMA4VQDhVPTJ4Bwmj5TLEIAAhCAwPwJIJzmz3wtZ0Q4rWXaCRoCEIDAyhFAOK1cSpczIITTcuYFryAAAQhAYDQCCKfReNF7TAIIpzHBMQwCEIAABJaKAMJpqdKxus4gnFY3t0QGAQhAYJ0IIJzWKdsLjBXhtED4TA0BCEAAAlMjgHCaGkoMtRFAOLXRoQ0CEIAABIZCAOE0lEwN3E+E08ATiPsQgAAEIFARQDixEOZCAOE0F8xMAgEIQAACMyaAcJoxYMz/gQDCiZUAAQhAAAKrQADhtApZHEAMCKcBJAkXIQABCECgkwDCqRMRHaZBAOE0DYrYgAAEIACBRRNAOC06A2syP8JpTRJNmBCAAARWnADCacUTvCzhIZyWJRP4AQEIQAACkxBAOE1Cj7G9CSCceqOiIwQgAAEILDEBhNMSJ2eVXEM4rVI2iQUCEIDA+hJAOK1v7ucaOcJprriZDAIQgAAEZkQA4TQjsJjdSgDhtJUHRxCAAAQgMEwCCKdh5m1wXiOcBpcyHIYABCAAgRoCCKcaKJyaPgGE0/SZYhECEIAABOZPAOE0f+ZrOSPCaS3TTtAQgAAEVo4AwmnlUrqcASGcljMveAUBCEAAAqMRQDiNxoveYxJAOI0JjmEQgAAEILBUBBBOS5WO1XUG4bS6uSUyCEAAAutEAOG0TtleYKwIpwXCZ2oIQAACEJgaAYTT1FBiqI0AwqmNDm0QgAAEIDAUAginoWRq4H4inAaeQNyHAAQgAIGKAMKJhTAXAginuWBmEghAAAIQmDEBhNOMAWP+DwQQTqwECEAAAhBYBQIIp1XI4gBieOCBB8o///M/l49//OPlBz/4wQA8xkUIQAACEIDAdgIIp+1MODMDAr/61a/Kj3/84+r16KOPzmAGTEIAAhCAAARmTwDhNHvGzAABCEAAAhCAwIoQQDitSCIJAwIQgAAEIACB2RNAOM2eMTNAAAIQgAAEILAiBBBOA07kb37zm7J79+6yY8eOcvTo0S2RHDp0qGxsbJQ9e/ZsOd908L3vfa+cccYZ5ROf+ET53e9+19Rtqc4fP3687Nq1q2Jw4sSJpfINZyAAAQhAYDUJIJwGnNdpCqc777yzEmAf/vCHEU4DXhO4DgEIQAACsyWAcJot35lan6ZwmqmjMzLOHacZgcUsBCAAAQg0EkA4NaJZ/oZRhJMe5b3gBS8on/3sZ8vrXve68pSnPKW85jWvKd/97nerQNWuR35+tKdHXxdeeGF5xjOeUb10J+olL3lJOXDgQNXfjwK116b+emyolx+b3XLLLZtzPf/5zy+XXXZZOXnyZNVf/+iR4Ac+8IHyohe9qDz44IOb5y+55JJy6qmnljvuuKM8/PDD5Z/+6Z/KM5/5zMrn17/+9UV/E0pbFk59fNLfkHr7299eTjnllMrmv//7v5fHH3+8shf9fc5znlO+8IUvlCeeeGLTL95AAAIQgAAEEE4DXgOjCicJo507d5avfOUr5brrrisSMxY6UTj9/ve/L5/+9KcrofIv//IvlYD5x3/8x+q4r3C66667KvtvfetbiwTJ5z//+XLaaaeVG264YQvxm266qTz96U+vRJUafvGLX5TXvva15d3vfnclaL7xjW+Ud7zjHeX6668vN998c3nFK16x2TaqcPrJT35SXvWqV1U2JLK+/OUvVz4qJv1tqTPPPLO86U1vqvy95ppryqWXXopw2pItDiAAAQhAAOE04DUwjnCy8JE4+tCHPlR9uVoCJAoni5dzzjmn/PrXv64Iud3ju+7u7N27txIl9913XzX+t7/9bXnPe95Tzj///C3fodIfxnzzm9+8KeAkpHSXS+KubtMdMX0hXD6PKpyuvPLKSqRpDm/yU2Lphz/8YSXYJNp0Fy7eGXNf9hCAAAQgAAGE04DXgMVP22/VSRhoy8JH56IIcbvOWZD4sV3d+C7hpLH6rb788h2uyqn/+0eP8PRo7rbbbqse3ekR4iOPPFK1SlhddNFFlQizrXGFk0SfbcS97eVHdZdffnkRYzYIQAACEICACSCcTGKge4kOfV9Jj5a8xUdtvnNjYeQ7RurbJJwkWvRILIqcPL5LOEmwnX766dVjPt8d0v6Xv/yl3dzc679iednLXlYuuOCCaq/vOGnTd4/e9773Vd+tuuqqq8qxY8eqPhY6Fnj2s8sn3XH6kz/5k6LHf9En3WGLAkmP7eTLn//5nxf9mYah/HmGTaC8gQAEIACBmRFAOM0M7XwMP/TQQ9WXvHXX6b//+7/LPffcU30/SY+7zj333M0vamfhI++ahJO/tC0b+m6S7sT87d/+bXW3xsJLX9zWXSLNoTtF+k6U+lvE6HGXvkOlx3P6bpJeH/nIR6rvFUWRIj90rL8f9dSnPrUSW36899hjj1WP0fRl9ttvv71cffXV1Xe0moRTl09mpS+YS2Spv74Ar5gknj74wQ+WgwcPFn0/S3FJzEnU8dhuPmuZWSAAAQgMgQDCaQhZ6vAx/uaZHkFJsHzqU5/aFE0aPopwUn+JDP32me5mvfSlL62EkX7TzMJJYkePsnROgkkCRHdpLJxk43//93/L2WefXdlQH4ko/VZb3SZhpS+J67fs4h0e3R3SHPotONnXnC9/+cs37xhJRHnOPj5p/r/7u7+r7MnmW97ylspP/SagmImdGOpxoQQjGwQgAAEIQCASQDhFGrxvJFAnvBo70wABCEAAAhBYUQIIpxVN7LTDQjhNmyj2IAABCEBgiAQQTkPMGj5DAAIQgAAEILAQAginhWBnUghAAAIQgAAEhkgA4TTErOEzBCAAAQhAAAILIYBwWgh2JoUABCAAAQhAYIgEEE5DzBo+QwACEIAABCCwEAL/D2vygQLy2zNXAAAAAElFTkSuQmCC)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "Checking format of y_pred"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 854,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']\n"
          ]
        }
      ],
      "source": [
        "print(y_pred[1])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making a list of diseases from test_sentences and predicted labels y_pred for test sentences"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 855,
      "metadata": {},
      "outputs": [],
      "source": [
        "diseases = []\n",
        "\n",
        "for sentence, label in zip(test_sentences, y_pred):\n",
        "    words = sentence.split()\n",
        "    disease_cache = \"\"\n",
        "\n",
        "    for word, label in zip(words, label):\n",
        "        if label == 'D':\n",
        "            disease_cache += word + \" \"\n",
        "        else:\n",
        "            if disease_cache:\n",
        "                diseases.append(disease_cache.strip().lower())\n",
        "                disease_cache = \"\"\n",
        "    \n",
        "    if disease_cache:\n",
        "        if disease_cache not in diseases:\n",
        "            diseases.append(disease_cache.strip().lower())\n",
        "\n",
        "diseases = list(set(diseases))# making a set and back to list to get rid of duplicates"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### diseases list from test sentences"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 856,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['duodenal ulcer',\n",
              " 'colon tumors',\n",
              " 'sclc',\n",
              " 'limited stage small cell lung cancer',\n",
              " 'hairy cell leukemia',\n",
              " 'pneumocystis carinii pneumonia',\n",
              " 'revascularizations',\n",
              " 'colonic polyps',\n",
              " 'pulmonary aspergilloma',\n",
              " 'restenosis',\n",
              " 'cerebral injuries',\n",
              " 'gastrointestinal tumours',\n",
              " 'b16 melanoma',\n",
              " 'advanced esophageal cancer',\n",
              " 'acute respiratory distress syndrome',\n",
              " 'reduced metastatic load',\n",
              " 'hemiretinal vein occlusion',\n",
              " 'preeclampsia',\n",
              " 'ventricular tachycardia',\n",
              " 'renovascular hypertension',\n",
              " 'partial seizures',\n",
              " \"oral crohn 's disease\",\n",
              " 'unstable angina',\n",
              " 'metastatic colorectal cancer',\n",
              " 'attention deficit hyperactivity disorder',\n",
              " 'left ventricular anterior wall',\n",
              " 'sclc , limited disease',\n",
              " 'fetalis',\n",
              " 'depression',\n",
              " 'ectopic pregnancy',\n",
              " 'contemporary asthma management',\n",
              " 'colds',\n",
              " 'mediastinal teratomas',\n",
              " 'rheumatic',\n",
              " 'large lesions',\n",
              " 'atrial fibrillation',\n",
              " 'chronic hepatitis c',\n",
              " 'macular degeneration',\n",
              " 'pathologic stage i non-small cell lung cancer',\n",
              " 'congenital bilateral aplasia',\n",
              " 'autoimmune hemolytic anemia',\n",
              " 'childhood acute lymphoblastic leukaemia',\n",
              " 'amyloidosis',\n",
              " \"low-grade non-hodgkin 's lymphoma\",\n",
              " 's.c. tumors',\n",
              " 'viral infections',\n",
              " 'non-q-wave myocardial infarction',\n",
              " 'pertussis',\n",
              " 'early bos',\n",
              " 'acute obstructive hydrocephalus',\n",
              " 'chronic hepatitis',\n",
              " 'duodenogastric reflux',\n",
              " 'hemorrhagic stroke',\n",
              " 'malignant tumors',\n",
              " 'perforated peptic ulcer',\n",
              " 'stage iii nsclc',\n",
              " 'congenital anomalies',\n",
              " 'cancer',\n",
              " 'rhinovirus colds',\n",
              " 'acute migraine treatment',\n",
              " 'haemophilus influenzae meningitis',\n",
              " 'multiple sclerosis',\n",
              " 'coronary endothelial dysfunction',\n",
              " 'retinoblastoma',\n",
              " 'irritable bowel syndrome',\n",
              " 'major pulmonary embolism',\n",
              " 'renal cell carcinoma',\n",
              " 'renal stones',\n",
              " 'diverticular hemorrhage',\n",
              " 'sore throat',\n",
              " 'darier disease',\n",
              " \"alzheimer 's disease\",\n",
              " 'melanoma',\n",
              " 'cervical adenocarcinoma',\n",
              " 'progressive liver',\n",
              " 'advanced stage ( tnm iib-ivb ) mycosis fungoides',\n",
              " 'biliary indication',\n",
              " 'cerebral palsy',\n",
              " 'tumor necrosis factor-alpha',\n",
              " 'leg pain',\n",
              " 'cloacal anomalies',\n",
              " 'malignant pleural mesothelioma',\n",
              " 'migraine',\n",
              " 'ovarian carcinoma brain metastasis',\n",
              " 'cardiac insufficiency',\n",
              " 'disseminated malignant melanoma',\n",
              " 'severe acute hepatitis accompanying cholestasis',\n",
              " 'breast cancer',\n",
              " 'perinatal',\n",
              " 'reduced ratio',\n",
              " \"eisenmenger 's syndrome\",\n",
              " 'sore',\n",
              " 'autologous cancer',\n",
              " 'chronic myelogenous leukemia ( cml )',\n",
              " 'lung carcinoma',\n",
              " 'brain hemorrhage',\n",
              " 'ovarian cancer',\n",
              " 'small-cell lung cancer',\n",
              " 'intra-abdominal injury',\n",
              " 'chronic bronchitis',\n",
              " 'postoperative pain relief',\n",
              " 'mouse-adopted strain of influenza a2 ( h2n2 ) virus',\n",
              " 'low-grade nhl',\n",
              " 'pi',\n",
              " 'chronic leg ulcers',\n",
              " 'left lung',\n",
              " 'carcinoma',\n",
              " 'hepatitis b',\n",
              " 'lung cancer )',\n",
              " 'hepatocerebral degeneration ( portal systemic encephalopathy )',\n",
              " \"laennec 's cirrhosis\",\n",
              " 'postraumatic stress disorder',\n",
              " 'myocardial perfusion defects',\n",
              " 'hearing loss',\n",
              " 'colorectal cancer',\n",
              " 'choroidal neovascularization',\n",
              " 'metastasis of laryngeal carcinomas',\n",
              " 'uterine bleeding',\n",
              " 'upper respiratory conditions',\n",
              " \"non-hodgkin 's lymphoma\",\n",
              " 'coronary-artery disease',\n",
              " 'deep vein thrombosis ( dvt )',\n",
              " 'childhood schizophrenia',\n",
              " 'preeclampsia ( proteinuric hypertension',\n",
              " 'darier disease gene',\n",
              " 'tumors',\n",
              " 'synovial sarcoma',\n",
              " 'cortical lesions',\n",
              " 'rheumatoid arthritis',\n",
              " 'non-small cell lung cancer',\n",
              " 'extensive disease',\n",
              " 'progressive sensorineural hearing loss',\n",
              " 'murine hepatitis virus strain 3 infection',\n",
              " 'proximal hypospadias',\n",
              " 'pulmonary hypertension',\n",
              " 'benign prostatic hyperplasia',\n",
              " 'foot infection',\n",
              " 'squamous cell carcinoma',\n",
              " 'colorectal metastases',\n",
              " 'portal hypertension',\n",
              " 'cbd stones',\n",
              " 'hyperammonemia',\n",
              " 'esophageal and tracheobronchial stenoses',\n",
              " 'unresectable stage iii nsclc',\n",
              " 'tumor',\n",
              " 'renal dysfunction',\n",
              " 'chronic neutropenia',\n",
              " 'congenital adrenal hyperplasia',\n",
              " 'hypothyroidism',\n",
              " 'midline incisional hernias',\n",
              " 'stable asthma',\n",
              " 'myocardial amyloidosis',\n",
              " 'small cell lung cancer',\n",
              " 'chronic progressive external ophthalmoplegia',\n",
              " 'postvitrectomy diabetic vitreous hemorrhage',\n",
              " 'disorder (',\n",
              " \"low-grade non-hodgkin 's lymphomas\",\n",
              " 'malignant melanoma',\n",
              " 'acute occlusion of the middle cerebral artery',\n",
              " 'psoriasis',\n",
              " 'pneumonia',\n",
              " 'primary pulmonary hypertension',\n",
              " 'multidrug resistant tb',\n",
              " 'esophageal cancer',\n",
              " 'bronchial asthma',\n",
              " 'biliary colic',\n",
              " 'large midline incisional hernias',\n",
              " 'advanced renal cell carcinoma',\n",
              " 'disconnection syndrome',\n",
              " 'intra-abdominal hemorrhage',\n",
              " 'asthma',\n",
              " 'endometriosis',\n",
              " 'large-bowel cancer',\n",
              " 'cancers',\n",
              " \"parkinson 's disease\",\n",
              " 'fibromyalgia',\n",
              " 'limited disease',\n",
              " 'bacterial meningitis',\n",
              " 'prostate cancer',\n",
              " 'intracranial hemorrhage',\n",
              " 'radiation-induced myelopathy',\n",
              " 'stroke',\n",
              " 'malignant lymphomas',\n",
              " 'gestational diabetes',\n",
              " 'ovarian carcinoma',\n",
              " 'hypertension',\n",
              " 'sensorineural deafness',\n",
              " 'blastocystis hominis infection',\n",
              " 'deafness',\n",
              " 'interstitial radiotherapy',\n",
              " 'supraclavicular node metastases in nsclc',\n",
              " 'hyponatremia',\n",
              " 'retinopathy',\n",
              " 'nsclc ( stage iiib',\n",
              " 'acute colonic pseudo-obstruction',\n",
              " 'heart congestive failure',\n",
              " 'mammalian gut-associated lymphoid tissues',\n",
              " 'neutropenia',\n",
              " 'pericardial effusions',\n",
              " 'rsv bronchiolitis',\n",
              " 'carbon monoxide poisoning',\n",
              " 'secondary peritonitis',\n",
              " 'pendred syndrome',\n",
              " 'frontal dysfunction blocks',\n",
              " 'mitomycin-resistant bladder cancer',\n",
              " 'pressure pain threshold',\n",
              " 'golf injuries',\n",
              " 'testicular bleeding',\n",
              " 'encephalopathy',\n",
              " 'coronary heart disease',\n",
              " \"early parkinson 's disease\",\n",
              " 'non-seminomatous germ-cell tumors',\n",
              " 'malignant pleural effusions from nsclc',\n",
              " 'sickle cell disease',\n",
              " 'stone disease',\n",
              " 'mild preeclampsia',\n",
              " 'pulmonary symptoms attributable',\n",
              " 'cranial nerve injuries',\n",
              " 'ischemic heart disease',\n",
              " 'advanced nsclc with manageable toxicities',\n",
              " 'myoepithelial carcinoma',\n",
              " 'autoimmune diseases',\n",
              " \"crohn 's disease\",\n",
              " 'primary cancer',\n",
              " 'new-onset angina preceding acute myocardial infarction',\n",
              " 'tangential gunshot wounds',\n",
              " 'concurrent acute rejection',\n",
              " 'splenomegaly',\n",
              " 'end-stage renal disease',\n",
              " 'acute rejection episode',\n",
              " 'myofascial trigger point pain',\n",
              " 'acute myocardial infarction',\n",
              " 'chlamydia trachomatis',\n",
              " 'fungal infections',\n",
              " 'acetaminophen overdose',\n",
              " 'hiv infection',\n",
              " 'lung abscess',\n",
              " 'tuberous sclerosis',\n",
              " 'untreated sclc',\n",
              " 'rhesus haemolytic disease',\n",
              " 'rectal cancer',\n",
              " 'acute repetitive seizures',\n",
              " 'head lice',\n",
              " \"leukaemia and non-hodgkin 's lymphoma\",\n",
              " 'cardiac disease',\n",
              " 'primary lung cancer',\n",
              " 'primary tumor',\n",
              " 'primary pulmonary hypertension ( pph )',\n",
              " 'lung lacerations',\n",
              " 'persistent asthma',\n",
              " 'al amyloidosis',\n",
              " '( hygromycin b',\n",
              " 'acute carbon monoxide poisoning',\n",
              " 'severe pain',\n",
              " 'lung metastasis',\n",
              " 'hepatic metastases from colorectal cancer',\n",
              " 'cervical carcinoma',\n",
              " 'diabetes',\n",
              " 'head and neck cancer',\n",
              " 'aids exceptionalism',\n",
              " 'malignancy',\n",
              " 'other b cell lymphomas',\n",
              " 'congestive heart failure',\n",
              " 'abdominal pain',\n",
              " 'kaposi sarcoma-associated herpesvirus infection',\n",
              " 'macrosomic',\n",
              " 'dog bite',\n",
              " 'arthritis',\n",
              " 'systemic lupus erythematosus',\n",
              " 'piglet influenza',\n",
              " 'disruptions caused by blunt thoracic trauma',\n",
              " 'heart failure',\n",
              " 'autosomal trisomies',\n",
              " 'insulin-dependent diabetes mellitus',\n",
              " 'limited-stage small-cell carcinoma of the lung',\n",
              " 'influenza',\n",
              " 'availability',\n",
              " 'gynaecological pain',\n",
              " 'peritoneal tumors',\n",
              " 'small lesions',\n",
              " 'esophageal achalasia',\n",
              " 'pph',\n",
              " 'phaeochromocytoma',\n",
              " 'common cold',\n",
              " 'free-recall learning',\n",
              " 'intractable seizures',\n",
              " 'adenocarcinoma ( ad )',\n",
              " 'platinum-pretreated ovarian cancer',\n",
              " 'adhd',\n",
              " 'foot infections',\n",
              " 'advanced nsclc',\n",
              " 'odontogenic infections',\n",
              " 'female stress urinary incontinence',\n",
              " 'non-obstructive azoospermia',\n",
              " 'stress urinary incontinence',\n",
              " 'acute cerebral ischemia',\n",
              " 'epilepsy',\n",
              " 'optic nerve head',\n",
              " 'auditory perception disorders',\n",
              " 'autoimmune hepatitis',\n",
              " 'chronic pulmonary disease',\n",
              " 'vertigo caused by',\n",
              " 'infection',\n",
              " 'chronic renal failure',\n",
              " 'nsclc',\n",
              " 'mild to moderate pain',\n",
              " 'locally advanced non-small-cell lung cancer',\n",
              " 'spontaneous splenic rupture',\n",
              " 'peritoneum metastases',\n",
              " 'diabetes mellitus',\n",
              " 'osteogenic sarcoma',\n",
              " 'perioperative mortality and myocardial infarction',\n",
              " 'gunshot wounds',\n",
              " 'malaria',\n",
              " 'refractory pouchitis',\n",
              " 'untreated small cell lung cancer ( sclc )',\n",
              " 'hormonal dysfunction',\n",
              " 'pleuritic pain',\n",
              " 'infantile gsdii',\n",
              " 'primary stomach lymphoma',\n",
              " 'primary uveal melanoma',\n",
              " 'confirmed infection',\n",
              " 'postoperative ileus',\n",
              " 'non-functioning endocrine pancreatic tumor',\n",
              " 'metastatic malignant mesothelioma',\n",
              " 'macrosomic infants in gestational diabetes cases',\n",
              " 'tss',\n",
              " 'upper aerodigestive tract',\n",
              " 'mesothelioma and non-small cell lung cancer',\n",
              " 'glaucoma',\n",
              " 'microcephaly',\n",
              " 'corpal gastritis',\n",
              " 'non-small-cell-lung-cancer ( nsclc ) patients',\n",
              " 'biliary dyskinesia',\n",
              " 'inducible nitric oxide',\n",
              " 'cardiac amyloid heart disease',\n",
              " 'acute lymphoblastic leukaemias',\n",
              " \"ovine johne 's disease\",\n",
              " 'bos',\n",
              " 'endometrial hyperplasia',\n",
              " 'spontaneous pneumothorax',\n",
              " 'hemorrhagic shock',\n",
              " \"barrett 's esophagus\",\n",
              " 'laryngeal obstruction caused by lingual thyroglossal duct cyst',\n",
              " 'quick value',\n",
              " 'essential hypertension',\n",
              " 'hbv recommendations',\n",
              " 'severe psoriasis',\n",
              " 'mantle cell lymphoma',\n",
              " 'bronchogenic carcinoma',\n",
              " 'paranasal sinuses',\n",
              " 'satisfactory analgesia',\n",
              " 'early-stage cervical carcinoma',\n",
              " 'aom',\n",
              " 'hepatitis c viremia']"
            ]
          },
          "execution_count": 856,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "#Diseases list from test_sentences\n",
        "diseases"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making a dictionary of treatments for each disease from the test_sentence. Treatments are also from test_sentences as instructed.\n",
        "key is the disease name and value is the treatment"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 857,
      "metadata": {},
      "outputs": [],
      "source": [
        "treatments = {}\n",
        "for disease in diseases:\n",
        "    for i, sentence in enumerate(test_sentences):\n",
        "        if disease in sentence.split():\n",
        "            sentence_cache = sentence.split()\n",
        "            labels_cache = test_labels[i].split()\n",
        "            treatment_cache = []\n",
        "            for j, label in enumerate(labels_cache):\n",
        "                if label == 'T':\n",
        "                    treatment_cache.append(sentence_cache[j].strip())            \n",
        "            if disease in treatments:\n",
        "                treatments[disease].extend(treatment_cache)\n",
        "            else:\n",
        "                treatments[disease] = treatment_cache\n",
        "\n",
        "for disease, treatment_list in treatments.items():\n",
        "    treatments[disease] = list(set(treatment_list))\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 858,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "sclc\n",
            "revascularizations\n",
            "restenosis\n",
            "preeclampsia\n",
            "fetalis\n",
            "depression\n",
            "colds\n",
            "rheumatic\n",
            "amyloidosis\n",
            "pertussis\n",
            "cancer\n",
            "retinoblastoma\n",
            "melanoma\n",
            "migraine\n",
            "perinatal\n",
            "sore\n",
            "carcinoma\n",
            "tumors\n",
            "hyperammonemia\n",
            "tumor\n",
            "hypothyroidism\n",
            "psoriasis\n",
            "pneumonia\n",
            "asthma\n",
            "endometriosis\n",
            "cancers\n",
            "stroke\n",
            "hypertension\n",
            "deafness\n",
            "hyponatremia\n",
            "retinopathy\n",
            "neutropenia\n",
            "encephalopathy\n",
            "splenomegaly\n",
            "diabetes\n",
            "macrosomic\n",
            "arthritis\n",
            "influenza\n",
            "availability\n",
            "phaeochromocytoma\n",
            "epilepsy\n",
            "infection\n",
            "nsclc\n",
            "malaria\n",
            "glaucoma\n",
            "microcephaly\n",
            "bos\n"
          ]
        }
      ],
      "source": [
        "for key, value in treatments.items():\n",
        "    print(key)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Predict the treatment for the disease name: 'retinoblastoma'. "
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 859,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[]"
            ]
          },
          "execution_count": 859,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "treatments['retinoblastoma']"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### From the above, it can be seen that the model is working fine and predicting from test data for the labels in the training data."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Predict the treatment for the disease name: \"hereditary retinoblastoma\"\n",
        "\n",
        "\n",
        "### <span style=\"color:red;\">Please scroll down to the last for explanation.</span>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 860,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Couldn't find the disease in the dictionary <class 'KeyError'> 'hereditary retinoblastoma'\n"
          ]
        }
      ],
      "source": [
        "try:\n",
        "    treatments['hereditary retinoblastoma']\n",
        "except KeyError as e:\n",
        "    print(\"Couldn't find the disease in the dictionary\", KeyError, e)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Making a dictionary of treatment from training dataset to see if there is any improvement"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 861,
      "metadata": {},
      "outputs": [],
      "source": [
        "treatments = {}\n",
        "for disease in diseases:\n",
        "    for i, sentence in enumerate(train_sentences):\n",
        "        if disease in sentence.split():\n",
        "            sentence_cache = sentence.split()\n",
        "            labels_cache = train_labels[i].split()\n",
        "            treatment_cache = []\n",
        "            for j, label in enumerate(labels_cache):\n",
        "                if label == 'T':\n",
        "                    treatment_cache.append(sentence_cache[j].strip())            \n",
        "            if disease in treatments:\n",
        "                treatments[disease].extend(treatment_cache)\n",
        "            else:\n",
        "                treatments[disease] = treatment_cache\n",
        "\n",
        "for disease, treatment_list in treatments.items():\n",
        "    treatments[disease] = list(set(treatment_list))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 862,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Couldn't find the disease in the dictionary <class 'KeyError'> 'hereditary retinoblastoma'\n"
          ]
        }
      ],
      "source": [
        "try:\n",
        "    treatments['hereditary retinoblastoma']\n",
        "except KeyError as e:\n",
        "    print(\"Couldn't find the disease in the dictionary\", KeyError, e)\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### It can be seen that hereditary retinoblastoma is not in the list of diseases extracted from the test_sentences using the model.\n",
        "### Even tried with extracting treatments from both training_sentences and test_sentences. Both couldn't identify \"hereditary retinoblastoma\"\n",
        "### Checking for the problems.\n",
        "### <span style=\"color:red;\">Please scroll down to the last for explanation.</span>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 863,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "['<', 'TO_SEE', '>', 'CONTEXT', ':', 'There', 'is', 'a', 'substantial', 'risk', 'of', 'a', 'second', 'cancer', 'for', 'persons', 'with', 'hereditary', 'retinoblastoma', ',', 'which', 'is', 'enhanced', 'by', 'radiotherapy'] \n",
            " ['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']\n",
            "46\n",
            "25 \n",
            " 25\n"
          ]
        }
      ],
      "source": [
        "for i in range(len(test_sentences)):\n",
        "    if \"retinoblastoma\" in test_sentences[i]:\n",
        "        print(test_sentences[i].split(), \"\\n\", test_labels[i].split())\n",
        "        print(i)\n",
        "        print(len(test_sentences[i].split()),\"\\n\", len(test_labels[i].split()))\n",
        "       "
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "#### It can be seen from the above that for test_sentences, test_labels for disease are not present for the word 'hereditary'. It is tagged as 'O'. Even 'retinoblastoma' is tagged as 'O' in the test sentence list"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Predicting the labels for same test sentence using the model"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 864,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "< TO_SEE > CONTEXT : There is a substantial risk of a second cancer for persons with hereditary retinoblastoma , which is enhanced by radiotherapy\n",
            "[['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'D', 'O', 'O', 'O', 'O', 'D', 'O', 'O', 'O', 'O', 'O', 'T']]\n"
          ]
        }
      ],
      "source": [
        "labels = crf_pa.predict([feature_definition_sentence(test_sentences[46])])\n",
        "print(test_sentences[46])\n",
        "print(labels)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### But, the model was able to predict the correct labels 'D' for \"retinoblastoma\", even for \"cancer\". This is a good sign. May be the fi-score will improve, if the test_data sentences are labelled correctly"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Checking the training dataset sentences for \"heredtiray retinoblasotma\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 865,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "88\n",
            "89\n",
            "90\n",
            "91\n",
            "92\n",
            "93\n",
            "95\n",
            "1169\n",
            "2464\n"
          ]
        }
      ],
      "source": [
        "#Printing indexes of the sentences where the word \"retinoblastom\" appears\n",
        "index = []\n",
        "for i in range(len(train_sentences)):\n",
        "    #labels = crf.predict([feature_definition_sentence(train_sentences[i])])\n",
        "    if 'retinoblastoma' in train_sentences[i]:\n",
        "        print(i)\n",
        "        index.append(i)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 866,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "< TO_SEE > OBJECTIVE : To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development \n",
            " O O O O O O O O O O O O O O O O O O O O O O O O O O O\n",
            "DESIGN : Cohort incidence study of patients with retinoblastoma followed for a median of 20 years , and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas \n",
            " O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O\n",
            "SETTING/PARTICIPANTS : A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis , identified from hospital records in Massachusetts and New York during 1914 to 1984 \n",
            " O O O O O O O O D O O O O O O O O O O O O O O O O O O O O O O\n",
            "RESULTS : Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma , in whom 190 cancers were diagnosed , vs 6.3 expected in the general population ( relative risk ( RR ) , 30 ( 95 % confidence interval , 26-47 ) ) \n",
            " O O O O O D O O O O O O O O O O O D O O O O D O O O O O O O O O O O O O O O O O O O O O O O O O O O\n",
            "Cumulative incidence ( +/-SE ) of a second cancer at 50 years after diagnosis was 51.0 % ( +/-6.2 % ) for hereditary retinoblastoma , and 5.0 % ( +/-3.0 % ) for nonhereditary retinoblastoma \n",
            " O O O O O O O O D O O O O O O O O O O O O O O D O O O O O O O O O O D\n",
            "All 114 sarcomas of diverse histologic types occurred in patients with hereditary retinoblastoma \n",
            " O O D O O O O O O O O O D\n",
            "< TO_SEE > CONCLUSIONS : Genetic predisposition has a substantial impact on risk of subsequent cancers in retinoblastoma patients , which is further increased by radiation treatment \n",
            " O O O O O O O O O O O O O O D D O D O O O O O O O T T\n",
            "Cancer incidence after retinoblastoma \n",
            " D O O D\n",
            "An experimental application of gene therapy for human retinoblastoma \n",
            " O O O O T T O D D\n"
          ]
        }
      ],
      "source": [
        "for i in index:\n",
        "    print(train_sentences[i], \"\\n\", train_labels[i])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### From the above it can be seen that the training labels are 'O' for the word 'hereditary'. If the labels are wrongly assigned, the model will not be getting trained in the right manner."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### Since the word \"retinoblastoma\" is marked correctly as a disease in the training dataset, let us check the treatment for that disease"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 867,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "['treatment', 'radiation', 'gene', 'therapy']"
            ]
          },
          "execution_count": 867,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "treatments['retinoblastoma']"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "### <span style=\"color:red;\">It can be seen that the treatments are correctly identified by the model from the test_sentences for \"retinoblastoma\". This is due to the fact that this word is correctly labelled in the training dataset. <br>Since \"hereditary\" is not marked as a disease and not marked as label 'D' in the training dataset, it wont be recognized as a disease name. <br><br></span>\n",
        "## <span style=\"color:red;\">Therefore concluded that the model has done it's job based on the training data provided to it.</span>"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "collapsed_sections": [],
      "name": "Assignment.ipynb",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.8.10"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
